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1 |  General introduction and outline of the thesis 
eTiology and ePidemiology
The most well-known risk factor for bladder cancer is smoking.1,2 Other risk factors that have 
been identified are agents used in the chemical dye, aluminium, iron and steel industries.3,4 Infection with the parasite Schistosoma haematobium is releated to an increased risk of bladder 
cancer, particularly squamous cell carcinoma.5 There is conflicting evidence for other agents 
such as arsenic acid and nitrates in drinking water.6-8  Micronutrients such as betacarotene, 
Vitamins C, E , and folate might have a protective effect.9 Bladder cancer is the fifth most 
common malignancy in the Netherlands.10 In 2009 the incidence of all bladder tumours was 
42.3/100.000 in males and in females 10.5/100.000. In the same year 2738 patients presented 
with non invasive bladder cancer (T0/a/is) and 2688 patients with invasive bladder cancer 
(≥T1). Between 1989 and 2009 the incidence of non-invasive bladder cancer increased.(figure 
1a) The incidence of invasive bladder cancer decreased in men and remained the same in 
women. (figure 1b) Almost 96% of all bladder tumours are urothelial carcinomas, 1.4% 
squamous cell carcinoma, 1.0% adenocarcinomas and 1.8% another type of carcinoma. 
About two thirds of patients present with non muscle invasive bladder cancer (NMIBC). NMIBC 
comprises a heterogenic group of tumours with variable biological behaviour and malignant 
Figure 1a and 1b 
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1potential. 50-70% of these tumours are highly recurrent. About 10% of these highly recurrent 
tumours eventually progress to muscle-invasive disease despite appropriate therapy.11 
Especially high grade NMIBC (T1G3) is known to be at high risk for progression.12 Carcinoma 
in situ (CIS) of the bladder is a non-papillary high grade non-invasive malignancy, which can 
be treated with intravesical immunotherapy. Despite this treatment, these patients remain at 
risk for progression from CIS to muscle invasive bladder cancer. This risk seems higher than 
in Ta and T1 tumours, although high grade Ta and T1 tumours are almost universally associated 
with CIS.13,14 About 30% of all tumours is muscle invasive, 60% to 80% of these tumours present 
themselves as primary muscle invasive.15,16
diagnosis and sTaging
The most common presentation of patients with bladder cancer is painless hematuria. In 
patients with macroscopic hematuria, bladder cancer is reported as the underlying cause in 
13% to 35% of patients.17 Irritative symptoms may be the initial presentation of bladder cancer, 
frequently seen as first presentation in patients with carcinoma in situ (CIS). Office cystoscopy 
and urinary cytology are the initial tools in diagnosing bladder cancer. Cytology has low 
sensitivity (38%) and high specificity (98%) for detection of bladder cancer in general.18 
However in the diagnosis of CIS and high grade cancer figures are much more favourable; 53-
90% sensitivity and 90-98% specificity. Moreover cystoscopy alone in patients with CIS is often 
false negative.14 
When a tumour is suspected after cystoscopy and/or positive cytology a transurethral resection 
of the tumour is performed. All visible tumour must be resected and adequate tissue must be 
obtained for pathological examination. 
Photodynamic diagnosis(PDD) can improve both visualization and quality of resection, as 
compared to white light cystoscopy alone. Especially in patients suspected of having CIS PDD 
can be helpful.19,20 If patients are suspected to have a T1 tumour or higher muscle should be 
included in the TUR specimen. A second TUR six weeks after the initial TUR can indentify 
patients that are at risk for early progression.21-23 All patients with macroscopic hematuria 
should undergo a CT scan to evaluate the upper urinary tract, the incidence of upper urinary 
tract tumours ranges from 0.3-1.1%.24 
Treatment and follow-up strategies are based on the stage (TNM classification) and histological 
grade (WHO).25,26 Figure 2 shows the current TNM classification system. The value of computed 
tomography (CT) and Magnetic Resonance Imaging (MRI) in evaluating the extent of the 
primary tumour and lymph node metastases is limited.27,28 Other imaging modalities such as 
ultrasmall supermagnetic particles of ironoxide(USPIO), diffusion-weighted magnetic resonance 
imaging (DW-MRI) are difficult to interpret, and conflicting results have been reported. 
Combined modalities such as USPIO-DW-MRI are promising.29,30 The value of fluorodeoxyglocose 
positron emission tomography (FDG-PET) is limited in bladder cancer patients because of the 
elimination of FDG via the efferent urinary tract. Although PET and PET-CT may provide 
diagnostic and prognostic information about the extent of distant disease the reliability of PET 
in preoperative nodal staging seems limited .31-33 
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surgical TreaTmenT
The therapy of first choice in muscle invasive bladder cancer patients is cystectomy and lymph 
node dissection. In patients with high grade non muscle invasive bladder cancer (T1G3) initially 
a bladder sparing approach with intravesical immunotherapy with Bacillus Calmètte Guerin 
(BCG) can be followed. However these tumours are at risk for progression and if bladder sparing 
therapy fails cystectomy is the definitive therapy. In this risk category the challenge is to better 
define failure, preferably before muscle invasion.24,34,35
When removing the bladder some form of urinary diversion is needed. In 1953 Eugene Bricker 
first performed an ileal conduit in a patient after pelvic evisceration.36 This incontinent diversion 
was followed by many other forms and modifications of incontinent and continent urinary 
diversions. In the Netherlands Cancer institute - Antoni van Leeuwenhoek hospital three 
deviations are being performed. The ileal conduit according to Bricker, the continent Indiana 
pouch according to Rowland, and the continent orthotopic neobladder according to Studer.37,38 
The number of patients that received an orthotopic neobladder gradually increased while the 
number of patients that received an Indiana pouch decreased. The number of patients that received an ileal conduit increased as the total number of cystectomies performed at our 
hospital in recent years. (figure 3) 
Radical cystectomy is associated with significant morbidity; postoperative complication rates 
vary from 28-68%.39-44 Lack of a standard reporting methodology might explain this wide range 
and makes it difficult to compare studies on this subject.45 When performing a radical 
cystectomy, parasympathetic and sympathetic nerves, essential for a normal sexual response, 
are often removed or damaged. In order to preserve erectile function, several nerve sparing 
techniques have been developed in well selected men (e.g. no prostate cancer, no tumour in 
bladder neck). The reported functional results are comparable with contemporary studies and 
Figure 2 TNM classification
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sexual functions can be preserved in up to 100% of men.46-52 At this moment the oncological 
safety of these nerve sparing approaches is still questioned.53-55
chemoTheraPy
For patients with locally advanced or metastatic disease multi-agent chemotherapy is the 
mainstay of treatment.56,57 Because of the high failure rates after cystectomy alone and 
chemosensitivity of bladder cancer, chemotherapy as additional therapy arose. 57-60 However, 
the role and timing of chemotherapy in addition to surgery is not well defined.  According to 
a meta-analysis based on 2688 patients from ten randomized trials,  neoadjuvant Cisplatinum 
combination chemotherapy resulted in a 5-year survival benefit of 5% in patients with invasive 
bladder cancer.61 The role of adjuvant chemotherapy is stil not clear. The major advantage as 
opposed to neoadjuvant chemotherapy is adequate patient selection after pathological staging. 
The major disadvantage is delay of therapy and the inability of response assessment. Patients 
with locally advanced and lymph node positive disease might benefit from adjuvant 
chemotherapy.62,63 However, well designed randomized controlled trials are scarce and the 
EORTC 30994 was closed prematurely because of poor recruitment.64
small cell bladder cancer 
Small cell carcinoma accounts for a fifth of lung cancer cases but is rarely observed in 
extrapulmonary primaries.65 The first case of primary small cell bladder cancer (SCCB) was 
reported in 1981.66 The prognosis of SCCB is poor and only cisplatin-based chemotherapy has 
been associated with significantly improved survival.67-69 Local therapy often fails due to 
micrometastases at diagnosis, but cases have been reported in which locally confined disease 
was curable.70 In contrast, small cell lung cancer (SCLC), which shares many clinicopathological 
features with SCCB, is far more common. A clinically relevant two-stage system of limited and 
extensive disease is widely used to determine prognosis and treatment. A consensus of 
combination chemotherapy and radiotherapy emerged, depending on the extent of the 
Figure 3 Number of deviations per year
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disease.71-73 In summary, there is evidence that systemic chemotherapy is the most important 
factor influencing survival in LD-SCCB and that the choice for cystectomy or radiotherapy as 
local consolidating treatment may be of lesser significance. In the last two years several larger 
series reported experience with cystectomy for LD-SCCB with either neoadjuvant or adjuvant chemotherapy 69,74
survival afTer cysTecTomy
Five year disease specific survival rates after cystectomy range from almost 90% in patients 
with T1 disease to less than 30% in patients with T4 disease. Patients with lymph node 
metastases have a disease specific survival rate ranging from 10 to 40% depending on the 
extent of the disease and response to systemic treatment.57,59,60,75-78
Recurrent disease after cystectomy is fatal in most patients. The five year survival rate after 
local recurrence in cystectomy patients in the CCCA region is in concordance with the literature 
and about 12%.42,79,80 The five year survival rate of patients that develop a distant recurrence 
after cystectomy is almost zero.
Follow-up aFter cystectomy
Local recurrence rates after cystectomy vary from 4-40% while distant metastases can occur 
in up to 50% of patients depending on the initial tumour stage. 42,80-82
Follow-up of cystectomy patients is recommended to detect pelvic recurrence and distant 
metastasis as early as possible to permit curative treatment if feasible. The 2008 EAU guidelines 
state that follow-up should be dependent on stage of the initial tumour.24
Recent studies doubt the efficacy of standard follow-up schedules as many patients present 
with symptoms of a recurrence.83,84 The poor prognosis of these patients despite subsequent 
therapy leads to the question if similar results can be achieved by simple symptom-guided 
follow-up.
volume and ouTcome in The ccca region
Many studies on the association of volume and outcome after cancer surgery have been 
performed. In most of them, the relation between volume and short term outcome is strong 
and consistent, especially for high risk cancer surgery.85-93 
Although no part of a consensus policy the tendency to centralization in CCCA region 
(Comprehensive Cancer Centre Amsterdam) is demonstrated by the rise in the annual 
percentage of cystectomies performed at the NKI-AVL in relation to the total number of 
cystectomies. (figure 4) At this moment, 30% of cystectomies in the greater Amsterdam region 
and almost 10% of the total number of cystectomies in the Netherlands is being performed at 
the NKI-AVL.
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1
ouTline of The Thesis
Chapter 2 describes the incidence, treatment and survival of bladder cancer patients in the 
Netherlands between 1989 and 2009. In Chapter 3 the survival after cystectomy of two groups 
of bladder cancer patients is compared. A group of patients presenting with NMIBC progressing 
to muscle invasive bladder cancer and a group primarily presenting with muscle invasive 
bladder cancer. Chapter 4 discusses a combination treatment of neoadjuvant chemotherapy 
and cystectomy in patients presenting with supraregional lymph node metastases from bladder 
cancer. 
The survival rates of patients with small cell carcinoma are poor, however with sequential 
chemoradiation long term survival can be achieved in patients with limited disease, as described in Chapter 5. In Chapter 6, complications and functional results after cystectomy 
in our institution are presented and discussed. In Chapter 7, the oncological safety of prostate 
sparing cystectomy is discussed. Chapter 8 deals with the question what the optimal follow 
up strategy after cystectomy would be and proposes a follow up scheme. Hospital volume and 
both short and long term outcome in the region of the Amsterdam comprehensive cancer centre are compared in Chapter 9. Complications, length of hospitalization after cystectomy in relation with two different peri-operative protocols in two different hospitals are compared in Chapter 10. Chapter 11 describes a patient with peritonitis carcinomatosa after a 20 year 
history of NMIBC eventually treated with cystectomy and nephrouretectomy. In Chapter 12 
a review of bladder sparing options in bladder cancer patients is given, in Chapter 13 a general 
discussion is presented and a summary is given in Chapter 14.
Figure 4 Annual number of cystectomies performed at the NKI- AVL
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Purpose
To analyze changes in incidence and survival for bladder cancer patients in the Netherlands.
Patients and Methods 
The Netherlands Cancer Registry was used to examine nationwide incidence and survival 
trends for bladder cancer (1989-2009). Patients were classified according to the stage grouping 
of the 5th edition of the UICC. 
Results
Between 1989 and 2009, the age standardized incidence of non-invasive (Ta or Tis) bladder 
cancer increased, while the incidence of invasive bladder cancer (≥T1) decreased in males and 
increased in females. The male-to-female ratio decreased from 5.3 in 1989 to 5.0 in 2009 for 
non invasive tumours and 5.0 to 4.0 for invasive tumours, respectively. The proportion of 
patients that underwent a cystectomy as primary treatment for bladder cancer for stage II and 
III increased significantly. We found small(non-significant) increases in survival by stage: 46% 
in 1989-1993 to 53% in 2004-2009 for stage II, 33% in 1989-1993 to 34% in 2004-2009 for 
stage III and only 11% in 1989-1993 and 12% in 2004-2009 for stage IV (figure 4). 
Conclusions 
We found an increasing incidence and proportion of non-invasive bladder cancer. Whether this 
is the result of earlier diagnosis or a genuine rise in incidence is uncertain. The decreased 
incidence of stage II bladder cancer and increased incidence in stage III and IV in both sexes 
might be the result of stage migration. Despite the increase of the number of cystectomies in 
stage II and III patients, survival of muscle invasive bladder cancer patients did not significantly 
improve.
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2inTroducTion 
Bladder cancer is the fifth most common invasive malignancy in males in the Netherlands after 
prostate, lung, colon and skin cancer. Bladder cancer survival in the Netherlands is among the 
highest in Europe. Because in the European Cancer Registries Study on Cancer Patients’ Survival 
and Care (EUROCARE) no data on stage is collected it remains unclear if differences in survival 
are the result of differences in stage at diagnosis.1,2 Already in the beginning of the 1950s, 
bladder cancer mortality in Dutch males was twice as high as in females. While mortality in 
males doubled between the 1950s and the 1980s and decreased thereafter, a slight decrease 
in mortality was observed among females since the 1950s. Changes in smoking patterns in the 
past, improvements in diagnosis, treatment, and increased patients’ awareness might have 
resulted in changes in incidence and survival. We analyzed trends in incidence and survival 
among Dutch bladder cancer patients during a period of twenty-one years.
PaTienTs and meThods 
Data collection
Data on incidence and survival of all bladder malignancies for the period 1989-2009 (n=94,412) 
were derived from the nationwide population-based Netherlands Cancer Registry (NCR). The 
quality of the data is high, due to thorough training of the administrators and computerized 
consistency checks at regional and national levels. Completeness is estimated to be at least 
95%.3 
The cancer registries receive lists of all newly diagnosed patients on a regular basis from the 
pathology departments, all participating in a nation-wide pathology network (PALGA). In 
addition, the medical records departments of hospitals provide lists of diagnoses of outpatients 
and hospitalised patients with a diagnosis of cancer. Following this notification, the necessary 
information of newly diagnosed tumours is abstracted from the medical records by trained 
tumour registration clerks. For this study, only first primary bladder tumours were analyzed. 
Patients were divided in three age-groups (45-59, 60-74, ≥75 years). The study period was 
divided in four categories: 1989-1993, 1994-1998, 1999-2003 and 2004-2009. Topography 
and morphology were coded according to the International Classification of Diseases for 
Oncology.4 Tumour morphology was grouped as urothelial carcinoma (UC), squamous cell 
carcinoma, adenocarcinoma or other morphologies (e.g., sarcoma, small cell carcinoma). Stage 
grouping was according to the fifth edition of the UICC TNM classification.5 During the study 
period WHO/ISUP classifications (1973, 2004/1998) changed several times.6,7 We have no 
information on the classification used by every single pathologist. For classification purposes 
all Nx and Mx tumours were considered to be N0 and M0, respectively.
Treatment data of five regional cancer registries were available from 1994 onwards and were 
divided into five categories: local (TUR, BCG/ intravesical chemotherapy), cystectomy, 
radiotherapy only, other therapy (e.g. chemotherapy), no therapy. For each clinical TNM stage 
these data were compared between two periods, 1994-98 and 2004-09. If clinical stage was 
unknown, pathological stage was used.
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Follow-up of vital status of all patients was calculated as the time from diagnosis to death or 
to  January 1st 2011. The information on vital status was initially obtained from municipal 
registries and from 1995 onwards from the nationwide population registries network. These 
registries provide virtually complete coverage of all deceased Dutch citizens.
statistical analyses
Incidence was age-adjusted by direct standardisation to the European Standard Population 
(European Standardised Rates, ESR). Changes were evaluated by calculating the estimated 
annual percentage change (EAPC) and the corresponding 95% confidence interval. A regression 
line was fitted to the natural logarithm of the rates, using the calendar year as regressor variable 
(i.e. y=ax + b where y = ln(rate) and x = calendar year, then EAPC = 100 * (ea – 1)). 
Relative 5-year survival was calculated as an estimation of disease-specific survival by using 
the traditional cohort-based relative survival analysis which reflects survival of cancer patients 
adjusted for survival in a background population with the same age structure.8 Survival was 
evaluated per stage (only first bladder tumour was included) and period of diagnosis.
Treatment was described as percentages per age group (<75 and >=75 years) and period. 
Differences in treatment over time were tested by the Cochran-Armitage trend test. SAS software 
(SAS system 9.2, SAS Institute, Cary, NC) was used to perform the statistical analyses.
resulTs 
incidence
Between 1989 and 2009, 94,412 bladder cancers were diagnosed in the Netherlands, 74,122 
in males and 20,290 in females. Non-invasive (Ta or Tis) bladder cancer was found in 45,433 
patients (48%) and invasive bladder cancer (≥T1) in 48,979 patients (52%). The proportion 
of non-invasive tumours increased from 43% in 1989 to 52% in 2009 (p<0.001).
Non-muscle invasive bladder cancer (Ta, Tis, and T1) was found in 65,898 patients (70%) and 
muscle invasive (≥T2) in 28,514 patients (30%). The proportion of non-muscle invasive 
tumours increased from 67% in 1989 to 72% in 2009 (p<0.001). The age-adjusted incidence 
rate (ESR) for bladder cancer increased for both males and females (figure 1).
Gender and age
Trends in incidence rates (ESR) stratified for age groups are shown in figures 2a, 2b (non-
invasive tumours), 2c and 2d (invasive tumours). The incidence of non-invasive tumours 
increased significantly among males between 60-74 and 75+. In females, incidence significantly 
increased among all age groups (figures 2a and 2b). 
The incidence of invasive bladder cancer decreased significantly in both males between 45-59 
and 60-74 years and was stable in the 75+ age group. In females, the incidence of invasive 
bladder cancer slightly increased in all groups (figures 2c and 2d). During the study period the 
male-to-female ratio for non-invasive tumours decreased from 5.3 to 5.0 and for invasive 
bladder cancer from 5.0 to 4.0.
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stage
Overall, in both males and females the incidence of bladder cancer increased. For men the EAPC 
was 0.3, 95% C.I.; 0.1-0.5%, and for women EAPC was 1.7, 95% C.I.; 1.5-2.0% (p<0.002).
In both males and females there was an increasing incidence of stage 0 (non-invasive) bladder 
cancer (fig 3a,b).
Most striking among the invasive tumours was a decrease in stage II, a decrease in stage I and 
an increase in stage III and IV disease in male patients. In females, a decrease in stage II and 
increase in both stage III and IV disease was found (figures 3a,b).
Treatment 
Patients under the age of 75 years 
The type of treatment according to clinical stage is displayed in table 1. In stage 0 patients, 
local therapy increased, while both cystectomy and radiotherapy decreased. 
In stage I high grade patients local therapy increased and radiotherapy decreased, the 
proportion of cystectomies remained stable at 10%, and did not differ significantly between 
the two periods.
In stage II and III patients, local therapy decreased and the proportion of cystectomies almost 
doubled in stage II patients, radiotherapy decreased in both stage groups.
In stage IV patients local therapy remained stable throughout the whole period, the proportion 
of cystectomies almost doubled and radiotherapy decreased and other therapies (e.g., systemic 
chemotherapy) increased significantly. 
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Figure 1 the age adjusted incidence rate(esr) for bladder cancer between 1989-2009
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Figure 2a  age-standardised incidence rates of non-invasive bladder (ta,tis) cancer in males according to age 
group, the Netherlands 1989-2009
Figure 2b  age-standardised incidence rates of non-invasive bladder (ta,tis) cancer in females according to age 
group, the Netherlands 1989-2009
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Figure 2c  age-standardised incidence rates of invasive bladder cancer  in males according to age group, the 
Netherlands 1989-2009
Figure 2d  age-standardised incidence rates of invasive bladder cancer in females according to age group, the 
Netherlands 1989-2009
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Figure 3a  age-standardised incidence rates (esr) of bladder cancer in males according to stage in the 
Netherlands, 1989-2009
Figure 3b  age-standardised incidence rates (esr) of bladder cancer in females according to stage in the 
Netherlands, 1989-2009
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2Patients above the age of 75 years
The type of treatment according to clinical stage is displayed in table 1b. 
In stage 0 patients, local therapy increased. In stage I high grade patients the proportion of 
cystectomies increased, and radiotherapy decreased. In stage II and III patients the proportion 
of cystectomies doubled. In stage III patients, local therapy decreased significantly. In stage IV 
patients the number of cystectomies doubled and radiotherapy decreased. 
survival
Overall five-year relative survival rate for all bladder cancer patients increased non-significantly 
from 72% (95% CI 70%-74%) to 75% (95% CI  73%-77%). Figure 4 shows that survival rates 
for non-muscle invasive bladder cancer (NMIBC) varied from 96%-77% (grade I non-invasive 
papillary tumours - grade III T1-tumours, respectively). There was hardly any difference 
between males and females for NMBIC (results not shown). The five-year survival rates of all 
muscle-invasive tumours combined were below 50%: 34% in 1989-1993 (95% CI 31-38%) 
and 32% in 2004-2009 (95%CI 29-36%). We found small increases in survival by stage: 46% 
in 1989-1993 to 53% in 2004-2009 for stage II, 33% in 1989-1993 to 34% in 2004-2009 for 
stage III and only 11% in 1989-1993 and 12% in 2004-2009 for stage IV (figure 4). The five-
year survival rates of muscle-invasive tumours for men and women were as follows: 51% and 
48% in stage II, 35% and 28% in stage III and 12% and 8% in stage IV. 
Table 1a treatment of bladder cancer patients younger than 75 according to clinical stage and period of diag-
nosis 
Stage & 
treatment
0
(n=15,927)
I low grade
(n=2,774)  
I high grade
 (n=3,438)
ii
(n=3,795)
iii 
(n=1,544)
iV 
(n=2,184)
% p* % p* % p* % p* % p* % p*
Local therapy
94-98
04-09
94
96
<0.001 91
93
0.03 78
85
<0.001 19
10
<0.001 8.1
4.4
0.01 14
13
0.83
cystectomy
94-98
04-09
1.3
0.4
<0.001 2.2
2.1
0.86 11
10 0.90
44
69 <0.001
49
61
<0.001 14
26
<0.001
radiotherapy
94-98
04-09 
 0.4
 0.1
0.002 1.4
0.4
0.01 5.9
1.1
<0.001 31
18
<0.001 30
19
<0.001 30
13
<0.001
other
94-98
04-09
3.3
3.0
0.23 5.2
4.0
0.22 5.7
3.3
0.01 3.8
2.3
0.05 4.9
7.5
0.09 26
34
0.002
No therapy
94-98
04-09
1.2
0.9
0.18 0.5
0.3
0.26 0.1
0.2
0.86 2.2
0.7
<0.001 7.9
7.9
0.59 16
14
0.14
p*: *cochrane-armitage trend test
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Table 1b treatment of bladder cancer patients aged 75 and over according clinical stage and period 
Stage & 
treatment
0
(n=7,644)
I low grade
(n=1,672)  
I high grade
 (n=2,328)
ii
(n=3,296)
iii 
(n=1,349)
iV 
(n=1,161)
% p* % p* % p* % p* % p* % p*
Local therapy
94-98
04-09
93
96
<0.001 92
95
0.01 87
90
0.05 38
32
0.01 20
10
<0.001 23
25
0.53
cystectomy
94-98
04-09
0.7
0.2
0.03 0.7
0.7
0.88 2.4
3.8
0.02 8.8
20
<0.001 13
20
0.01 3.1
8.3
<0.001
radiotherapy
94-98
04-09 
0.9
0.2
0.004 2.5
0.7
0.02 6.1
2.6
<0.001 42
39
0.16 50
39
0.001 30
22
0.01
other
94-98
04-09
2.8
2.1
0.04 4.2
3.0
0.29 3.7
2.6
0.23 1.9
1.8
0.78 3.3
4.9
0.17 11
13
0.12
No therapy
94-98
04-09
3.0
1.0
<0.001 0.8
0.3
0.28 1.1
0.7
0.39 9.5
6.7
0.002 14
26
<0.001 33
33
0.25
p*: *cochrane-armitage trend test
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Figure 4  relative 5-year survival of patients with bladder cancer according to stage and period of diagnosis, 
the Netherlands, 1989-2009
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2discussion
Gender, age and stage-specific incidence
The incidence of non-invasive bladder cancer almost doubled in both males and females. Others 
also found an increasing incidence of non-invasive bladder cancer.9 Although one would expect 
a decrease in incidence of bladder tumours in men due to the decreasing prevalence of smoking 
an increase in incidence stratified for age group was seen in non-invasive tumours, both in 
males (75+) and in females (60-74, 75+). In females the incidence increased as expected 
because of the increasing prevalence of female smokers. In 2010, smoking prevalence was 
almost equally distributed; 28% in males and 26% in females. Smoking as a risk factor in the 
development of bladder cancer is not as strong as in lung cancer. 
For invasive bladder cancer incidence rates remained stable in males and slightly increased in 
females. Earlier diagnosis of non-invasive tumours might be an explanation for this observation, 
possibly due to increased patient awareness of the signs and symptoms of bladder cancer. More 
adequate treatment of non-invasive tumours by means of intravesical chemotherapy or 
immunotherapy instillations and better transurethral resection techniques (photodynamic 
diagnosis (PDD) and more re-resections after initial TURT) might have contributed to the 
prevention of invasive tumours following non-invasive tumours. Unfortunately, this could not 
be evaluated because only the first bladder tumour was recorded in our registry. 10,11 Females 
present with bladder cancer at higher stages, as already described by others.12,13 We found a 
decrease in the incidence rate of stage II tumours and an increase in stage III and IV tumours 
in both sexes. These shifts are probably due to stage migration caused by improved imaging 
modalities as well as an increased proportion of patients undergoing cystectomy. In our study, 
cystectomy resulted in pathological upstaging in 12% of clinical stage III and even 23% in 
clinical stage II. These percentages are in accordance with recent literature.14 Data from the 
Florida cancer data registry also showed a decreased incidence of localized disease (stage I 
and II) and decreased incidence of advanced bladder cancer (stage III and IV) in both sexes.9
Treatment
In muscle invasive disease standard therapy is radical cystectomy, but even in experienced 
hands, this procedure has a high morbidity.15 In the past, primary radiotherapy was often chosen 
as an alternative in patients above the age of 75 years.
In an earlier study of bladder cancer patients in the Greater Amsterdam region (population 
3.0 million) we found that only 30% of stage II or III patients under the age of 75 years was 
treated with cystectomy.16 In this study both patients under and above 75 years with stage II or III bladder cancer were treated with cystectomy more often at the cost of primary 
radiotherapy. The reasons for this shift are not completely clear.17 In the most recent European 
guidelines radical cystectomy as curative therapy is considered standard of care.18 Cystectomy 
is associated with the greatest risk reduction in disease-related and non-disease related death 
even in patients older than 80 years.19 Declining complication and perioperative mortality rates 
after cystectomy even in patients above 75 years might be another reason.20-22 Furthermore, 
the rise of orthotopic continent ileal reservoirs providing better quality of life might have 
contributed to the shift in this age group.22,23
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survival 
In stage 0 patients survival was below 100% because the stage of the first tumour was recorded 
and used for survival analysis. A small percentage of patients that progressed to invasive disease 
after a non-invasive tumour were grouped according to the first tumour and had a poorer 
survival as expected based on their first tumour. Furthermore, survival in patients with NMIBC 
that progresses to muscle invasion is worse as compared to primary muscle invasive 
patients.24,25
Despite the increase of cystectomies in patients with muscle invasive bladder cancer overall 
survival did not increase statistically significant. An explanation for this observation is that 
25-40% of patients have lymph node metastases or occult haematogenous dissemination at 
the time of cystectomy and have a high chance to develop a local or distant recurrence.The lack of improvement in survival is universal as shown by hospital and population based 
studies.26 The only improvement in survival (for muscle invasive disease) was achieved by the 
combination of neoadjuvant chemotherapy and cystectomy resulting in a modest 5% 5-year 
survival benefit.27 
The increased survival of stage II patients may be the result of the “Will-Rogers” phenomenon.28 
Due to better imaging modalities, more cystectomies and more extensive lymph node 
dissections, stage specific survival seems improved but in fact this is not the case because 
overall survival remains unchanged.28,29 It remains an enigma why the stage specific survival 
of women is worse than for men.12
Differences in staging and treatment strategies make it difficult to compare survival rates 
between nations. For example, the difference in treatment policies between the US and the 
Netherlands is illustrated by the following numbers: in 1993, the US patients with stage II or 
III were treated with cystectomy in one third and half of the cases, respectively.13 In the 
Netherlands, this figures were 28% for stage II and 32% for stage III.30
The Surveillance, Epidemiology, and End Results (SEER) program is a population-based cancer 
registry in the US which covers 10% of the population of the United States. The five year overall 
survival rates for 1990 to 1999 were: 97%, 65%, 56%, and 22% for stages I to IV. The National 
Cancer DataBase (NCDB), which covers about 75% of all newly diagnosed cancers in the US, 
published survival figures for all bladder cancer cases diagnosed in 1998 and 1999 (70,310 
patients). Stage specific 5-year survival was 72%, 62%, 39%, 28%, and 12% for stages 0 till IV, 
respectively. Our rates were 94%, 86%, 53%, 34%, and 12%, respectively. 
Others already described better survival rates comparing SEER patients with those from the 
Netherlands.12 However, our survival rates for stages I till IV are in between both US databases. 
For stage 0 our survival rates are better than the NCDB rates. An explanation for these 
differences might be the differences in stage classification and staging procedures and treatment 
between the US and the Netherlands. For other types of cancer a better survival in the US is 
also observed, reasons for this difference are unclear.
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2conclusions 
An increased incidence and proportion of non-invasive bladder cancer was observed in the 
Netherlands. Whether this is a true rise in incidence or the result of earlier diagnosis because 
of increased patients’ and physicians’ awareness is not clear. Despite decreasing numbers in 
male smokers and increasing numbers in females, the male to female rate of bladder cancer 
only slightly decreased. Stage migration in muscle invasive bladder cancer may have resulted 
in more stage III and IV and less stage II probably due to better imaging, more cystectomies, 
and nodal staging dissections. This is also reflected in a non-significant improved survival rate 
for stage II. Muscle invasive disease remains a lethal condition for the majority of patients and 
it is a sobering fact that no change in overall survival was observed despite the increasing 
number of cystectomies in stage II and III disease.
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Purpose
To determine the difference in survival after cystectomy between patients presenting with 
primary muscle infiltrating bladder cancer and patients with progression to muscle infiltration 
after treatment for initial non muscle invasive bladder cancer (NMIBC). 
Patients and Methods 
We retrospectively analyzed the files of 188 patients who underwent cystectomy for transitional 
cell carcinoma between 1987 - 2005. Two groups were defined: patients presenting with muscle 
invasive tumours and those progressing to muscle invasion after initial treatment. This second 
group was further divided into low-intermediate and high risk according to the EAU grouping 
for NMIBC.
Results
The 5-year disease specific survival (95% confidence intervals) for all patients was 50%(42%-
59%); 49%(40%-60%) in the primary muscle infiltrating group and 52%(37%-74%) in the 
progressive group (p=ns). The 5-year disease specific survival in the progressive group 
according to EAU risk groups was 75%(58%-97%) for the initially diagnosed low-intermediate 
risk tumours and 35%(17%-71%) for the initially diagnosed high risk tumours (p= 0.015). 
The percentage of patients with non-locally confined tumours (pT3/4-N0 // any pT-N+) was 
31% // 45% and 24% // 46% in the primary muscle infiltrating and progressive group, 
respectively.
Conclusions
Despite close observation of patients treated for non muscle invasive bladder cancer, the sur-
vival of patients who progress to muscle invasion is not better than survival of patients pre-
senting with primary muscle infiltrating cancer. Patients with high risk non-invasive tumours 
(EAU risk categories) who progress to muscle invasive disease have a worse prognosis com-
pared to patients with low or intermediate risk tumours.
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3inTroducTion
Non muscle invasive bladder cancer (NMIBC) comprises of a heterogenic group of tumours, 
with variable biological behavior and malignant potential. The probability to progression to 
muscle invasion varies from 6%-48%.1 Identifying the patients in whom NMIBC will progress 
despite bladder sparing therapy is a major challenge. The 2006 EAU guidelines on bladder cancer 
defined three risk groups for NMIBC: a low-risk group (single, low grade (G1), non-invasive (Ta) 
lesion smaller than 3 cm); a high risk group (lamina propria invasion (T1), high grade (G3), 
multifocal or highly recurrent, or CIS) and an intermediate group with all other non muscle 
invasive tumours (e.g. Ta-T1, G1-G2, over 3 cm ).2 In low risk NMIBC, a bladder sparing regimen 
is uniformly advised, consisting of transurethral resection (TUR) followed by a single immediate 
instillation of intra-vesical chemotherapy. High risk disease is usually treated with TUR followed 
by intra-vesical BCG. The undisputable indication for cystectomy is histological evidence of 
muscle invasion during follow-up. We hypothesized, that the intensive monitoring of patients 
with NMIBC during bladder sparing management would lead to an early discovery of muscle 
invasion with consequently better survival than patients presenting initially with muscle 
invasion. To test this hypothesis, we compared survival in patients presenting with NMIBC that 
progressed to muscle invasive disease with patients presenting with primary muscle invasive 
bladder cancer, all treated by cystectomy and regional lymph node dissection. 
 
PaTienTs and meThods
preoperative assessment and patient selection
Between 1987 and 2005, 286 patients underwent cystectomy for transitional cell carcinoma 
(TCC) at our institute. Being a tertiary referral centre, patients were referred after diagnosis 
and/or treatment at other hospitals. Reasons for referral were: NMIBC progressing to muscle 
invasive disease or muscle invasive disease at first diagnosis. Data from referring hospitals 
were reviewed for date of initial diagnosis of bladder cancer and follow-up until referral. Forty-
four patients presented with high risk non muscle invasive urothelial cancer treated with 
cystectomy before muscle invasion and were excluded from analysis. Four patients were 
excluded from analysis because of incomplete data. Another 50 patients were excluded from 
analysis as they underwent salvage cystectomy after brachytherapy or external beam 
radiotherapy (EBRT). They have been reported earlier.3 The remaining 188 patients were 
divided into two groups based on initial presentation. We distinguished a primary muscle 
invasive group: patients with muscle invasion at first presentation (pT≥ 2) and a progressive 
group: patients with a history of non muscle invasive disease progressing to muscle invasion 
after TUR with or without adjuvant intravesical therapy. The progressive patients were stratified 
according to EAU risk-categories after last TUR for NMIBC.2 Patients with muscle invasive 
disease within three months after first TUR for non muscle invasive bladder cancer were 
included in the primary muscle infiltrating group. 
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staging 
Clinical stage was determined by physical examination, TUR, chest x-ray, and pelvic/abdominal 
computerized tomography scan (CT-scan). All stages were converted to the IUCC 2002 TNM 
classification.4 When imaging was highly suspicious for tumour positive lymph nodes, a bilateral 
regional lymph node dissection or fine needle biopsy was performed before cystectomy. 
Otherwise patients underwent regional lymph node dissection at cystectomy. The accuracy of 
clinical staging was assessed by comparing clinical primary stage and pathological tumour 
stage after cystectomy. 
Treatment
Patients with NMIBC were initially treated with TUR at the referring hospitals. Patients with 
muscle-invasion at follow-up were referred for cystectomy and regional lymph node dissection. 
Boundaries of pelvic node dissection until 2000 where: distally the circumflex vein and the 
node of Cloquet, laterally the external iliac artery, medially the bladder and the prostate and 
proximally the hypogastric artery. From 2000 the boundaries were enlarged proximally to the 
crossing of the ureter over the common iliac artery and laterally to the genitofemoral nerve. 
Patients with histologically or cytologically proven positive lymph nodes before cystectomy 
received neo-adjuvant chemotherapy. Since 2000 patients considered high risk for recurrence 
after cystectomy (≥ pT3and/or ≥N1) have been randomized between early or late chemotherapy, 
according to the EORTC-30994 protocol. 
Table1a patients’ characteristics
Progressive Inv.
N=54
Primary Inv.
N=134
Total 
N=188
Significance
Gender male 41 (76%) 103 (77%) 144 (77%) ns
female 13 (24%) 31 (23%) 44 (23%)
Age (years) mean 63 61 61 ns
Clinical T stage
ctis/a/1 n0 - - -
cT2 n0 30 (56%) 53 (40%) 83 (44%) ns
ct3/4 n0 11 (20%) 39 (29%) 50 (27%)
ct any n+ 13 (24%) 42 (31%) 55 (29%)
Path. T stage
ptis/a/1 n0 1 (1%) 1 (1%) ns
pt2 n0 16 (30%) 31 (23%) 47 (25%)
pt3/4 n0 13 (24%) 42 (31%) 55 (29%)
pt any n+ 25 (46%) 60 (45%) 85 (45%)
Focality
single 13 (24%) 81 (60%) 94 (50%) p<0.001
multifocal 40 (74%) 50 (37%) 90 (48%)
unknown 1 (2%) 3 (2%) 4 (2%)
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3statistical analysis
Disease specific survival was defined as time between cystectomy and death of disease or 
treatment or last contact. Survival estimates and 95% confidence intervals were calculated 
using the Kaplan-Meier method. Log-rank tests were used to assess differences in survival 
between the primary muscle infiltrating and progressive group. To evaluate the impact of EAU 
risk stratification on survival we compared the initially low-intermediate non muscle invasive 
with the initially high risk non muscle invasive tumours in the progressive group. A multivariate 
Cox proportional hazards model was constructed to determine the association of gender, 
focality (single or multiple), age, and patient grouping (primary and progressive muscle 
infiltrating) with disease specific survival. A backward stepwise elimination procedure was 
performed to identify factors associated with survival at the 0.05 significance level. The 
association between number of TUR (≤2 TUR and >2 TUR before cystectomy) disease specific 
survival, tumour upstaging after cystectomy was assessed in the progressive invasive patient 
group using a log-rank test and Chi square test. Differences in characteristics of patients in 
Table1b patients’ characteristics progressive subgroups
Low-intermediate 
risk
N=25
High risk
N=29
Significance
Gender male 21 (84%) 20 (69%) ns
female 4 (16%) 9 (31%)
Age (years) mean 62 63 ns
NMIBC Stage
taG1-2 11 -
t1G1-2 14 -
tis - 11
T1g3 - 14
Tag3 - 4
Clinical T stage
  ctis/a/1 n0 - - ns
  cT2 n0 16 (64%) 14 (48%)
  ct3/4 n0 6 (24%) 5 (17%)
  ct any n+ 3 (12%) 10 (34%)
Path. T stage
  ptis/a/1 n0 - - ns
  pt2 n0 8 (32%) 8 (28%)
  pt3/4 n0 7 (28%) 6 (21%)
  pt any n+ 10 (40%) 15 (52%)
Focality
  single 5 (20%) 8 (28%) ns
  multifocal 19 (76%) 21 (72%)
  unknown 1 (4%) 0 (0%)
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progressive and primary muscle infiltrating groups were tested using chi-square, Fisher-exact 
and Mann-Whitney-Wilcoxon tests where appropriate. No imputation of missing data was 
performed. The significance level was set at 0.05 for all tests. 
resulTs 
patient characteristics
134 patients presented with primary muscle infiltrating bladder cancer and 54 patients with 
progressive bladder cancer. The distribution of patient and tumour characteristics between 
these two groups are presented in Table 1a. Mean age at cystectomy was 61 years and the male 
to female ratio was roughly 3:1. The definitive pathological stage of the primary tumour (pT-
stage) was higher than the pathological stage of the TUR specimen in 19% of primary muscle 
infiltrating patients, while 2% had pathological stage lower than clinical stage. This was 26% 
and 0% for the progressive group. Pathological lymph node stage (pN) was higher than clinical 
lymph node stage (cN) in 16% of primary patients and 26% in the progressive group. There 
was no significant difference in stage distribution after cystectomy between both groups. The 
proportion of patients with multifocal tumours was significantly higher in the progressive 
group than in the primary muscle infiltrating group (p<0.001) (see Table 1a). Patients’ 
characteristics and both clinical (NMIBC and muscle invasive stage) and pathological stage for 
the progressive subgroups are shown in table 1b. There was no significant difference in stage 
distribution after cystectomy between both subgroups. Both the definitive pathological stage 
of the primary tumour (pT-stage) and the pathological lymph node stage (pN) were higher 
than in the TUR specimen in 28% (N=7) of the low risk patients, and 24% (N=7) in the high 
risk patients. No patients had lower pathological T or N stage than clinical stage. 
treatment History
A total of 61 patients received neoadjuvant chemotherapy, 46 in the primary muscle infiltrating 
group and 15 in the progressive invasive group. In the primary muscle invasive group 44 achieved 
a complete or partial response to neoadjuvant chemotherapy, in the progressive invasive group 
this was 15. Ten patients received adjuvant chemotherapy, 7 in the primary muscle infiltrating 
group and 3 in the progressive invasive group. There was no significant difference in the number 
of patients receiving either neoadjuvant or adjuvant chemotherapy. In the high- and low-risk 
progressive subgroups, neoadjuvant chemotherapy was given to 4 and 11 patients respectively, 
and adjuvant chemotherapy was given to two and one patients respectively. Again there was no 
significant difference in clinical response to neoadjuvant treatment.
survival
At the time of analysis 89 patients had died, all but twelve of either bladder cancer or treatment. 
The median follow-up after cystectomy was 3.4 years, which was not different between groups. 
The 5-year disease specific survival estimate (95% confidence intervals) for all patients was 
50% (42%-59%); 49% (40%-60%) in the primary muscle infiltrating group and 52% (37%-
74%) in the progressive group (Figure 1a, log-rank, p=ns); stratified by risk group: 75% (58%-
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397%) in the low and 35% (17%-71%) in the high risk tumours (Figure 1b p= 0.015). The 
difference in disease specific survival between muscle invasive and low-intermediate risk 
tumours was not significant (Figure 1c).
Patients with organ confined lymph node negative tumours (pT2N0) had a 5-year disease 
specific survival of 80% (65%-97%) and 93% (82%-100%) for the primary muscle infiltrating 
Figure 1a Disease specific survival curves comparing primary muscle infiltrating and progressive groups (p=ns).
Figure 1b Disease specific survival after cystectomy for muscle invasive bladder cancer comparing low-inter-
mediate and high risk tumours in the progressive group (p= 0.015).
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group and the progressive group respectively (p=ns, Table 2a). Stratified by risk group these 
figures were: 100% and 88% (67%-100%), for the low and high risk groups respectively. (Table 
2a, p=ns). Survival at 5 years of patients with non-organ confined disease and tumour negative 
nodes was: 56% (42%-75%) for the primary muscle infiltrating group and 37% (14%-97%) 
for the progressive group (p=ns, table 2a). Stratified by risk group: 71% (45%-100%) and 0%, 
for the low and high risk groups respectively (Table 2a; p=ns). 
Eighty-five patients had tumour positive lymph nodes after cystectomy: 60 (45%) in the primary 
muscle-invasive group and 25 (46%) in the progressive group. Stratified by risk group: there 
were 10 (40%) in the low risk and 15 (51%) in the high risk subgroup.
The 5 year disease specific survival rates for lymph node positive patients were 28% (17%-
46%) for the primary muscle infiltrating group and 40% (24%-69%) for the progressive group. 
Stratified by risk group: 63% (37%-100%) and 25% (9%-67%), for the low and high risk 
groups respectively. (Table 2a; p=0.04)  In the multivariate analysis gender was significantly 
associated with disease specific survival. Females had a higher risk of dying from disease than 
males (HR=2.16 (1.7-2.8); p=0.0009). Focality, age, and patient grouping (primary vs. 
progressive) showed no significant association with survival. (Table 2b)
Finally, there was no significant association between the number of TUR disease specific 
survival, and upstaging in the progressive group.
Figure 1c Disease specific survival after cystectomy for muscle invasive bladder cancer comparing low-interme-
diate risk tumours in the progressive group and the primary muscle infiltrating group (p= ns).
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3Table2a Disease specific survival according to tumour group 
stratified according to tumour extension
Tumour Group N 5-year DSS % 
(95% C. I.)
Primary muscle infiltrating 134 49 (40 60)
organ confined, N- 32 80 (65-97)
extravesical, N- 42 56 (42-75)
Node positive, n+ 60 28 (17-46)
Progressive 54 52 (37-74)
organ confined, N- 16 93 (82-100)
extravesical, N- 13 37 (14-97)
Node positive, n+ 25 40 (24-69)
Low risk 25 75 (58-97)
organ confined, N- 8 100 (-, -)
extravesical, N- 7 71 (45-100)
Node positive, n+ 10 62 (37-100)
High risk 29 35 (17-71)
organ confined, N- 8 88 (67-100)
extravesical, N- 6 0 (-, -)
Node positive, n+ 15 25 ( 9-67)   
Table2b cox-regression multivariate analysis
hr 95%  ci P
Group progressive 0.97 0.55 - 1.71 0.9
 primary  
Gender male
 female 2.16 1.70 - 2.80 <0.001
age 0.99 0.97 - 1.02 0.5
Focality single 1.23 0.74 - 2.04 0.4
 multi
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discussion
The undisputable indication for cystectomy in patients with NMIBC is progression to muscle 
invasion. Follow up schedules are aimed at the earliest possible detection of progression, 
leading to the best possible survival. In our study all patients were followed up according to 
the EAU-guidelines which in theory should lead to low stage disease at cystectomy.2  
Nevertheless, patients with NMIBC progressing to muscle invasion had no better survival after 
cystectomy than patients with primary muscle invasive bladder cancer. This is in accordance 
to others, while some showed an even worse survival.5-7 These studies suggest that cystectomy 
should ideally be done before any bladder muscle invasion occurs or at a stage when the bladder 
tumour is still locally confined. This notion is not new and has been echoed by those who 
advocate an early cystectomy.
understaging, swift progression and poor survival of the progressive group
What could be the reasons and explanations for these findings? First, standard follow up was 
unable to detect occult progression, exemplified by 26% under staging in non locally confined 
disease and 26% under staging in tumour positive lymph nodes. It is a sobering fact that despite 
close monitoring these figures are not different at all from clinical under staging in patients 
presenting primarily with invasive disease.8 Because our hospital is a tertiary center patients 
with higher stages are referred to our hospital, exemplified by a relatively high incidence (45%) 
of positive lymph nodes after cystectomy in both groups as compared to contemporary cystectomy 
series.8-10 Secondly the swift occurrence of progression, indicated by 24% non locally confined 
disease and 46% lymph node invasion after cystectomy in the progressive group. Most of these 
patients have a history of non muscle invasive disease and are under surveillance for NMIBC so 
one would expect these percentages to be lower than in the primary invasive group. Thirdly the 
poor survival rates of high-risk non invasive bladder cancer progressing to muscle invasion. This 
was significantly worse compared to patients with a low-intermediate-risk tumour (76% versus 
20%). As there was no difference in TNM distribution after cystectomy for both groups this 
difference in prognosis must be explained by other factors, like tendency for early dissemination 
of these high grade tumours. This underlines the poor prognosis of the high-risk group providing 
further weight to arguments for early cystectomy. Five year survival rates of approximately 90% 
have been published  when cystectomy is performed before evidence of muscle invasion.10,11 Our 
study also demonstrates a rather good prognosis for patients with muscle invasive disease after 
cystectomy for locally confined disease. Fourthly the urological community is alert on the high 
risk of progression in patients presenting with T1G3 tumours and the subsequent poor survival.1 
However our study suggests equal (poor) survival rate in high grade Ta-disease.12 In addition we 
find patients with low grade (low or intermediate risk) tumours that have progressed rapidly to 
a locally advanced tumour with lymph node metastases.
the number of prior tur and survival
Analysis of TUR prior to cystectomy did not show survival differences and upstaging in those 
who had less than 2 TUR in comparison to those with more than 2 TUR. This is in contrast to 
a recent study by Wiesner et al. who reviewed the files of 219 patients with non-muscle-
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3invasive TCC that progressed to muscle invasion. They found tumour positive lymph nodes in 
33 patients (15%). The number of TURs correlated with the prevalence of lymph node 
metastases.13 Survival in women stage for stage is less than in males. Findings that are 
supported by others.14
optimal timing of cystectomyHow can we solve the dilemma of too early cystectomy (increase of survival but at the cost of 
too many bladders removed) and too late cystectomy (jeopardizing survival of the patient)? 
In clinical practice, the heart of the matter lies in defining progression and the early notion of 
therapy resistance. In high risk disease the above notion has led to a “change of paradigm”, 
advising early cystectomy before histological proof of muscle invasion.15 Failures of BCG therapy 
in high risk disease are now defined as progression to higher grade or T-category, the appearance 
of carcinoma in situ during therapy and a recurrence at both 3 and/or 6 months. In low-
intermediate risk disease, the indication for cystectomy has traditionally been histological 
proof of muscle invasion. In this risk category the challenge is to better define failure, preferably 
before muscle invasion. The EORTC risk tables, based on six tumour characteristics (number 
of tumours, tumour size, prior recurrence rate, T category, carcinoma in situ, and grade) are 
currently the most accurate tool to predict the risk of recurrence and progression in non muscle 
invasive bladder cancer patients.1,16
The major limitations of our study are the retrospective character, the potential selection bias, 
and the limited number of patients. Our patients with progressive non muscle invasive bladder 
cancer come from a large undefined pool of patients. Therefore our results can only be used 
as an illustration of the fate of patients progressing to muscle invasion. It is our belief that follow-up should be aimed at the detection of failures at the earliest possible moment, preferably 
before muscle invasion has occurred. In this respect, identifying patients in whom initial therapy 
is not successful is the major challenge.
conclusions
Despite close observation of patients treated for NMIBC, survival in patients who progress to 
muscle invasion is not better than patients presenting with primary muscle infiltrating cancer. 
Patients with high-risk NMIBC who progress to muscle invasive disease before cystectomy 
have a worse prognosis compared to patients with low-intermediate risk NMIBC who progress 
to muscle invasion. The number of patients with locally advanced and lymph node positive 
disease was unexpectedly high in the progressive group, underlining the need for improved 
identification of the patient in need of early cystectomy. For now, we advocate active restaging 
(re-TUR) during conservative management of non muscle invasive bladder cancer. The indication 
for cystectomy should be at a stage preferably before histological proof of muscle invasion, 
EORTC tables can be helpful. T-stage and grade progression are probably just as important 
signs for early cystectomy as the traditional criterion of muscle invasion.
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lisT of abbreviaTions
NMIBC: Non Muscle Invasive Bladder Cancer
HR:   Hazard Ratio
CIS:   Carcinoma in situ
TUR:  Transurethral resection
BCG:  Bacillus Calmette Guérin 
TCC:  Transitional Cell Carcinoma
EBRT:  External Beam Radiotherapy 
IUCC: International Union Against Cancer 
MMC: Mitomycin C
EORTC: European Organisation for Research and Treatment of Cancer 
EAU: European Association of Urology
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long term survival after combined modality treatment 
in metastatic bladder cancer patients presenting with 
supra-regional tumour positive lymph nodes 
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Purpose
To evaluate if combined treatment should be offered to bladder cancer patients presenting 
with supra-regional lymph node metastases only and a clinical complete or partial response 
after chemotherapy. 
Patients and methods
We identified 14 patients with supra regional lymph node metastases out of 394 patients with 
transitional cell carcinoma (TCC) treated in our institute with cystectomy and regional and 
supra-regional lymph node dissection between 1987-2007. Prior to cystectomy neoadjuvant 
chemotherapy had been given. The patients received a total of four cycles of platinum based 
chemotherapy. 
Results 
Five patients had a CR, nine patients had a PR after neoadjuvant chemotherapy. Histopathological 
proof of complete response in the bladder was confirmed in all five cases. One of these five 
patients had a CR in the bladder but pelvic lymph nodes still contained vital tumour. Five 
patients had no tumour in the lymph nodes, whereas four had tumour in the lymph nodes. 11 
patients died due to bladder cancer, seven of them within one year after cystectomy. The 3- and 
5-year disease-specific survival rates were 36%(95% C.I.:10%-60% and 24% (95% C.I.: 0%-
49%). Mean follow-up was 2,5 years. 
Conclusions
Combination therapy consisting of neo-adjuvant chemotherapy and surgery in selected patients 
with tumour positive supra regional lymph nodes only can result in durable long term survival 
rates (24% 5-year survival). Response evaluation after neoadjuvant chemotherapy might play 
a decisive role in the selection of patients undergoing subsequent surgical removal of all known 
tumour sites.
4 |  supraregional lymphnode metastases
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4inTroducTion
Bladder cancer patients with lymph node metastases outside the true pelvis (regional lymph 
nodes: the nodes below the bifurcation of the common iliac arteries) are classified within the 
TNM system as distant metastases. In general, patients with metastatic disease are treated with 
palliative intention. A small proportion of bladder cancer patients presents with supra-regional 
lymph node metastases only( positive para-aortic and/or para-caval lymph nodes) without 
synchronous hematogenic metastases. It has been our policy to treat these patients with 
platinum based chemotherapy followed by surgical removal of all tumour bearing sites in those 
patients showing no sign of progression after chemotherapy response evaluation. The purpose 
of this study was to asses the results of combination therapy with neoadjuvant chemotherapy 
and surgery in bladder cancer patients presenting with supra-regional metastases only.
PaTienTs and meThods 
preoperative assessment and patient selection
Between 1987 and 2007, 394 patients with transitional cell carcinoma (TCC) were treated with 
cystectomy, regional and supra regional lymph node dissection at the Netherlands Cancer 
Institute-Antoni van Leeuwenhoek Hospital. 14 patients presented with para-aortic / para-caval 
lymph node metastases without evidence of other distant metastases. Diagnostic workup 
consisted of physical examination, transurethral resection, chest x-ray and pelvic abdominal 
computerized tomography. All stages were converted to the 2003 TNM classification of the 
International Union Against Cancer.1
combination therapy
12 patients underwent fine needle aspiration biopsy of a supra regional lymph node and two 
patients underwent regional lymph node dissection at other hospitals before referral. The 
selection criteria to perform surgery were apart from a complete or partial clinical response 
after chemotherapy, good performance status to undergo surgery. In total, 14 patients received 
neoadjuvant chemotherapy followed by complete retroperitoneal lymph node dissection, 
regional lymph node dissection, cystectomy and urinary deviation (table 1). 
Patients treated with MVAC received either classic 
MVAC (six cycles) or high-dose intensity MVAC (HD-
MVAC) (four cycles). Details are reported in the series 
by Nieuwenhuijzen et al.2 In patients with renal 
function impairment, a combination of Gemcitabin and 
Carboplatin (GC) (four or five cycles), was given.
response evaluation
Response was evaluated using RECIST; after every two 
cycles of chemotherapy by cystoscopy, abdominal/
pelvic imaging and chest X-ray. Complete response was 
Table1  patient characteristics
male 11
 female 3
 median age(years) 58
 uIcc tumour classification
     T2 6
     T3 2
     T4 6
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defined as complete disappearance of disease on physical examination, imaging and cystoscopy. 
Partial response was defined as a decrease of more than fifty percent of the summed products 
of all diameters of all measured lesions, without simultaneous increase in size of any lesion or 
appearance of new lesions.3 
complications
Early (post-operative) complications were defined as those occurring in-hospital or within 30 
days after surgery in case of shorter stays. Thereafter complications were classified as late.
oncological outcome
Survival estimates were calculated using the Kaplan-Meier method. Disease specific survival 
was defined as time from cystectomy until death from urothelial cancer or last contact.
resulTs
chemotherapy
Classic MVAC was given to eight patients, five patients received HD-MVAC and one patient 
received GC. 
clinical and pathological response
In five patients there was a complete clinical response, in nine patients there was a partial 
response after neoadjuvant chemotherapy. After surgery, histopathological proof of complete 
remission in the bladder was confirmed in all five cases. One patient still had tumour in the 
pelvic lymph nodes, in four others no tumour was present after chemotherapy. No tumour 
could be detected in the bladder specimens in three out of nine patients with a PR. Five patients 
had no tumour in the lymph nodes, whereas four had tumour in the lymph nodes. 
complications
Seven patients developed early post operative complications: wound infection (4), sepsis (1), 
one abcess(1) and hematothorax(1). Late complications were seen in five patients, ureteral 
stenosis(2) , lymphocele(1), urinary tract infection(1), ileus(1).
recurrences and survival
Ten out of 14 patients had a distant recurrence of disease in one or more regions: distant lymph 
nodes (3), brain metastases (2), liver metastases (3), abdominal metastases (2), and lung 
metastases (1). Of these ten patients all but one died within 16 months after cystectomy. The 
remaining patient died after 40 months (Table 2). Mean follow-up was 2,5 years. The 3-and 
5-year disease-specific survival rates were 36%( 95% C.I.:10%-60%) and 24% (95% C.I.: 0%-
49%), the median survival was 10.1 months (95% C.I.:5.60-13.8) (Figure 1).
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discussion
Patients presenting with tumour positive regional lymph nodes have a 5-year disease specific 
survival of 20-40% after surgery alone depending on primary tumour stage and number of 
lymph nodes involved.2,4
the role of combination therapyIn an attempt to improve survival rates, patients with positive lymph nodes are treated with 
Cisplatin based combination chemotherapy. Response to chemotherapy is often used as a 
selection criterion to continue with surgery after chemotherapy. In this small series, there was 
no statistically significant difference in survival between clinical complete and partial responders 
(after chemotherapy), which is to be expected given the small numbers. In a previous report on 
combined modality treatment with surgery, 5-year survival rates of pathological complete or 
partial responders were 42% and 19% respectively.2 The same treatment strategy is applied to 
patients with supra-regional lymph node metastases only, provided they are amenable to 
complete surgical removal. This strategy has been described by others.5,6
Table 2  treatment and outcome according to pathological response in 14 patients with urothelial cancer and 
positive para-aortic and/or para-caval lymph nodes
Chemotherapy No. of Patients Outcome
mVac/ hd mVac pCR (n=4) pPR (n=10)
Neoadjuvant 13 2 patients dead at;
3 and 96 months
8 patients dead at;
4,5,6,8,10,10,12,39 months
2 patients alive at 
16 and 130 months 
1 patients alive at 
23 months
Gc pCR pPR
Neoadjuvant 1 1 patient dead at 6 months
Figure 1  survival after cystectomy in 14 urothelial cancer patients with para-aortic and/or para-caval lymph 
node metastases treated with combination therapy.
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Sweeney et al. described a group of 11 patients with biopsy proven positive retroperitoneal 
lymph nodes and no evidence of visceral metastases. All patients showed a significant response to chemotherapy and underwent cystectomy and bilateral retroperitoneal lymph node 
dissection. Four year disease specific and recurrence free survival rates were 36% and 27%, 
respectively. Our results are in agreement with this report. Viable tumour in no more than two 
lymph nodes correlated with greater disease specific and recurrence free survival.7 In this small 
series, in two out of three patients that were alive pathological examination confirmed complete response after chemotherapy in both bladder and lymph nodes, the other still had tumour in 
the bladder and lymph nodes. In two patients that reached a survival of more than three and 
six years, the first still had tumour in the bladder and lymph nodes, the other had no tumour 
in both bladder and lymph nodes. In the patient that survived more than 6 years after 
cystectomy, no tumour was present in both bladder and lymph nodes after chemotherapy.  
Since a 5-year survival of 24% can be reached, a treatment offer should be made to patients 
presenting with tumour positive supra-regional lymph nodes without evidence of visceral 
metastases. From these small patient series one could intuitively deduct that surgery might 
play a role in eliminating residual disease after chemotherapy thus leading to a complete 
surgical response. Moreover complete removal of all tumour bearing sites is the most adequate 
method of response evaluation. This strategy is not uncommon in surgical oncology (e.g. 
testicular cancer in urology). The question remains whether surgical removal is truly 
advantageous. This question can only be answered within the framework of a randomized 
study, comparing chemotherapy with or without surgery. In the absence of such a study it is 
reasonable to offer combined modality treatment to patients presenting with supra regional 
lymph nodes amenable to complete surgical removal. Response to neoadjuvant chemotherapy 
is then used as a selection criterion for surgery. Patients not responding to chemotherapy 
should probably not be subjected to surgery as their prognosis is dismal on short term. 
tNm classification
The TNM classification reflects the poor prognosis of metastasized patients. However, when 
combination therapy is given to this selected group of patients, 3-year survival is achieved by 
a higher percentage of patients compared to patients with distant metastases.8
Hall and Prout already proposed an alternative classification system in 1990. Patients with 
positive para-aortic lymph nodes should be classified as N
3
 and not as M
1
. This should be 
contemplated in the light of these and previous results of combination therapy.7,9
conclusions
An attempt can be made to treat patients with supra-regional tumour positive lymph nodes 
without other distant metastases with combination therapy of chemotherapy and surgery. 
Patients achieving a partial or complete remission after chemotherapy could undergo 
subsequent surgery aiming at removing all cancer bearing sites. In this series, 24% of patients 
survive five years after combination therapy. 
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long-term survival after sequential chemoradiation for 
limited disease small cell carcinoma of the bladder
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Purpose 
To evaluate response, time to progression and survival of patients with limited disease (LD) 
small cell carcinoma of the bladder (SCCB) treated with sequential chemoradiation in analogy 
to LD small cell lung cancer (SCLC).
Patients and Methods
Of 42 patients with SCCB treated at our institution between 1993 and 2007, 17 with LD SCCB 
treated with chemoradiation were identified and retrospectively analysed. LD was defined as 
any pT, cN0-1, cM0. SCCB was defined according to WHO criteria. All patients had platinum-
based chemotherapy after transurethral resection (TUR)  prior to local radiotherapy with 
56-70 Gy.
Results
Sixteen patients were male, 1 female. Median age was 62 years. Median overall survival is 32.5 
months. All had a clinical local response (15 CR, 2 PR). Systemic progression occurred in 8 (47 
%) with a median time to progression of 6 months (range 1-16 months), 8 died with a median 
survival of 17.5 months. Currently, 7 are free of disease (FOD) including 2 at 80 and 87 months. 
Four (23.5 %) had a local recurrence as late as 43 and 50 months; 3 required a salvage 
cystectomy. 
Conclusions
Clinical results of sequential chemoradiation for LD SCCB are comparable to contemporary 
series of LD SCCB treated with cystectomy and upfront or adjuvant chemotherapy. Long-term 
survival of more than 5 years after chemoradiation can be achieved. The risk of local recurrence 
is lower than reported, but late recurrences occur. These data support bladder sparing with 
systemic chemotherapy and local control by radiotherapy in this aggressive disease.
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Small cell carcinoma accounts for a fifth of lung cancer cases but is rarely observed in 
extrapulmonary primaries.1 The first case of primary small cell bladder cancer (SCCB) was 
reported in 1981.2 Since then some 300 cases diagnosed according to World Health Organization 
(WHO) criteria 3 have been published in small series and case reports.4-13   
The prognosis of SCCB is poor and only cisplatin-based chemotherapy has been associated 
with significantly improved survival.8,14,15 Local therapy often fails due to micrometastases at 
diagnosis, but cases have been reported in which locally confined disease was curable.9 The 
low incidence of SCCB precludes prospective randomized trials and the optimal therapeutic 
strategy is still unknown. Cystectomy with neoadjuvant and adjuvant chemotherapy has been 
propagated 10,15 as well as combinations of chemotherapy with transurethral resection (TUR), 
partial cystectomy and radiotherapy.7-9 In contrast, SCLC, which shares many clinicopathological 
features with SCCB, is far more common. A clinically relevant two-stage system of limited and 
extensive disease is widely used to determine prognosis and treatment. A consensus of 
combination chemotherapy and radiotherapy emerged, depending on the extent of the 
disease.16-18 Due the dismal prognosis of SCCB an organ sparing treatment strategy of 
chemotherapy and radiotherapy in analogy to its pulmonary counterpart depending on a simple 
two stage system is an attractive concept. Here we retrospectively evaluated clinical and 
oncological outcome in a series of patients with limited-disease SCCB, who were treated with 
sequential chemoradiation.
PaTienTs and meThods
Between 1993 and 2007, 42 patients with a histopathological diagnosis of primary SCCB based 
on the WHO criteria were treated at our institution.19 The tumours were staged according to 
the 2002 TNM classification. In analogy to SCLC, patients with any local stage, no distant 
metastases and involvement of maximally one locoregional lymphnode less than 2 cm on 
imaging (pTx cN0-1 cM0) were defined as having limited disease (LD), all others (Tx Nx M1/ 
Tx N2-3 M0) as extensive disease.20 Patients with LD were offered a bladder sparing approach 
with systemic chemotherapy followed by external beam radiotherapy with curative intent. 
Seventeen patients were identified and received sequential chemoradiation for LD-SCCB and 
their medical records were retrospectively analysed. The other 25 patients were treated as 
follows: ten patients had distant metastases (extensive disease) and were offered chemotherapy 
only. In 7 patients SCCB was not known at the time of treatment, revealing SCCB in the 
cystectomy specimen in addition to the earlier diagnosis of urothelial carcinoma at TUR. These 
patients had LD but did not receive adjuvant chemotherapy as this was no policy at our 
institution. Two patients with known LD-SCCB underwent cystectomy because either 
radiotherapy (prior prostate cancer radiotherapy) or chemoradiotherapy (large bleeding 
tumour with renal dysfunction) could not be applied. Four patients with LD-SCCB and a median 
age of 80 years (range 79-87 years) did not receive chemotherapy due to age-associated 
comorbidity and were treated with radiotherapy only. One patient refused any treatment. 
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chemoradiation
Chemotherapy for LD-SCCB would follow the accepted protocols for SCLC, with the exception 
that patients with < 50 % SCCB in combination with TCC in tumourtissue obtained at TUR 
received 4 courses methotrexate 30 mg/m2, vinblastine 3 mg/m2, doxorubicine 30 mg/m2 and 
cisplatin 70 mg/m2 (M-VAC). Over the course of 10 years the cisplatin-based SCLC-regimen 
changed. Four courses ifosfamide 1.2 g/m2 (maximum 1.75 g), VP-16 (etoposide) 75 mg/m2 
and cisplatin 20 mg/m2 (VIP) day 1-4, repeated after 21 days were later replaced by 4 courses 
cisplatin 75 mg/m2 day 1 with etoposide 100mg/m2 i.v. (CE) day 1-3, repeated after 21 days. 
Patients with contraindications for cisplatin but a PS WHO ≤ 2, received 5 courses 
cyclophosphamide 1.0 g/m2 (day 1), doxorubicine 45 mg/m2 (day 1) and etoposide 100 mg/m2 (day 1-3) (CDE) repeated after 21 days. Later that regimen was changed to carboplatin AUC 
5 (day 1) with etoposide 100mg/m2 i.v. (CaE) day 1-3, repeated after 21 days. 
Radiotherapy was applied using 8-18 MV photons with a three or four-field technique. The 
mean dose was 60 Gy varying from 56 to 70 Gy. The target area consisted of  the bladder and 
the tumour. In case the total dose was 70 Gy (n=3), 50 Gy was given to bladder and tumour 
with a 20 Gy boost to the bladder tumour area only.
assessment of tumour stage and response
All patients were staged with CT scan of abdomen, chest x-ray, bone scan, laboratory evaluation, 
cystoscopy and cytology before chemotherapy, repeated in three- to six-monthly intervals 
during follow-up. RECIST criteria were used to assess tumour stage, local response to 
chemotherapy and potential systemic progression. Local response in the bladder was clinically 
assessed during and after chemotherapy by cystoscopy, cytology and CT scan and was repeated 
at three-monthly intervals following radiotherapy. Best objective response was assessed 
clinically by cystoscopy and CT scan after subsequent radiotherapy, as the termination of the 
combined therapy was considered the end of definitive treatment. Progression free survival 
was therefore time from first diagnosis of best response after termination of radiotherapy until 
first documentation of progression. Overall survival was time from start of treatment to either 
death or last follow-up. Because the TUR had not been complete in all patients the start of 
treatment was defined as start of systemic chemotherapy. A pathological assessment of response 
by TUR was exclusively performed in case of any finding at cystoscopy suspicious for 
macroscopical residual disease or suspicious cytology following chemotherapy and radiotherapy 
or during follow up.
resulTs
Sixteen patients were male, 1 female. Median age was 62 years (range 44-78 years). All were 
defined as having LD-SCCB and were cN0 without evidence of lymphnode involvement on 
imaging. Fourteen patients had a local pT2 stage, 2 a pT3 and 1 a pT4a. The  survival estimate 
is 56% at two years (C.I. 0.26-0.96), 47 % at three years (C.I. 0.21-0.72) and 36 % at 5 years 
(C.I.0.14-0.61). Median overall survival (OS) is 32.5 months (range 4-87 months). Eight patients 
are still alive: Currently, 7 are free of disease with a median of 49 months (range 16-87 months), 
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5including 2 at 80 and 87 months. 9 patients died: 8 died of disease with a median survival of 
17.5 months (range 5-52 months); 1 died due to chemotherapy-related pancytopenic septicemia 
during the 3rd course (patient no. 4, table 1). Only one patients is alive with disease with bone 
metastases at 21 months.
All patients had a clinical local response (15 CR, 1 PR) though initial TUR was macroscopically 
not complete in four patients. The local PR occurred in the patient who died of pancytopenic 
septicemia. Systemic progression occurred in 8 (47 %) with a median time to progression of 
6 months (range 1-16 months). Sites of systemic progression were liver in 3, lung in 2, bone 
in 5 and brain in 1. Four patients experienced a local recurrence (23.5 %, C.I. 0.06-0.49 ): One 
patient after 24 months, with a surgical CR of 11 months after salvage cystectomy and disease 
related death at 52 months. The two other patients had a locally confined recurrence after a 
CR of 43 and 50 months, respectively, and are currently FOD after a salvage cystectomy with 
neobladder and ileal conduit. Histology of the local recurrence revealed pT2 transitional cell 
carcinoma in 2 and pure SCC in one patient. In one patient a carcinoma in situ was diagnosed 
after a CR of 18 months. He is currently FOD with an OS of 27 months after a TUR and BCG 
bladder instillations.
Table 1  characteristics of patients with sccB treated with sequential chemoradiation
No. sex age
(y)
TNm
(clinical)
Chemo-
therapy
PFs
(months)
Site of
progression
Additional
therapy
Overall Sur-
vival (months)
Histology
1 male 78 T4an0m0 cDe (5) 3  liver, lung none 13 dod scc
2 male 55 T2n0m0 VIp (4) 84+ 87+ fod  scc
3 male 58 T2n0m0 VIp (4) 3 liver none 16 dod scc,tcc,aD,sQ
4 male 59 T2n0m0 mVac (3) - 4 dood scc,tcc,aD
5 male 73 T3n0m0 cDe (5) 24 local (tcc) salvage cp 52 dod scc
6 male 63 T2n0m0 mVac (4) 44 local (scc) salvage cp 53+ fod scc,tcc 
7 male 52 T2n0m0 mVac (4) 3 bone none 11 dod scc,tcc
8 male 76 T2n0m0 VIp (3) 78+ 80+ fod scc,tcc,aD
9 male 54 T2n0m0 cDe (4) 15 brain cae (4) 29 dod scc,tcc
10 male 66 T3n0m0 ce (4) 45 local (tcc) salvage cp 49+ fod scc
11 female 44 T2n0m0 ce (4) 13 liver,lung,bone none 21 dod scc,aD,sQ 
12 male 62 T2n0m0 ce (4) 16 bone 21+ aWd scc,tcc
13 male 71 T2n0m0 cae (4) 14+ 18+ fod scc
14 male 74 T2n0m0 cae (4) 18 local (cIs) bcg 27+ fod scc,tcc
15 male 58 T2n0m0 ce (4) 13+ 16+ fod scc
16 male 58 T2n0m0 ce (4) 9 bone none 19 dod scc
17 male 73 T2n0m0 ce (3) 1 bone none 5 dod scc,tcc 
PFS progression free survival; (y) years; CP cystoprostatectomy; DOD dead of disease ; FOD free of disease ; 
DOOD dead of other disease; AWD alive with disease; SCC small cell carcinoma; TCC transitional cell carci-
noma; AD adenocarcinoma; SQ squamous cell carcinoma; CIS carcinoma in situ; BCG topical bladder therapy 
with Bacille Calmette Guerin; + ongoing; for abbrevations of chemotherapy see text; (n) number of courses 
given. 
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Chemotherapy consisted of  MVAC in 3, VIP in 3, CE in 6, CDE in 3 and CaE in 2.  Seven (41 %) 
had pure SCC, 10 (59 %) mixed tumours with urothelial carcinoma in all and further components 
of adenocarcinoma in 4 and squamous cell in 2. 
discussion 
Sufficient data demonstrate a similarity of the clinical course of SCCB and SCLC.12 In SCLC 
survival increased only after the introduction of multi-agent chemotherapy regimens. Most of 
the benefit occured in patients less than 65 years of age.21 The definition of limited-SCLC takes 
early metastasis into account with tumour confined to the hemithorax of origin, the mediastinum 
or the supraclavicular lymph nodes. All patients with tumour beyond these confinements have 
extensive disease. The current treatment of limited-SCLC comprises a combination of cisplatin 
and etoposide plus chest irradiation preferably during the first or second cycle of 
chemotherapy.18,22,23 A prophylactic cranial radiation follows in patients with a complete 
response. This strategy may result in median survival of 18 to 24 months and 50% 2-year 
survival. 18,22,24 Due to early micrometastasis the overall survival of SCLC remains poor with 5% 
to 10% after 5 years.25
SCCB is usually staged according to the TNM classification which fails with regard to 
micrometastases. In the largest retrospective analysis of SCCB 8, tumour stage was not 
independently associated with survival suggesting that micrometastases are often present in 
clinically localized disease. Because of the clinicopathological similarities between both tumour 
sites, the simplicity of the two-stage system and its clinical relevance for treatment decisions, 
we decided to define limited- and extensive-SCCB in analogy to SCLC. To account for the 
presence of micrometastasis, LD-SCCB, as LD-SCLC, would not differentiate between locoregional 
N0 and N1 disease. Extensive-SCCB would require larger lymph nodes or distant metastasis. 
Other centers have reported a similar staging approach.26
The benefit of platinum-based chemotherapy for SCCB has been observed in earlier studies.7,10-12 
In a large review metastatic disease predicted poor outcome while only cisplatin therapy, not 
primary surgery, improved survival in SCCB.8 Combinations without cisplatin were not 
associated with prolonged survival, though this should be interpreted with caution.8 Good 
performance status required for cisplatin-based chemotherapy may explain the observed 
association of this drug with improved survival in retrospect. In this analysis, 3 patients received 
a combination containing no cisplatin. In SCLC 2 or more drugs are needed for maximal effect 
but most regimens produced similar survival outcomes regardless of cisplatin.16,18 In summary, 
there is  evidence that systemic chemotherapy is the most important factor influencing survival 
in LD-SCCB and that the choice for cystectomy or radiotherapy as local consolidating treatment 
may be of lesser significance. In the last two years several larger series reported experience 
with cystectomy for LD-SCCB with either neoadjuvant or adjuvant chemotherapy 15,27, but only 
few centers offered a bladder sparing approach with sequential chemoradiation.28-30 In our 
series 47 % of the patients staged as LD-SCCB developed systemic progression after a median 
time of 6 months, indicative of the aggressive nature of the disease. Though 5 year survival 
times following bladder sparing with chemoradiation have been reported in a small case 
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5series28, this approach has been criticized for the relatively high rate of local recurrences. Local 
recurrence rates of 20-69% have been reported 28,30 in small series of 5 and 8 patients, 
respectively. In our series 23.5 % of the patients developed a local recurrence (C.I. 0.06-0.49), 
though histology revealed a TCC in 3 of the 4 patients. The late recurrences after 43 and 50 
months indicate that long-term follow-up by cystoscopy is necessary. Considering the typical 
biases of retrospective analyses which influence the comparability of data, it appears that 
overall and progression free survival are similar for local therapies such as cystectomy and 
radiotherapy as long as systemic chemotherapy had been applied. Cheng et al. retrospectively 
analyzed 64 cases and found no survival difference between those who had cystectomy and 
those who had not. Consequently, the authors raised doubt about the effectiveness of cystectomy 
as initial treatment. The 1- and 5 year survival times of those who had a cystectomy were 57% 
and 16% versus 55% and 18% for those who had no cystectomy.31 In our series the 1- and 5 
year survival estimate is 82 % (C.I. 0.56-0.92) and 36 % (C.I. 0.14-0.61), respectively. For 
surgery, the best timing of chemotherapy is not known, though evidence from a retrospective 
series supports neoadjuvant treatment.15
Evidence from the literature supports that the presence of SCCB in combined bladder tumours 
is the leading prognosticator 8-10,15 and that it should be managed like pure SCCB with cisplatin-
based chemotherapy. If the TCC component obtained at TUR was significantly present (> 50 
%) we applied MVAC as suggested in the literature. The TCC, adenocarcinoma or squamous 
cell components have no apparent prognostic influence.6-8,12
The patients in this series have been treated by sequential radiotherapy, though for SCLC, 
concurrent radiotherapy has been introduced between 1999 and 2002. Currently it is not 
known, whether concurrent radiotherapy should be preferred. We did not perform prophylactic 
cranial irradiation and only one of the patients in our series died of a brain metastasis. 
Patients with SCCB are typically elderly men and in some series more than half of the patients 
were over 70 years of age.6,7 In this retrospective series median age was 62 years. This is obviously due to a selection bias for systemic chemotherapy, as those elderly with a reduced 
performance were not treated with cytostatic drugs. Four patients at our institution not 
included in this analysis with a median age of 80 years received radiotherapy only. Disease 
related survival and time to progression do not differ from the literature, in which a median 
survival of 13 months for all stages is reported in the larger series. 
conclusions
SCCB has a poor prognosis which may only be influenced by extent of the disease at diagnosis 
and cisplatinum based combination chemotherapy. There is increasing evidence that the choice 
of treatment to gain local control is of inferior significance. Therefore, in LD-SCCB, a bladder-
preserving strategy with sequential chemoradiation is an attractive concept. Long-term 
remission and potentially cure can be achieved in some, with 2 of the patients (11.7 %) in this 
series still FOD after more than 5 years at a local recurrence rate of 23.5 %. The fact that none 
of the patients died of locoregional tumour progression supports our view that cystectomy is 
not the preferred initial treatment for LD-SCCB. Given the late recurrences we recommend long 
term follow-up. 
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urinary diversions after cystectomy: the association of clinical 
factors, complications and functional results of 4 different diversions 
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absTracT
Purpose
We present a single institute experience of the four most widely used diversions after cystectomy 
in 281 patients, and evaluated the association between clinical factors, complication rates, 
functional results and metabolic complications.
Patients and Methods
Between 1990 and 2005, 281 consecutive cystectomies were performed at our institute. Four 
different diversions were offered; an ileal conduit according to Bricker (IC; 118 patients), an 
Indiana pouch (IP; 51 patients), and orthotopic diversions after cystectomy/neobladder, (N; 
62 patients) or Sexuality preserving Cystectomy and Neobladder (SPCN; 50 patients). 
Results
44% developed early complications; IC 48%, IP 43%, N 42%, and SPCN 38%. High ASA-score 
was the only variable significantly associated with early major complications (ASA 1 vs. 3: HR 
0.32; 95%C.I. 0.14-0.72). Late complication rate was 51% with less complications in the IC-
group; IC 39%, I 63%, N 59%, and SPCN 60% (HR 0.32; 95%C.I. 0.14-0.72), which was explained 
by less uncomplicated urinary tract infections (1/3 of all late complications) in the I.C. group. 
There were no differences in experienced late major complications. We found no significant 
association between tumour stage, ASA, age, pre-operative radiotherapy, gender and diversion 
related complication rates.
Complete day-night time continence was achieved in 96%-73% after IP, 90%-67% after 
Neobladder, and 96%-67% after SPCN. Metabolic changes were found in 24% of the patients; 
21% after IC, 26% after IP, and 28% after orthotopic diversion (neobladder and SPCN 
combined). Low vitamin B12 was measured in 23%, 15% and 15% respectively. 
Conclusions
Cystectomy with any subsequent diversion remains a procedure with considerable morbidity. 
High ASA-score was associated with more early complications. Orthotopic diversions provide 
good functional results, but at the cost of more late complications compared to ileal conduits. 
We found no evidence that age, ASA-score, positive lymph nodes, extravesical tumour growth, 
or previous radiotherapy are contraindications per se for any diversion.
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6inTroducTion 
Radical cystectomy with a urinary diversion is still considered the gold standard for muscle 
invasive and refractory superficial bladder cancer. Different techniques and types of urinary 
diversions have been presented. The recent debate on cystectomy versus radiotherapy in the 
elderly underlines the controversies related to age and ASA-score in surgery, and controversies 
exist on whether any type of diversion can be used in any patient.1,2 Many considerations 
determine the final choice of urinary diversion in the individual patient; it should be oncologically 
safe, technically feasible and secure, provide good functional results, and comply with the 
patient’s choice if possible. Some investigators advocate against the use of an orthotopic 
diversion after previous radiotherapy or in advanced stages of disease, while these factors are 
no exclusion criteria for others.3,4 A urinary diversion should allow sufficient urinary flow 
without compromising renal function, and in case of continent diversions provide good functional 
results. Increasingly emphasis is placed on decreased hospital stay for patients who undergo 
various surgical procedures, underlining the need for technically safe procedures reflected in 
low peri-operative and late complication rates.5 Continent urinary diversions may be of great 
psychological benefit to selected patients, but may be associated with different side effects. Hyperchloremic metabolic acidosis can occur because of  re-absorption of ammoniumchloride 
and secretion of sodiumbicarbonate by ileal tissue of the neobladder.6,7 Resection of part of the 
ileum for urinary diversion may also lead to vitamin B12 or folic acid deficiencies.8,9 
Evaluating complications and functional results between different studies is hampered due to 
different definitions of complication rates, continence and voiding dysfunction, and the different 
surgical techniques used. In this study we assessed early and late complication rates, functional 
results, and metabolic changes in the four different urinary diversions that we have used 
between 1990 and 2005. We analyzed the association of tumour stage, ASA-score, age and 
previous received pelvic radiotherapy on these variables.
PaTienTs and meThods
Between 1990 and 2005, 281 consecutive patients underwent a cystectomy with subsequent 
urinary diversion at our institute. Median age was 63 years (range 32-85 years).
Tumours were staged according to the UICC-classification rules of 2002. Pathological stage 
(pT) was assigned according to the highest stage after diagnostic TUR or cystectomy. In general 
patients with positive lymph nodes were treated with adjuvant or neoadjuvant chemotherapy 
according to trials open at the time of diagnosis. Four types of urinary diversions were used: 
an ileal conduit according to Bricker, a continent cutaneous diversion according to Indiana, an 
orthotopic neobladder after radical cystectomy (neobladder), and an orthotopic neobladder 
after a sexuality preserving procedure (SPCN).10 
Selection of the type of diversion is essentially based on local tumour status, the capability of 
performing clean intermittent catheterisation (CIC), and renal function: patients are primarily 
offered an orthotopic neobladder, with SPCN in highly selected patients (wish to preserve 
sexual function, no tumour in prostate and/or bladder neck). In patients with urethral tumours 
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or cT4b tumours a heterotopic diversion was used. Additionally, an ileal conduit was advised 
to all patients with a compromised renal function or the incapability to perform CIC. The 
definite type of diversion was chosen after thorough consultation of the patient by the urologist 
and enterostomal-therapist accordingly.
Cystectomy included dissection of the lymph nodes as described earlier.10 An ileal conduit 
(Bricker) was constructed in a standard fashion, using the minimal amount of ileum. Indiana 
reservoirs were constructed according to the original description of Rowland.11 Ureters were 
simply pulled through the reservoir wall and sutured to the colonic epithelium after placement 
of single-J stents. No attempt was made to construct an antireflux mechanism of the ureters. 
An orthotopic bladder substitute was constructed according to Studer.12 The ureters were 
anastomosed with a spatulated elliptic end-to-side and side-to-end technique according to 
Nesbit (with single-J stents). From 1995 onwards, a Studer type bladder substitute was 
anastomosed to the rim of the prostate (or the urethra in females) with preservation of vasa 
deferentia, prostate and seminal vesicles in males (or all internal genitalia and anterior vaginal 
wall in females) in suitable patients.10
Postoperative routine comprised anticoagulants (heparin), early ambulation, serum electrolytes 
monitoring, and parenteral nutrition via central venous intravascular devices, since 2000 
replaced by early enteral feeding via postpyloric tubes. Single-J stents and the suprapubic 
catheter were removed at the 10th day, preceded by a cystogram to exclude extravasation. All patients were intensely accompanied by an enterostomal-therapist for stoma care in case of 
incontinent diversions or voiding instructions in case of orthotopic diversions.
Patients were followed at 3-month intervals during the first year, semi-annually the next two 
years, and annually hereafter, or more frequent if indicated. Follow-up included physical 
examination, radiographic evaluation by pelvic-abdominal CT-scan, ultrasound and chest 
X-ray, cystoscopy in patients with an orthotopic diversion, and cytological examination of 
urine. During follow up bloodgas pH, bicarbonate, and chloride were routinely obtained in 
the majority of patients, vitamin B12 and Folic acid at the discretion of the urologist. 
Hyperchloremic acidosis was diagnosed in patients with a chloride level above 105 mmol/l 
and a HCO3- value below 23 mmol/l at the same time. Hypochloremic acidosis was diagnosed 
in patients with a chloride level below 105 mmol/l and a HCO3- value below 23 mmol/l at 
the same time. To exclude metabolic acidosis in the early post-operative period these clinical 
laboratory values were excluded from analysis. Vitamin B12 injections were administered at 
vitamin B12 levels below 150 mmol/l. Over 90% of patients had one or more years of follow-
up, 5 patients were lost to follow-up.
Morbidity was assessed with detailed hospital and outpatient clinical records. Early 
(postoperative) complications were defined as those occurring in-hospital or within 30 days 
after surgery in case of shorter stays. Thereafter, complications were classified as late. All events 
leading to a prolonged hospital stay or requiring medication or surgical intervention were 
scored as complication. Complications were scored as minor (requiring no treatment or 
medication only) or major (requiring surgical intervention, prolonged hospitalisation and/or 
admission to an intensive care unit). The complications were stratified whether or not 
associated with the diversion used. Kidney function was assessed by serum creatinine, CT-
scanning, ultrasound and/or intravenous pyelography. Lasix-renography was done in case of 
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6obstruction. If this confirmed functional outflow obstruction, patients were considered for 
treatment with percutaneous nephrostomy, double-J stenting, balloon dilatation or AcuciseTM 
incision, open revision, or nephrectomy if renal function was below 10%.
The functional results of continent diversions were evaluated with stringent norms on day- and 
night continence. Complete continence was defined as no involuntarily loss of urine and no 
pad use, satisfactory continence as incontinence requiring one pad or less per day/night, and 
poor continence as requiring multiple pads per day/night. Voiding function was evaluated by 
post-void residual measurements by ultrasound or clean intermittent catheterisation (CIC). 
Indications for regular CIC were symptomatic post-void residual urine of >150 cc or an 
a-symptomatic post-void residual of >250 cc. 
Patients with a treatment related death or a survival of less than 30 days were excluded from 
the analysis of complication rates. Uni- and multivariate logistic regression analyses were 
performed to investigate the association between complication rate and organ confined disease, 
nodal status, age, type of diversion, previous radiotherapy, gender and ASA-score. Both the 
main and interaction effects were considered to include in the models. P-values lower than 
0.05 were considered statistically significant. All analyses were performed in SAS 9.1.3.
resulTs
patient characteristics
In total 212 male patients and 69 female patients underwent cystectomy. Of these patients 118 
received an ileal conduit, 51 an Indiana pouch, 62 a neobladder, and 50 a SPCN.  Patient 
characteristics according to type of diversion are summarized in table 1. Of all female patients 
90% received a cutaneous diversion (Ileal conduit and Indiana pouch combined), which was 
50% in the male population. Patients with an orthotopic diversion (neobladder and SCPN 
combined) were younger than patients with a cutaneous diversion (mean 58.3 and 65.7 years 
respectively, t-test: p<0.001), and had less often locally advanced disease (stage 3 + 4 in 34% 
and 53% respectively, p = 0.02) pre-operatively. Patients with an ileal conduit more often had 
a compromised renal function compared to the other patients (28% vs. 14%, p= 0.003). 
early complications
124 patients developed one or multiple complications within the first 30 days, leading to an 
early complication rate of 44%. There were no significant differences in early complication 
rates according to the different diversions used (figure 1). Early complications according to 
urinary diversion are summarized in table 2, eight patients (3%) died because of treatment. 
High ASA-score was the only factor significantly associated with early major complications in 
both univariate (ASA 1 vs. 3: HR 0.32; 95%C.I. 0.14-0.72) and multivariate analyses (HR 0.36; 
95%C.I. 0.14-0.91). None of the other variables were associated with early major or minor 
complications. There were no significant differences between the median length of hospital 
stay between the different diversion used; 17 days (range 6-53) following ileal conduit, 17 
(range 9-42) following Indiana, 15 days (range 8-44) following neobladder, and 16 days (range 
11-52) following SPCN.
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Table 1  patient characteristics according to type of diversion
Ileal conduit
n(%)
indiana
n(%)
Neobladder
n(%)
sPcN
n(%)
Total
n
Gender
male 88 (75) 19 (37) 59 (95) 46 (92) 212
female 30 (25) 32 (63) 3   (5) 4     (8) 69
Clinical tumour category
No tumour (t0) 2     (2) 2     (4) 1   (2) 2     (4) 7
organ confined (≤ t2) 39 (33) 25 (49) 37 (59) 38 (76) 139
Non organ confined (≥ t3) 77 (65) 24 (47) 24 (39) 10 (20) 135
Nodal status                                 
Negative 70 (59) 38 (75) 47 (76) 35 (70) 190
positive 48 (41) 13 (25) 15 (24) 15 (30) 91
Age in years
median [range] 70 [46-85] 61 [35-72] 62 [32-73] 55 [35-77]
Previous radiotherapy                  
yes 35 (30) 15 (29) 5   (8) 7   (14) 62
no 83 (70) 36 (71) 57 (92) 43 (86) 219
ASA-score
asa 1 / 2 67 (57) 37 (73) 49 (79) 43 (86) 196
asa 3, > 25 (21) 2     (4) 4   (7) 0 31
unknown 26 (22) 12 (23) 9   (15) 7   (14) 54
Total 118 51 62 50 281
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Figure 1  complications rates (number of patients with complications) according to type of diversion.
201288 proefschrift Remco de Vries.indd   76 25-09-2012   22:57:14
urinary diversions after cystectomy
77
6late complications
Late complications occurred in 139 patients (51%), of whom 75 (28%) suffered from major 
complications (figure 1). Patients with an ileal diversion have lower risk of developing late 
complications (major and minor combined) compared to patients with a neobladder (univariate 
analyses: HR 0.32; 95%C.I. 0.14-0.72, multivariate analyses: HR 0.36; 95%C.I. 0.14-0.91). There 
was no difference in major complications (HR 0.81; 95%C.I. 0.28-1.14). The most common 
complication was urinary tract infection treated with antibiotics and/or irrigation of the 
reservoir only (table 3). Positive lymph nodes was the only factor significantly associated with 
late complications in univariate analyses (HR 1.67; 95%C.I. 1.00-2.77), but not in multivariate 
analyses (HR 1.71; 95%C.I. 0.94-3.10). None of the other factors were associated with late 
major or minor complications. 
Functional results
Stoma stenosis occurred in three patients (3%) following ileal diversion and six patients (13%) 
after Indiana pouch, requiring surgical revision. Figures of day/night time continence and 
CIC-rates are summarised in figure 2. 
metabolic complications
Of 271 patients surviving more than 30 days serum samples for acidosis were obtained in 237 
patients, for vitamin B12 in 141 patients, and for folic acid in 117 patients. 
Hyperchloremic acidosis was found in 52 patients; with an incidence of 17% after ileal conduit, 
24% after Indiana pouch, and 26% after orthotopic diversion (neobladder and SPCN combined)
(table 4). 20 patients needed treatment with sodium bicarbonate and four patients were 
hospitalised because of acidosis and salt losing hypovolemia. All other patients experienced 
mild metabolic acidosis only, requiring no treatment.
Abnormal vitamin B12 values were measured in 24 out of 271 patients (8,8%) during follow-
up. Low vitamin B12 was not associated with type of diversion (table 4). 16 patients with low 
vitamin B12 values were treated, 1 patient received treatment because of symptoms of low 
vitamin B12 while serum vitamin B12 was in the low range of normal values. The median time 
between cystectomy and abnormal vitamin B12 values was 41 months.
One patient (after ileal conduit) developed a low folic acid value together with a low vitamin 
B12, but was not treated.
discussion
Cystectomy with subsequent urinary diversion is still associated with considerable 
complications. Reported rates and types of complications vary widely, and many series report 
on one type of diversion, which makes them hard to compare. To evaluate complication rates and functional results of the four most commonly used diversions, we report on all consecutive 
diversions performed in our institute. 
The early- (44%)  and late complication rates (51%) at our institute are in the higher ranger 
of earlier reports rates, which vary widely between 16-61% (early) and 24-66% (late).4,5,9,13-21 
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Moreover the types of reported complications differ between reported series. Some series do not include urinary tract infections in the calculation of complication rates, which accounted 
for 1/4 of the early and 1/3 of the late complications in this series. Comparison of late 
complication rates between series is even more complex as these are highly dependent from 
duration of follow-up. Madersbacher illustrated that late complication rates might increase in 
time till over 90% after 15 years, and stated that the entire morbidity spectrum is only covered 
after one decade. 
Table 2  early complications according to diversion. In some patients multiple complications occurred
Complication  Total Ileal conduit indiana Neobladder sPcN
 n (%)  n (%)  n (%)  n (%)  n (%)
Re
la
te
d 
to
 c
ys
te
ct
om
y/
di
ve
rs
io
n
Minor
wound infection 23 (8.2) 14 (11.9) 4 (7.8) 1 (1.6) 4 (8.0
prolonged ileus 8 (2.8) 4 (3.4) 1 (2.0) 2 (3.2) 1 (2.0)
urinary tract infection 36 (12.8) 14 (11.9) 7 (13.7) 9 (14.5) 6 (12.0)
stoma necrosis 2 (0.7) - 1 (2.0) 1 (1.6) -
Major
Necrosis of diversion 2 (0.7) 1 (0.8) - 1 (1.6) -
rectal injury 2 (0.7) 2 (1.7) - - -
Fascial dehiscence 14 (5.0) 6 (5.1) 1 (2.0) 5 (8.1) 2 (4.0)
ureteroileal leakage 3 (1.1) 1 (0.8) - - 2 (4.0)
Intestinal suture leakage 2 (0.7) 1 (0.8) - - 1 (2.0)
pelvic/abdominal abscess 3 (1.1) 2 (1.7) - - 1 (2.0)
Bleeding 4 (1.4) 3 (2.5) - - 1 (2.0)
Death 8 (2.8) 3 (2.5) 3 (5.9) 2 (3.2) -
Fistula 1 (0.4) - - 1 (1.6) -
sepsis 27 (9.6) 13 (11.0) 6 (11.8) 5 (8.1) 3 (6.0)
Re
la
te
d 
to
 c
ys
te
ct
om
y/
di
ve
rs
io
n
Minor
Pneumonia 22 (7.8) 13 (11.0) 4 (7.8) 3 (4.8) 2 (4.0)
Deep venous trombosis 4 (1.4) - - 2 (3.2) 2 (4.0)
sacral pressure ulcus 1 (0.4) 1 (0.8) - -
Delirium tremens 2 (0.7) 2 (1.6) - -
Major
pulmonary embolus 7 (2.5) 3 (2.5) 2 (4.0) 2 (3.2) -
myocardial infarction 6 (2.1) 3 (2.5) 1 (2.0) 2 (3.2) -
respiratory failure 3 (1.1) 2 (1.7) - - 1 (4.0)
peG-leakage 1 (0.4) - - - 1 (2.0)
201288 proefschrift Remco de Vries.indd   78 25-09-2012   22:57:15
urinary diversions after cystectomy
79
6
Cystectomy appears to be safe in the elderly, but urologists should realize that the superiority 
of cystectomy above radiotherapy is still debated, especially in patients with high age and ASA-
score.1,2 We found an (expected) association between early major complications and high 
ASA-score, but this was independent from the type of diversion that was used. Furthermore 
patients with an ileal conduit experienced less late complications. No specific complication 
was dominant in any type of diversion. Comparison however might still be hampered by 
inherent biases. Although the patient has great influence on the definite type of diversion, the 
clinician’s preference and information remain an important determinant in choice, considering 
the differences in age and ASA between the patients opting for an ileal conduit and continent 
diversions. We found no significant association between tumour stage, ASA, age, pre-operative 
radiotherapy, gender and diversion related complication rates, but conclusions have to be 
interpreted with caution due to the methodological limitations inherent to retrospective studies. 
Additionally, the comparison of functional results of orthotopic and external diversions is highly 
debatable. The chance of involuntary urine loss however can be of significant importance for 
a patient in the decision of type of diversion. For this reason these figures are provided, but 
the reader has to be aware of the methodological restrictions when comparing these figures.  
The high percentage (11%) of ureteroileal strictures is remarkable and deserves our attention. 
In 17 out of 23 patients an irreversible partial loss of renal function at the strictured site had 
occurred despite treatment. Reported rates vary between 0.6% and 9%.13,21,22 However, some 
report stricture-rates per renal unit, which would be 6% in these series. Madersbacher found 
deterioration in 2/3 of his patients after 5 years17, so our percentage might even increase over 
time. This and the irreversible partial or total loss of the ipsilateral kidney function, even after 
treatment, underline the importance of close monitoring of these patients.
Voiding methods
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Figure 2  Functional results according to type of deviation. Gray bars represent daytime continence rates; blue 
bars represent nighttime continence rates. complete continence: no involuntary loss of urine and no pad use. 
satisfactory continence; one pad per day/night. poor continence: multiple pads per day/night. pies represent 
voiding methods.
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 The rates of satisfactory to complete continence of the SPCN are slightly better than those for 
neobladder. In the SPCN series mainly women experienced incontinence, while continence in 
males approached 100%. These rates are in accordance with other reports which vary between 
88%-100%, although nightly incontinence was experienced frequently in the neobladder 
group.9,13,21,23,24 Many of these patients though experience periods of incontinence associated 
with UTI’s, which decline after antibiotics. 
Metabolic abnormalities can occur when intestine is incorporated in the urinary tract. Renal 
impairment, large bowel surface, and long contact are factors associated with the development 
and severity of the disorder. We found no difference in incidence of metabolic abnormalities 
according to the diversion used. Although 52 patients developed a hyperchloremic acidosis, 
only 20 needed treatment with bicarbonate and 4 were re-hospitalized. The risk of clinically important acidosis after urinary diversion therefore seems small but substantial and is in 
concordance with previous publications, although the incidence in the ileal conduit group is 
higher than described in the literature.9,17 Theoretically large resections of ileum lead to vitamin 
B12 malabsorption.6 As a consequence we expected more often deficiencies after continent 
diversions, but we found the opposite. However, serum samples were more often obtained as 
a routine procedure in the continent diversion groups, while patients with an ileal conduit are 
only tested when showing symptoms. Furthermore, insufficient intake instead of malabsorption 
might be another important cause for low serum samples. 
Table 3  late complications according to diversion. In some patients multiple complications occurred
Complication  Total Ileal conduit indiana Neobladder sPcN
 n (%)  n (%)  n (%)  n (%)  n (%)
Minor
urinary tract infection 89 (32.8) 26 (22.8) 20 (41.7) 24 (40.7) 19 (38.0)
Herniation 14 (5.2) 7 (6.1) 2 (4.2) 2 (3.4) 3 (6.0)
Diarrhea 2 (0.7) - - 1 (1.7) 1 (2.0)
Broken JJ stent 1 (0.4) - - - 1 (2.0)
Dehydration/metabolic 
disorders
5 (1.8) - - 2 (3.4) 3 (6.0)
Major
ureteroileal stricture 29 (10.7) 13 (11.4) 5 (10.4) 5 (8.5) 6 (12.0)
urethral stricture 12 (4.4) - - 10 (16.9) 2 (4.0)
Fistula 10 (3.7) 3 (2.6) 4 (8.3) 1 (1.7) 2 (4.0)
Herniation 25 (8.5) 4 (3.5) 6 (12.5) 9 (15.3) 6 (12.0)
stoma stenosis 9 (3.3) 3 (2.6) 6 (12.5) - -
lymphocele 4 (1.5) 2 (1.8) 2 (4.2) - -
Ileus 7 (7.4) 2 (1.8) 1 (2.1) 3 (5.1) 1 (2.0)
Vaginal prolapse 2 (0.7) 1 (0.9) 1 (2.1) - -
severe reflux 1 (0.4) - - 1 (1.7) -
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6Improved surgical techniques, such as laparoscopic cystectomy, and improvements in anaesthesia 
and peri-operative care may have resulted in reduced morbidity and shorter hospital stay.5,25 
Nevertheless cystectomy remains associated with significant morbidity, but this seems not 
diversion related. In our opinion type of diversion should be selected according to local tumour 
stage, hand function and renal function, not by the presumed fear of complications.  
conclusions
Cystectomy with any subsequent diversion remains a procedure with considerable morbidity. 
High ASA score is associated with more early complications. Orthotopic diversions provide 
good functional results, but at the cost of more late complications compared with cutaneous 
diversions. Provided that patients’ choice is based on thorough pre-operative consultation, we 
found no evidence that age, ASA-score, positive lymph nodes, extravesical tumour growth, or 
previous radiotherapy are contraindications per se for any diversion.
Table 4  metabolic complications according to diversion
Complication  Total Ileal conduit indiana orthotopic
 n (%)  n (%)  n (%)  n (%)
Hyperchloremic acidosis
no 185 (78.1) 77 (82.8) 32 (76.2) 76 (74.5)
yes 52 (21.9) 16 (17.2) 10 (23.8) 26 (25.5)
measured 237 93 42 102
unknown 34
Hypochloremic acidosis
no 231 (97.5) 90 (96.8) 41 (97.6) 100 (98.0)
yes 6 (2.5) 3 (3.2) 1 (2.4) 2 (2.0)
measured 237 93 42 102
unknown 34
Low vitamin B12
no 117 (83.0) 31 (77.5) 22 (84.6) 64 (85.3)
yes 24 (17.0) 9 (22.5) 4 (15.4) 11 (14.7)
measured 141 40 26 75
unknown 130
Low Folic acid
no 116 (99.2) 29 (96.7) 23 (100) 64 (100)
yes 1 (0.8) 1 (3.3) 0 0
measured 117 30 23 64
unknown 154
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Purpose 
To analyze the oncological outcome of prostate sparing cystectomy (PSC). 
Patients and Methods
Between 1994 and 2006, 63 male patients were treated with Prostate Sparing Cystectomy 
(PSC) after meeting the inclusion criteria (no tumour at bladder neck, no prostate cancer). 
Results were compared with patients who underwent standard cystoprostatectomy (SC) during 
the same study period, after matching for clinical and pathological characteristics.
Results 
The 3 and 5-year disease specific survival rates were 77% and 66% in the PSC group and 68% 
and 64% in the SC group (log-rank, p=0.6). Local recurrence rate was 7.9% and 16% for the 
PSC and the SC group, respectively. Distant recurrence rate was 29% and 33% for the PSC and 
SC group, respectively. Subsequent prostate cancer was detected in 3% in the PSC group. None 
of these patients died of prostate cancer. In the SC group final pathology disclosed 18% prostate 
cancer. 
Conclusions
Local recurrences were not diagnosed more frequently in the PSC group compared to SC. 
Outcomes of both procedures are comparable with contemporary cystoprostatectomy series. 
We consider this procedure oncologically safe and offer this to selected patients. However, 
selection is the key to success and our results should further be corroborated by the experience 
of others.
7 |  prostate sparing cystectomy
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The standard technique of radical cystectomy in male patients consists of removal of the bladder 
together with removal of the prostate, seminal vesicles and part of the vasa deferentia.
Parasympathetic and sympathetic nerves, essential for a normal sexual response, are often 
removed or damaged. In order to preserve erectile function, nerve sparing cystoprostatectomy 
was developed.1 To improve the success rates, various modified cystectomy techniques followed, 
with the aim to further improve the preservation of erectile function.2,3 The techniques and 
inclusion criteria vary. In some procedures the prostate or part of the prostate remains in situ 
after transurethral resection of the prostate. While in other procedures the prostate is partially 
removed with preservation of the vasa deferentia, seminal vesicles and ejaculatory ducts.4
In 1994 we started with prostate sparing cystectomy (PSC), (initially named sexuality preserving 
cystectomy and neobladder, SPCN), in a selected group of patients. Aim was preservation of 
sexual function with anatomic reconstruction of the lower urinary tract without compromising 
the oncological results. The indications, technical aspects, functional and oncological results 
have been published.5 A cystectomy is performed, after lymph node dissection, with preservation 
of the prostate, seminal vesicles and vasa deferentia. The bladder neck, prostate and prostatic 
urethra are sampled extensively before PSC, but no effort is made to remove all prostatic 
urothelium. Patients considered for this procedure represent a selection of the population 
presenting with bladder cancer and the majority of patients are not eligible for a PSC (tumour 
at the bladder neck and/or prostate cancer) and are treated with a “standard” cystoprostatectomy 
(SC) with or without an orthotopic bladder substitution. In this study we assessed retrospectively 
the oncological results of PSC and SC in a cohort of patients treated at the same institute during 
the same study period.
PaTienTs and meThods
Between 1994 and 2006, 268 male patients with urothelial cancer were treated with cystectomy 
and urinary diversion for bladder cancer. 107 males received an ileal conduit, 25 an Indiana 
pouch, 63 a PSC, and 73 received an orthotopic neobladder. The inclusion criteria for PSC are; 
indication for cystectomy and motivation for preserving sexual functions. Exclusion criteria 
are: tumour localization in the bladder neck or prostatic urethra (excluded by (re)TURB), 
prostate cancer (excluded by digital rectal examination, Prostate Specific Antigen (PSA), Trans 
Rectal Ultrasound and biopsies irrespective of PSA levels). In addition, preoperative impotence 
and patients’ decision for a SC were exclusion criteria. The diagnostic work up is summarised 
in Figure 1. 
63 selected male patients were treated with a PSC. After pelvic lymph node dissection, the 
bladder was removed, leaving the prostate and seminal vesicles in place. Boundaries of pelvic 
node dissection until 2000 where: distally the circumflex vein and the node of Cloquet, laterally 
the iliac artery, medially the bladder and the prostate and dorsally the hypogastric artery and 
the obturator nerve. From 2000 the boundaries were enlarged  proximally to the crossing of 
the ureter over the common iliac artery, laterally to the genitofemoral nerve and dorsally/
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caudally the bottom of the obturator fossa. An orthotopic pouch according to Studer is then 
anastomosed to the outer rim of the prostate in males. Details of the operation technique have 
been described in previous articles.5
The SC patients were selected from our cystectomy database and matched for clinicopathological 
characteristics with the PSC patients from the same database. During the study period 73 male 
patients were treated with a SC. We excluded patients with urethral tumours, previous 
radiotherapy with curative intent, and patients with a clinical T4 tumour. 63 patients remained 
for analysis. Before cystectomy a pelvic lymphadenectomy with the above mentioned boundaries 
was performed. No attempt was made to preserve the neurovascular bundles in all these 
patients. All tumours were staged according to the 2002 TNM classification, pathological stage 
(pT) was assigned to the highest stage after transurethral resection.6 Tumour positive lymph 
nodes were considered neither a contra-indication for PSC, nor for standard cystectomy and 
neo-bladder. These patients were eligible for (neo) adjuvant chemotherapy. Patients were 
followed every 3 months in the first year, ever 6 months in the next 2 years and then yearly. 
Oncological follow-up consisted of history, patient self administered questionnaires, cystoscopy, 
Figure 1  algorithm of inclusion/exclusion and diagnostic evaluation.
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7urine cytology, CT-imaging, and PSA tests. Pelvic or local recurrences were defined as any 
urothelial cancer recurrence below the iliac bifurcation within the pelvic soft tissue.    
Kaplan-Meier survival estimates were used in survival data analysis and follow up. Log rank 
tests were performed to compare survival between the two groups. Cox proportional hazards 
regression analysis was performed to investigate the relation between type of surgery or other 
factors and disease specific survival. The following variables were included: age, type of surgery 
(PSC vs SC), tumour extension, margins, and bladder neck infiltration.
resulTs
patients’ characteristics
There were 63 males in the PSC group and 63 males in the SC group. Median age was 55 years 
in the PSC group and 61 years in the SC group. Median follow-up was 56 months in the PSC 
group and 76 months in the SC group. In both groups, all patients had a minimal follow up of 
12 months, 91% of patients more than two years, and 78% of patients more than three years. 
Apart from age and follow-up there was no significant difference between the two groups. 
Patients’ characteristics are shown in table 1.
Three patients in the PSC and six patients in the SC group had a grade 2 tumour; all other 
tumours were poorly differentiated. In the SC group 22 patients had tumour infiltration in the 
bladder neck. Two patients in the PSC and five patients in the SC group had tumour positive 
margins after surgery.
chemotherapy
Eleven patients in the PSC and eight in the SC group received cisplatin based chemotherapy 
for tumour positive lymph nodes in a neo-adjuvant setting. Adjuvant chemotherapy was given 
to one patient in the PSC and eight patients in the SC group, all patients had tumour positive 
lymph nodes. There was no significant difference in chemotherapy setting between the two 
groups. Six patients in the SC group received palliative chemotherapy at the time of tumour 
progression. 
oncological outcome
No statistically significant differences were found in local recurrence rate or distant metastases 
(7.9% and 16%, p=0.1; 29% and 33%, p=0.4 in the PSC and in the SC, respectively, see table 
2). The 3 and 5-year disease specific survival rates were 77% and 66% in the PSC group and 
68% and 64% in the SC group (log-rank, p=0.6). (Figure 2) In the multivariate analysis, only 
extravesical disease (HR 3.58, p=0.003) and tumour positive lymph nodes (HR 5.75, p=0.0004) 
were significantly associated with survival. Two patients in the PSC group developed prostate 
cancer, one died after 126 months due to metastatic bladder cancer; the other is still alive at 
50 months of follow-up. In the SC group, incidental prostate cancer was found in nine patients 
(18%). None of the local recurrences in the PSC group was in the remnant prostatic urethra or 
prostate. However, in one patient recurrent carcinoma in situ in the prostatic urethra developed 
after a follow-up of 41 months. He was successfully treated with BCG.
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Table 1  patients’ characteristics 
all Tcc Psc sc p-value
N 63 63
median age 55 yr 61 yr P<0.002
Clinical Tumour stage
t1,a,is 15 17
T2 38 31 n.s
T3 10 15
Clinical N-status
n0 56 56
n+ 7 7 n.s
Pathological Tumour stage   
t1,0,a,is 16 15
T2 31 26 n.s
T3 16 19
T4 - 3
Pathological N-status
n0 45 51
n1 7 4 n.s
n2 11 8
Bladder Neck infiltration
yes - 22
no 63 41
margins
negative 61 58 n.s
positive 2 5
Table 2  local and distant recurrences comparing psc and sc.  
Psc sc
local % distant % local % distant %
No./total No Stage(%)
ptis,1,2-N0 3/35    9 7/35 20 5/34 14 4/34 12
pt3-4N0 0/10 0 4/10 40 1/17 7 8/17 47
ptN+ 2/18 11 7/18 39 4/12 33 9/12 75
Total 5/63 8 18/63 29 10/63 16 21/63 33
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discussion
It is widely reported that PSC can preserve sexual function in up to 100% of patients.3,4 In our 
study, information on erectile function was available in 55 of 63 patients.  Five patients could 
not be evaluated because of early death and three were not sexually active after PSC. In almost 
90% of these 55 evaluable patients erectile function could be maintained. 
However, the oncological safety of PSC is controversial and intensively debated.7-9 The oncological 
concerns against PSC are the presumed higher incidence of distant metastases, the risk of a 
local recurrence in the remaining prostate, and the risk of developing prostate cancer. The 
comparison between PSC and SC series is hampered by lack of randomized studies, different 
techniques and selection criteria.10 In the absence of a randomized study we compared the 
outcomes of patients treated with a PSC or SC after matching for clinical and pathological criteria. 
However, this comparison is second best as compared to a randomized study. We acknowledge 
that our results have to be interpreted within the limitations of retrospective matching.
local and distant recurrences
Stratified for these clinical and pathological factors we found no difference in survival. More 
importantly: no statistically significant difference was found in local recurrence rate (LRR) in 
the PSC group compared to the SC group (7.9% versus 16%, p=0.1). Although the median follow 
up in the PSC group (56 months) is significantly shorter than in the SC group (76 months), a 
median follow-up of more than four years in the PSC group is considered sufficient for the 
assessment of local recurrences, as most local recurrences come to light in the first two years 
after surgery.11
Figure 2  Km curves comparing disease specific survival of psc and sc.
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Local failure after cystoprostatectomy ranges from 7%-25%, depending on pathological 
stage.12,13 In a population based study in the greater Amsterdam region comprising 18 hospitals, 
a LRR of 19% after cystectomy was found for all patients.11 Local recurrence rates after prostate 
sparing procedures in other series range from 0 - 6.7%. 3,4,14 These lower rates can be explained 
by the selection of low risk patients, mostly non-muscle invasive bladder cancer. Only one report included also patients with locally advanced disease and positive lymph nodes, similar 
to our patient population, accounting for higher reported local and distant recurrence rates in 
this series. In the SC group, the distant recurrence rate is in the high region of the reported 
rates (33%, compared to 17-35% in the literature).13,15 The rate of distant metastasis, 29% in 
the PSC group is within the reported range. Vallancien et al. found a distant recurrence rate of 
34% in a patient group comparable to ours.16 Other reports on prostate sparing procedures, 
found an apparently higher distant recurrence rate than expected. Some authors suggested 
that TURP prior to PSC may be instrumental for metastatic spread of bladder cancer cells into 
the vessels of the prostate.10 However preoperative TURP has not been our practice. Also direct 
tumour spill is suggested.10 To diminish the risk of spill the ureters are clamped at an early 
phase during surgery and the bladder neck is closed immediately after dissection off the 
prostate.  
local recurrences in the remaining prostatic urothelium
Pettus et al. reported on the incidence of prostatic urothelial cancer (PUC) in cystoprostatectomy 
specimens. Risk factors for prostatic urothelial cancer were tumour located at or distal to the 
trigone, and carcinoma in situ.17 They found an incidence of PUC in cystoprostatectomy 
specimens of 33%-48%. While these data concern a population of unselected male bladder cancer patients treated with cystoprostatectomy, they are not applicable to patients in this 
series selected for PSC, where attention was focused on the identification of these risk factors. 
With success, exemplified by the fact that none of the local (urothelial cancer) recurrences in 
the PSC group occurred in the remaining prostatic urethra. 
the risk of prostate cancer
Two patients in the PSC group developed prostate cancer (3%). One was treated with external 
radiation therapy and died because of metastases of bladder cancer nine years after cystectomy. 
The other patient is being observed because of radiotherapy for concomitant colon cancer. He 
is still alive at 50 months of follow-up. This rate of detection in these selected patients is not 
at all uncommon. When reviewing the published series on PSC, consisting of more than 300 
cases only 2 patients developed prostate cancer five years after surgery.5,17 These rates are 
clearly different from the rates usually found in the literature. The reported incidence of 
incidental prostate cancer in unselected patients varies widely from 18%-46%.13,18,19
Incidental prostate cancer was found in 18% of the patients in the SC group. This percentage 
is relatively low as compared to the literature. However, the median age in the SC group was also relatively low as compared to other series17,18 Standard removal of the prostate in this 
selected group of patients with bladder cancer is therefore not deemed necessary considering 
the low detection rate of prostate cancer. Moreover, with early detection due to a strict follow 
up all therapeutic modalities can be offered. 
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7Most importantly no difference was seen in local and distant recurrence rate between both 
groups. In addition, outcomes of both procedures are comparable with contemporary 
cystoprostatectomy series. 
Although patient numbers are small and patients undergoing a PSC are highly selected, we 
consider PSC for bladder cancer to be as safe as SC. Provided that patients eligible for PSC 
undergo a meticulous preoperative screening, focused on the presence of occult prostate cancer 
and risk factors for recurrence in the prostatic urethra. However, conclusions have to be 
interpreted within the limitations of retrospective matching.
conclusions 
Local or systemic recurrences were not diagnosed more frequently in the PSC group compared 
to the SC. After meticulous pre-operative screening the risk of both local recurrences in the 
remaining urothelium or clinically significant prostate cancer seems to be low. We consider 
this procedure oncologically safe and offer this to selected patients. However meticulous 
selection is the key to success and our results should further be corroborated by the experience 
of others.
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Background
There are no uniform follow-up schedules after cystectomy for bladder cancer. Follow-up can 
be regularly scheduled, risk adjusted, or symptom based. 
Purpose
To evaluate the efficacy of follow-up based on the patterns of recurrence, relapse presentation 
and survival after cystectomy, and to define a risk adjusted follow-up schedule. 
Patients and Methods
The records of 343 patients with regular follow-up after cystectomy were reviewed for primary 
site of recurrence, accompanying symptoms, means of recurrence diagnosis, and 
clinicopathological factors. Based on Cox proportional hazard models, and the results of imaging 
studies low and high risk groups are identified and a risk adjusted follow-up protocol is 
proposed.
Results
The risk of a recurrence was related to increasing pT, tumour positive lymph nodes, tumour 
positive surgical margins, and pre-operative dilatation of the upper urinary tract, and low and 
high risk groups were defined consequently. 84% of all recurrences occurred within 2 years, 
with only one recurrence beyond 2 years in the low risk group. Although the minority of all 
patients (34%) is asymptomatic at time of recurrence, symptomatic recurrences were adversely 
associated with survival. CT-scans and chest X-rays accounted for 90% of the diagnostic tools 
to detect a recurrence in patients without symptoms. 
Conclusions
Asymptomatic patients may benefit from early treatment after disease recurrence. A risk 
adjusted follow-up strategy based on stage of disease and additional clinicopathological factors 
can dichotomise patients at high and low risk for recurrence, resulting in less frequent and 
more cost-effective follow-up. 
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8inTroducTion
Cystectomy is the treatment of choice for patients presenting with muscle invasive bladder 
cancer and for patients in whom local treatment for non muscle invasive bladder cancer fails. 
After cystectomy pelvic recurrence rates vary between 4-34%, while distant metastases occur 
in up to 50% of all patients, both highly dependent on stage.1-4 Follow-up of these patients is recommended to detect pelvic recurrence and distant metastasis as early as possible to permit 
additional treatment if indicated. According to the 2007 EAU guidelines the oncological follow-
up after cystectomy should be guided by prognostic factors, of which pT and pN-stage are the 
most important in determining the most efficient schedule5. Three-monthly assessments 
postoperatively include physical examination, urine and blood analysis, ultrasonography of 
kidney, liver and retroperitoneum, and chest X-ray. In case of pN+ additional CT scans and bone 
scintigraphy are recommended. 
The 2008 EAU guidelines state that follow-up should be dependent on stage of the initial tumour.6 
Recent studies doubt the efficacy of standard follow-up schedules as many patients present with 
symptoms of a recurrence.7 Combined with the poor prognosis of these patients despite 
subsequent therapy this leads to the question if similar results can be achieved by simple 
symptom-guided follow-up. To evaluate this we analysed patterns of recurrence and relapse 
presentation in association with clinicopathological factors, and the tools used for diagnosis.
PaTienTs and meThods
We studied 343 consecutive patients treated with cystectomy and bilateral lymphadenectomy for bladder cancer at the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL) from 1990 till 2006. Patients were retrieved from our database. Cystectomy consisted 
in the majority of patients of excision of the bladder (including peritoneal covering with 
perivesical fat) and neighbouring organs; i.e. the prostate, seminal vesicles and when indicated 
urethra in males, and anterior vagina, uterus and adnexa in females. From 1995 onwards, a 
sexuality preserving cystectomy with neobladder (SPCN) is performed in suitable patients, with preservation of the vasa deferentia, prostate and seminal vesicles in males, and all internal 
genitalia in females.8 Four types of urinary diversions are routinely offered to patients at our 
institute, either incontinent (ileal conduit/Bricker) or continent with or without orthotopic 
reconstruction( Indiana Pouch, Neobladder, SPCN). Before cystectomy a meticulous pelvic 
lymphadenectomy is performed Untill 2000 this included the lymph nodes in both obturator fossae, medial aspect of the iliac artery, and all nodes around the obturator nerve until the 
hypogastric artery. From 2000 the proximal margin reached the common iliac artery until the 
crossing of the ureter and the lateral margins until the genitofemoral nerve. 
(Neo)adjuvant therapies  
Neoadjuvant radiotherapy (RT) was not routinely administered. Adjuvant RT (45–60 Gray) 
was applied in 14 patients, in the majority of these patients because of tumour positive margins 
after resection. The use of chemotherapy evolved during the study time period according to 
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EORTC protocols. Neoadjuvant chemotherapy was administered in 69 patients, adjuvant 
chemotherapy in 13 patients (usually multiagent, Cisplatin based). Five patients received both 
neoadjuvant radiotherapy and chemotherapy. In total 47 patients underwent a salvage 
cystectomy after failure of previous treatment with radiotherapy with curative intent (>54 
Gray) for bladder cancer. 
staging  
Patients were staged pre-operatively by pelvic-abdominal CT, chest X-ray, transurethral 
resection (TUR), and physical examination. Bone-scans were performed on indication (increased 
alkaline phosphatase or pain). All stages were converted to the 2002 TNM-system.9 Based on 
the TNM classification a stage of disease was assigned. Pathological stage was assigned 
according to highest stage after diagnostic TUR and/or cystectomy and lymphadenectomy. 
Surgery was considered to be irradical when tumour was present at the resection margins of 
the resected bladder specimen, perivesical tissue, ureters or urethra.
Follow-up
Patients in the NKI-AvL are followed at 3 to 4 month intervals during the first year, semi-
annually the next two years, and annually hereafter, or more frequent if clinically indicated. 
Follow-up included physical examination, routine serum chemistry, regular radiographic 
evaluation by pelvic-abdominal CT-scan and chest X-ray, cystoscopy when a neobladder was 
used as deviation, and cytological examination of urine. Bone-scans were performed on 
indication. Over 97% of the patients had a follow-up exceeding one year, 7 patients were lost 
to follow-up, median follow-up was 64 months (range 2-196 months).
statistical analysis
Overall survival (OS) and disease specific survival (DSS) were calculated from date of cystectomy 
until date of death of any cause or last follow-up. For OS an event was defined as death of any 
cause. In disease specific analysis an event was defined as death of urothelial cancer or 
treatment. Time to recurrence or disease-free interval (DFI) was calculated from date of 
cystectomy to the date of first documentation of pelvic or distant recurrence or date of last 
follow-up or death. Pelvic recurrences were defined as radiographic or histological evidence of tumour presence in the soft tissue within the true pelvis, while tumour recurrences outside 
the pelvis in non urothelial tissue were considered as distant metastases. Univariate and 
multivariate Cox proportional hazard models were used to investigate the association between 
clinical or pathological factors and survival resp. recurrence. These factors included gender, 
age, salvage cystectomy, the presence of carcinoma in situ (CIS), intention of sexuality 
preservation, surgical margins, dilatation of the upper urinary tract, histopathological grading, 
pathological tumour category (pT), and pathological lymph node status (pN). Age was included 
as a continuous variable and its shape was studied by means of restricted cubic splines. Time 
to first event (either local or distant recurrence or both concurrently) was analysed using 
competing risk adjusted cumulative incidence.10 All reported P-values are two sided.
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Patient characteristics and clinical-pathological factors are summarized in table 1. Median age 
was 62 years (range 32 – 84).  Indication for cystectomy was muscle invasive disease in the 
majority of patients. Of the 41 patients with non muscle invasive bladder cancer, 38 underwent 
cystectomy because of insufficient response to repeated local treatments, while 3 patients had 
de novo non-invasive bladder cancer: the reasons for cystectomy in these patients were 
concurrent prostate cancer (2 patients) and non muscle invasive disease in a bladder with 
insufficient bladder capacity after previous radiotherapy (1 patient). Ninety-two percent of all 
tumours were transitional cell carcinomas, 3% squamous cell carcinoma, 3% adenocarcinomas, 
and 2% other cancer types. 
survival
At the end of registration 176 (51%) patients had died after a median follow up exceeding 5 
years. Treatment related death occurred in 8 patients (2%), 134 (39%) patients died of disease, 
and 34 patients (10%) died because of non disease related causes (with or without recurrent 
bladder cancer). 5-year overall and disease specific survival rates for the entire cohort were 
46% (95% CI: 40-52) and 53% (95% CI 47-59) respectively. In univariate analyses, pathological 
tumour category (Figure 1a), lymph node involvement (Figure 1b), female gender, preoperative 
dilatation of the upper urinary tract, salvage cystectomy, and tumour positive surgical margins 
of the resected specimen were associated with decreased disease specific survival. In 
multivariate analyses using disease specific death as endpoint, higher T classification, positive 
lymph nodes, tumour positive surgical margins, and salvage cystectomy were independently 
associated with decreased survival (table 1). 
patterns of recurrence
In total 158 (46%) patients experienced a recurrence of disease; 104 (30%) developed distant 
metastases, 33 (10%) a local pelvic tumour recurrence, whereas 21 (6%) patients experienced 
concomitant distant metastases with pelvic recurrent disease (figure 2). Five patients developed 
a urethral recurrence. Pelvic recurrences were more often seen after increasing pT, and after non-
radical procedures. Sexuality preserving procedures were associated with less pelvic recurrences. 
Only pT4b tumours were independently associated with pelvic recurrence in multivariate analyses 
(table 2). Distant recurrences were associated with higher pT, positive lymph nodes, poorly 
differentiated tumours, non-radical procedures and upper tract dilatation. In multivariate analyses tumour positive lymph nodes, and pre-operative dilatation of the upper urinary tract remained 
independent risk factors for development of distant recurrences (table 2).
The median time to any tumour recurrence was 8.7 months. 84% of all recurrences occurred 
within 2 years, the latest recurrence was detected 7.9 years after cystectomy. This was 7.9 and 
8.9 months for pelvic and distant recurrences respectively. Of all recurrences 64% was 
symptomatic at the time of diagnosis, while the minority (34%) was diagnosed at the standard 
follow-up. The remaining recurrences (2%) were diagnosed coincidentally (neither because 
of symptoms nor at standard follow-up; e.g. autopsy). The diagnostic tool revealing recurrences 
was CT-scan in the majority of patients (table 3). 
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Table 1  patient characteristics and disease specific survival according to characteristics. 
Variable
Number 
of Patients 
(%)
Disease Specific Survival
      Univariate Analysis Multivariate Analysis       
HR (95% C.I.) P-value HR (95% C.I.) P-value
age (median 62.3 years) 1.005 (0.99-1.02) 0.515 1.00 (0.98-1.02) 0.933
Gender
   male 256  (75%) r
   female 87    (25%) 1.54 (1.08-2.20) 0.017 0.81 (0.55-1.19) 0.271
Salvage cystectomy
   no 296  (86%) r r
   yes 47    (14%) 1.61 (1.06-2.45) 0.026 1.97 (1.24-3.12) 0.004
pT classification
   t1/ta/tis 41    (12%) 0.29 (0.12-0.74) 0.009 0.45 (0.16-1.32) 0.147
   T2 137  (40%) r r
   T3 97    (28%) 1.89 (1.26-2.81) 0.002 1.52 (0.98-2.36) 0.055
   T4a 43    (13%) 2.11 (1.28-3.48) 0.004 1.42 (0.82-2.44) 0.210
   t4b 25    ( 7% ) 4.1   (2.37-7.09) <0.001 1.93 (1.33-3.82) 0.040
Lymph node status    
   N negative 227  (66%) r r
   N positive 116  (34%) 2.47 (1.77-3.45) <0.001 1.93 (1.33-2.79) <0.001
Carcinoma in situ
   absent 257  (75%) r
   present 86    (25%) 0.48 (0.30-0.76) 0.002 0.84 (0.51-1.37) 0.472
Differentiation 
   Good  (<G3) 24    ( 7% ) r
   poor   (  G3 ) 317  (92%) 1.71 (0.84-3.51) 0.138 1.41 (0.64-3.11) 0.400
   unknown 2      ( 1% )
surgical margins
   Negative 308  (90%) r
   positive 35    (10%) 3.58 (2.29-5.61) <0.001 2.22 (1.31-3.75) 0.003
Upper tract
   normal 212  (62%) r
   dilated 116  (34%) 2.61 (1.87-3.65) <0.001 1.75 (1.22-2.50) 0.002
   unknown 15    ( 4% )
Sexuality preserving
   no 284  (83%) r
   yes 59    (17%) 0.43 (0.25-0.74) 0.003 0.68 (0.36-1.27) 0.226
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Figure 1a  stage specific survival after cystectomy Figure 1b  survival after cystectomy according to 
lymph node status
Table 2  the association of local an distant recurrences and patient characteristics
Variable
Local recurrence
      Univariate Analysis Multivariate Analysis       
HR (95% C.I.) P-value HR (95% C.I.) P-value
pt1/ta/tis 0.75 (0.20-2.78) 0.671 1.06 (0.25-4.48) 0.933
pt2 r r
pt3 2.32 (1.09-4.97) 0.030 2.04 (0.90-4.63) 0.087
pt4a 2.52 (0.99-6.40) 0.051 1.91 (0.70-5.22) 0.204
pt4b 6.36 (2.38-17.0) <0.001 3.44 (1.04-11.3) 0.042
lymph nodes positive    1.42 (0.79-2.59) 0.243 1.05 (0.53-2.05) 0.564
salvage cystectomy 1.55 (0.72-3.34) 0.265 1.29 (0.54-3.06) 0.564
carcinoma in situ present 0.55 (0.26-1.18) 0.125 0.89 (0.38-2.10) 0.797
Grade 3 tumours 0.94 (0.31-2.86) 0.908 0.78 (0.22-2.78) 0.705
tumour positive surgical margins 3.30 (1.53-7.14) 0.002 1.73 (0.67-4.52) 0.261
Dilatation of upper urinary tract 1.71 (0.94-3.12) 0.078 1.20 (0.62-2.30) 0.595
sexuality preserving 0.16 (0.04-0.66) 0.012 0.27 (0.06-1.18) 0.081
Distant recurrence
pt1/ta/tis 0.40 (0.16-1.03) 0.057 0.74 (0.24-2.27) 0.599
pt2 r r
pt3 2.03 (1.18-3.48) 0.011 1.66 (0.89-3.10) 0.110
pt4a 2.24 (1.11-4.51) 0.025 1.28 (0.56-2.94) 0.554
pt4b 2.16 (0.91-5.14) 0.081 0.99 (0.33-3.01) 0.987
lymph nodes positive    4.76 (2.94-7.69) <0.001 4.04 (2.35-6.96) <0.001
salvage cystectomy 1.22 (0.65-2.28) 0.542 1.72 (0.81-3.66) 0.156
carcinoma in situ present 0.51 (0.30-0.89) 0.017 0.82 (0.43-1.58) 0.553
Grade 3 tumours 3.09 (1.03-9.25) 0.044 2.76 (0.69-11.0) 0.152
tumour positive surgical margins 2.26 (1.12-4.58) 0.023 1.51 (0.60-3.79) 0.386
Dilatation of upper urinary tract 3.05 (1.90-4.90) <0.001 2.36 (1.39-4.01) 0.002
sexuality preserving 0.54 (0.29-1.02) 0.056 0.83 (0.39-1.74) 0.620
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treatment and survival after recurrence 
In total 19 patients (12%) were treated with curative intent after recurrence; radiotherapy in 
seven patients, surgery (with or without chemotherapy) in 12 patients. Patients with a pelvic 
recurrence only were treated more often with curative intent (36.4%) as compared to patients 
with distant metastasis (5.6%,). Median survival after development of a pelvic recurrence was 
8.2 months compared to 3.2 months in patients with distant metastases. (Figure 3; log rank 
p=0.026). After distant metastases 22% of the patients survived one year. Prognosis after a 
pelvic recurrence only was slightly better with a 1-year survival of 33%, but long lasting 
remissions were more often seen after pelvic recurrence (Figure 3). 
Of 101 patients presenting with symptoms 10 (9.9%) were treated with curative intent, while 
9 out of 57 (15.8%) asymptomatic patients were treated with curative intent (chi-square 
p=0.274). Survival after a symptomatic recurrence however was shorter compared to 
asymptomatic recurrences in univariate analyses (HR 1.58, p=0.013) (Figure 4). 
Symptoms at time of recurrence remained independently associated with survival in all 
multivariate models (corrected for initial pT and local vs distant recurrence; HR 2.40, 95%CI: 
1.61-3.58; p=0.013).
Figure 2  time to first event after cystectomy; either 
local or distant recurrence or both concurrently 
Figure 4  survival after symptomatic or asymptomat-
ic recurrence
Figure 3  survival after cystectomy according to type 
of recurrence
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discussion 
An appropriate oncological follow-up schedule (besides the follow-up related to the urinary 
diversion used) after cystectomy should be based on the probability and timing of recurrence, 
and the potential treatment options after disease recurrence. The 2007 EAU guidelines advised 
3-monthly physical exams, serum samples, sonography of the kidney, liver and retroperitoneum 
and chest-X-ray for follow-up screening after cystectomy. In the 2008 EAU guidelines follow-up 
procedures after cystectomy changed. Based on experts opinion oncological follow-up should 
be dependent on initial tumour stage and may be stopped after 5 years, to be continued by 
functional surveillance. We found only four recurrences (1.2%) beyond a follow-up of 5 years. 
Two in stage-1 patients, two in stage-4 patients. Therefore it seems reasonable to continue 
beyond 5 years with a follow-up programme focussed on urinary diversion related problems 
only, while oncological follow-up changes to a symptom guided follow-up.
CT-scans and chest X-rays accounted for 90% of the diagnostic tools to detect a recurrence in 
patients without symptoms. The role of sonography of the retroperitoneum and liver was 
limited in these patients and should probably not routinely be encompassed in a regular 
oncological follow-up schedule but only be used in patients with symptoms. Ultrasound 
however is also used to assess dilatation of the upper urinary tract after urinary diversion. If 
this is the sole indication, sonography is technically less demanding and can easily be done by 
urologists at the office at reduced costs. Cystoscopy of neobladders resulted seldom in detection 
of tumour recurrence, but plays a role in tumour detection of the remnant urethra. Tumour 
recurrences in the remaining urothelial tissue however were not included in this study. 
The frequency of follow-up remains difficult to determine. Our data support the idea of risk 
adjusted follow-up strategies. Table 4 shows the percentage of recurrences found at regular 
follow-up times for patients with a low (stage disease ≤ 2, no ureteral dilatation, and tumour free 
margins after resection) and high risk (all other patients) of recurrence according to our analyses. 
If patients with a low risk of recurrence would have had a CT-scan and X-thorax at 4 and 12 
months, the majority of recurrences would have been detected in an reasonably early stage, 
reducing the number of CT-scans, chest X-rays and sonographies. Noteworthy is the high number 
of early recurrences; 44 out of 158 recurrences were already present at a follow-up of 3 months 
(table 4). Although some of these patients might have been operated upon with undetected 
metastases despite careful selection of cystectomy candidates, others (especially patients at high 
risk of recurrence) might benefit from an earlier first round of follow-up than at 3 months, e.g. 
at 6 weeks. Our data however can not provide an optimal risk adapted schedule by itself. Many 
other cystectomy series provide information on the odds and timing of recurrences, and the 
combination of results should be the base of risk adjusted follow-up after cystectomy. 
Table 3  Diagnostic tools used for detection of recurrences at standard follow-up and symptomatic recurrences
Diagnostic tool
Recurrence ultrasound X-chest CT-scan bonescan mRi other Total
at standard follow-up 1 (1.9%) 5 (8.8%) 42 (73.7%) 2 (3.5%) 0 7 (12.3%) 57
with symptoms 10 (9.9%) 3 (3.0%) 43 (42.6%) 8 (7.9%) 14 (13.9%) 23 (22.8%) 101
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Bochner et al suggested CT-scans and chest x-ray at 3, 6, 12, and 18 months, followed by yearly 
examinations. For patients with ≤ P2N0M0 disease exams at 6 and 18 months and after 3 years 
may be omitted.11 Recently, Soukup et al performed a literature analysis on follow-up strategies 
after cystectomy. They proposed a risk adjusted scheme based on experts’ opinion and large 
cystectomie series. For patients with pT2N0 disease CT-scans and chest x-ray are performed at 
6,12,18, and 24 months and then yearly.12  High stage disease is a known (and probably the most 
important) variable predicting recurrence and survival.1;3;4;13;14 Our current data confirm this 
and suggest that other variables besides these pathologic criteria should play a role in 
determining an acceptable risk adjusted follow-up schedule. Positive surgical margins and 
hydronephrosis increase the risk of recurrence and death in this and other series.15-18 Nomograms 
have been proposed to determine the probability of recurrence and survival after cystectomy. 
Both the Bladder Cancer Research Consortium (BCRC) and the International Bladder Cancer 
Nomogram Consortium (IBCNC) demonstrated that nomograms are more accurate in predicting 
survival and recurrence compared to stage grouping alone.19;20 These nomograms add clinical 
and pathological factors to TNM staging to increase predictive accuracy, but provide 2-, 5- and 
8-years (BCRC) and 5-year (IBCNC) predictions only. As over 80% of the recurrences occur in 
the first 2 years, these nomograms are useful to stratify patients that are at risk for recurrent 
disease but for follow-up-schedules their value seems limited. Furthermore, these nomograms 
are based on retrospective data and different follow-up regimens and therefore cannot be 
entirely recommended for the estimation of the risk of recurrence. Biomarkers may add 
important information for follow-schedules, but need further prospective evaluation.21 
Other series from high volume centres suggest that symptom guided follow-up, compared to 
regular follow-up, may offer similar results at lower costs7, as no survival benefit was found in 
patients with early asymptomatic recurrences. Although the majority of patients presents with 
symptoms our data contradict these findings.7;22 In another study from a high volume centre a 
higher survival was found in patients with asymptomatic recurrence so routine follow-up (chest 
and abdominal imaging) was recommended.23 
Lead time bias and more aggressive tumours in symptomatic patients may partially be responsible 
for the significant difference in survival. However, long term survival was achieved more often 
in patients with asymptomatic recurrences, suggesting that patients with early detected 
recurrences have a better prognosis after early additional treatment with curative intent. 
Table 4  Number of recurrences / number of patients in follow-up found within the first 3 years after cystectomy 
for patients with a small chance (stage disease ≤ 2, no ureteral dilatation, and tumour free surgical margins) and 
high chance (all other patients) of recurrence.
Months after cystectomy 3 6 9 12 18 24 30 36
  all patients 44/343 28/311 26/286 24/262 11/220 4/184 7/160 3/143
patients with
stage ≤ 2
No dilatation
margins tumour free
and
and 2/105 3/99 4/98 1/88 1/88 1/81 1/74 0/67
patients with
stage ≥ 3
Dilatation
margins not tumour free
or
or 42/238 25/212 22/188 20/168 10/132 3/103 3/86 3/74
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location and primary pTNM. The present study is limited because of its retrospective character 
(as all studies identified on recurrences and follow-up), with inherent biases. 
Results have not been adjusted for the cancer history of these patients, previous intravesical 
therapies, and neoadjuvant and adjuvant therapies, and although follow-up regiments in the 
NKI/AvL are very strict, not all patients are followed at exact identical intervals. Given these 
limitations, the present study suggests a benefit of early recurrence detection by regular follow-
up with CT-scan and chest X-rays, of which the frequency can be adjusted according to 
pathological and clinical criteria. Based on the combination of the schedule suggested by 
Bochner et al. and our data, such a schedule might be based on dichotomy of high and low-risk 
patients, with an optional earlier round of follow-up at 6 weeks in high risk patients, as depicted 
in table 5.11 Risk adapted follow-up strategies however should be based on large data of multiple 
centres, and prospectively validated in time. Until now, there are no prospective trials 
demonstrating the effectiveness of follow-up after cystectomy. At the same time it is important 
to realise that follow-up after cystectomy at this time not only aims at identifying recurrences. 
It is also important for determining functional results of the used diversions, the recording of 
complications, and reassuring patients in case no recurrence is found. 
conclusions
Follow-up after cystectomy should be based on risk adjusted schedules. Although the majority 
of recurrences presents with symptoms, long term survival was more often achieved in patients 
with asymptomatic recurrence. High pT, positive lymph nodes, pre-operative dilatation of the 
upper urinary tract, and tumour positive surgical margins are clinicopathological factors that 
can help dichotomise patients at high and low risk for recurrence, resulting in less frequent and 
more cost-effective follow-up.  
Table 5  suggested oncological follow-up schedule after cystectomy (not taken in account the used urinary 
diversion)  
Low-risk patients
months after cystectomy 4 12 18 24 year 3, 4 and 5
ct abdomen & pelvis X X (X) X (X)
chest x-ray X X X X X
physical examination X X X X X
urethral wash / urine cytology X X X X X
High-risk patients
months after cystectomy 1.5 3 6 9 12 18 year 2, 3, 4 and 5
ct abdomen & pelvis (X) X X X X X X
chest x-ray (X) X X X X X X
physical examination (X) X X X X X X
urethral wash / urine cytology (X) X X X X X X
Suggested examinations between brackets are optional. - Ct-scans at 3 (or 4), 12 and 24 months should be 
replaced by CT-urography for detection upper urinary tract tumours. - After 5 years symptom guided follow-up 
(optional)
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absTracT
Purpose
To evaluate the effect of volume of cystectomies in the Greater Amsterdam region on 
postoperative outcomes.
Patients and Methods
All primary bladder tumours diagnosed between 1989-2003 were selected from the Amsterdam 
Cancer Registry, a population based cancer registry (population 3.0 million). For all patients 
who underwent cystectomy during 1989-2003 at 20 participating hospitals medical records 
were reviewed for information on postoperative mortality, locoregional recurrences, and 
relative risk of death. To asses the effect of volume outcomes  at an oncology centre and low 
volume hospitals were compared.
Results 
During 1989-2003 a total of 1185 cystectomies were performed in twenty hospitals of the 
Greater Amsterdam region. Postoperative mortality was 3.2%. During 1989-1997, 8% of 
cystectomies were performed at the oncology centre, increasing to 30% in 1998-2003. Although 
postoperative mortality at this centre decreased from 4.0% in 1989-1997 to 1.1% in 1998-
2003, the latter percentage was not statistically significantly different from the other hospitals 
during 1998-2003 (OR 0.3; p=0.09). No statistically significant difference in locoregional 
recurrence rate and in the relative risk of death was observed between the oncology centre 
and all other hospitals combined.
Conclusions
We observed a lower postoperative mortality rate in the oncology centre compared to the low 
volume hospitals, however this difference did not reach statistical significance. Neither could 
we prove a  statistically significant relation between hospital volume, local recurrence rate and 
survival after cystectomy was found. To answer the question if centralization of cystectomies 
is beneficial more procedures have to be compared.
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Indicators of outcome after cystectomy (postoperative mortality, recurrence rates and 
complications) have been compared between high and low-volume surgeons and hospitals in 
the United States. High volume surgeons and high volume hospitals achieve superior outcomes 
after cystectomy for bladder cancer patients.1-11 However, definitions and thresholds for high- 
and low volume are not defined, and vary from a minimum of 3 to a minimum of 10. In the US, 
the regionalization of cystectomies is encouraged by a coalition of private and public purchasers 
of health insurance (Leapfrog group), contrary to the Netherlands. 9 Almost all studies on 
volume-outcome relation were performed in the United States and describe the postoperative 
mortality as indicator of outcome. 
This is the first study in the Netherlands comparing volume and outcome after cystectomy for 
bladder cancer. In recent years a tendency to centralization of cystectomies, although no part 
of a consensus policy, has taken place in the greater Amsterdam region. To evaluate the effects 
of this centralization we compared results of an oncology centre with other regional hospitals 
in the region of the Comprehensive Cancer Centre Amsterdam (CCCA).
PaTienTs and meThods
cancer registry data
All primary bladder tumours diagnosed and treated during 1989-2003 were selected from the 
CCCA Registry, a population based cancer registry with complete regional coverage (population 
3.0 million). Patients treated with cystectomy were compared with bladder cancer patients 
treated with cystectomy at the oncology centre. As the number of annual cystectomies in the 
oncology centre raised from 7 to 21 between 1997 and 1998, this was chosen as cut-off point 
for comparison of two periods( 1989-1997 and 1998-2003). Registration clerks extracted 
demographic data, morphology, stage (TNM) and primary treatment from detailed hospital 
records. We converted all TNM-data to the sixth version.12
Follow-up of vital status
The vital status of all patients was updated by linking the cancer registry to a file derived from 
the national Municipal Population Registry network comprising all legal Dutch residents who 
had died or emigrated, as of October 1st, 1994 until February 1st, 2007. The vital status of 
patients dying before October 1st, 1994 was updated using electronic data files, covering 1988 
to 1994, which were made available by the majority of municipal population registries and 
included all deceased residents irrespective of the cause of death. Completeness of follow-up 
of vital status is estimated to approximate 100%.
active follow-up after cystectomy
A subset of patients was defined by selecting patients from the cancer registry who underwent 
a cystectomy during 1989-2003. Data for 1989-1997 were collected in 2002. For that period data from two small hospitals out of twenty could not be included because one hospital refused 
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permission to extract data from the medical records and because many patient files had been 
destroyed in the other. Data for 1998-2003 were collected in 2006. A supplementary data set 
which was extracted from the medical records included date of surgery, margins after surgery 
and the development and date of locoregional recurrence (i.e recurrence in the soft tissue in 
the true pelvis). In the second period the occurrence of distant metastases was also collected 
in order to be able to distinguish between isolated locoregional recurrences and locoregional 
recurrence with concomitant metastases. 
Follow up of after cystectomy was minimally 5 years for patients treated until 2002 and 
minimally four and three years for patients treated in 2002 and 2003.
Because active follow-up was not always done at the oncology centre, we cannot guarantee 
that all recurrences in patients with residence outside the region were known to our registry. 
Therefore, patients referred to the oncology centre but living outside of the CCCA region, were 
not included in the analysis of locoregional recurrence and survival after cystectomy.
statistical methods
All statistics were performed in STATA, version 9.0. The postoperative mortality was compared 
between the oncology centre and all other hospitals using a Cox-regression analysis, correcting 
for age groups (<60, 60-74, 75 years or older) and sex. The relative risk of developing a 
locoregional recurrence and risk of death was analyzed using a Cox-regression model. The 
model included the following variables: sex, morphology, T-stage, N-stage, margins, hospital 
type, and treatment period. Kaplan-Meier survival curves were also calculated with STATA. 
Survival analysis after local recurrence included only patients surviving a minimum of three 
months after cystectomy.
resulTs  
centralization and number of cystectomies per hospital 
During 1989-2003 a total of 1185 cystectomies were performed in the twenty hospitals of the 
CCCA region. Table 1 shows that between 1989-1997 cystectomies were performed in all 
hospitals, ranging from less than one to a maximum of nine cystectomies per year. Between 
1998-2003 three hospitals performed more than 10 cystectomies per year. The annual number 
of cystectomies in the oncology centre increased from 7 between 1989-1997 to 30 between 
1998-2003. In the most recent years the proportion of patients with residence in the CCCA 
region that undergoes cystectomy in the oncology centre has further increased to about 30%.
postoperative mortality
The postoperative mortality (≤ 30 days after cystectomy) for all hospitals combined was 3.2%, 
but ranged from 0% to almost 10% (table 1). Between 1989-2003 the postoperative mortality 
was 1.8% at the oncology centre compared to 3.5% in all other hospitals combined (Cox-
regression analysis, correcting for age group and sex: odds ratio [OR] 0.6; p=ns). Between 
1989-1997 postoperative mortality in the oncological centre exceeded the postoperative 
mortality in the other hospitals (4.0% versus 2.9%; OR 0.7; p=ns), while during 1998-2003 
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hospitals (OR 0.3; p=0.09). The median age in the oncology centre was significantly lower than 
in the low volume hospitals (table 1).
locoregional recurrence 
After exclusion of patients with residence outside the CCCA region, stage 0 patients, salvage 
cystectomies, and cases with postoperative mortality, 926 patients remained for the analysis 
of local recurrence: 122 patients were operated in the oncology centre and 804 in one of the 
Table 1  Number of cystectomies and postoperative mortality according to hospital in the region of the com-
prehensive cancer centre amsterdam (ccca), 1989-2003
Number of cystectomies
Hospital 1989-1997 1998-2003 Total
Postoperative 
mortality (%)
median age 
(range)
low volume (<5 cystectomies/year)
a 20 7 27 - 68 (49-83)
b 3 5 8 - 69 (60-75)
d 6 - 6 - 70 (68-77)
e 7 4 11 - 65 (49-72)
f 46 25 71 2.8% 65 (31-82)
g 42 29 71 7.0% 70 (48-85)
h 38 28 66 - 70 (39-84)
i 20 35 55 9.1% 65 (46-85)
J 21 13 34 2.9% 69 (49-75)
l 10 10 20 - 69 (50-75)
m 18 - 18 - 69 (49-81)
n 23 5 28 3.6% 63 (38-79)
o 12 6 18 - 66 (44-77)
s 29 25 54 3.7% 65 (37-87)
T 43 23 66 - 61 (41-84)
Subtotal 338 215 553 2.8% 67 (31-87)
medium volume (5-10 cystectomies/year)
c 31 64 95 5.3% 67 (31-87)
K 46 41 87 5.7% 66 (43-88)
P 80 68 148 4.0% 70 (41-93)
Q 52 25 77 2.6% 62 (32-78)
Subtotal 209 198 407 4.4% 68 (31-93)
high volume (>10 cystectomies/year)
Oncology centre 50 175 225 1.8% 63 (30-80)
Total 597 588 1185 3.2% 66 (30-93)
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other hospitals (table 2). 184 patients (19.9%) developed a locoregional recurrence after 
cystectomy, including six more than five years after cystectomy. The vast majority (91%) of 
recurrences occurred within three years after cystectomy, 81% within two years. Of the patients 
who underwent surgery during 1989-1997, 102 (21.2%) developed a locoregional recurrence. 
During 1998-2003, 82 (18.4%) patients developed a locoregional recurrence (HR 0.7, 95% CI 
0.5-0.9), including 44 (9.9%) isolated locoregional recurrences with no evidence of concomitant 
Table 2  relative risk of locoregional recurrence following cystectomy in patients with invasive bladder cancer, 
region comprehensive cancer centre amsterdam (ccca), 1989-2003
Parameter
Number
of 
cystectomies
Percentage 
locoreg. 
Recurrence
Hazard Ratio
Univariate 
(95% CI)
Multivariate
(95% CI)
sex
males 722 19.7 1 (ref.) 1 (ref.)
Females 204 20.6 1.1 (0.8-1.6) 1.1 (0.8-1.6)
Morphology
transitional cell ca. 844 19.4 1 (ref.) 1 (ref.)
squamous cell ca. 39 12.8 0.5 (0.2-1.4) 0.4 (0.2-1.2)
adenocarcinoma 26 34.6 1.8 (0.9-3.5) 1.5 (0.7-2.9)
undifferentiated ca. 17 35.3 2.7 (1.2-6.1)* 2.2 (1.0-5.0)
T- stage
T1 109 11.9 1 (ref.) 1 (ref.)
T2 410 13.9 1.2 (0.7-2.2) 1.2 (0.7-2.2)
T3 323 26.6 3.1 (1.7-5.5)* 2.9 (1.6-5.3)*
T4 84 33.3 4.7 (2.4-9.1)* 3.9 (2.0-7.7)*
N-stage
Negative 803 18.2 1 (ref.) 1 (ref.)
positive 123 30.9 2.5 (1.8-3.6)* 2.0 (1.3-2.9)*
margins
r0 813 18.5 1 (ref.) 1 (ref.)
r1 70 32.9 2.6 (1.7-4.1)* 1.8 (1.2-2.9)*
rX 43 25.6 2.4 (1.3-4.5)* 1.7 (0.9-3.2)
Hospital
low volume hospital 804 20.0 1 (ref.) 1 (ref.)
oncology centre 122 18.9 1.0 (0.7-1.6) 0.9 (0.5-1.4)
Treatment period
1989-1997 481 21.2 1 (ref.) 1 (ref.)
1998-2003 445 18.4 0.8 (0.6-1.1) 0.7 (0.5-0.9)*
TOTAL 926
* p<0.05, r0= negative, r1= positive, rX= unknown
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9distant metastases. Using the actuarial method to calculate the odds of recurrence, the rates 
were 25% during 1989-1997 and 21% during 1998-2003. 
No statistically significant difference in locoregional recurrence rate was observed between 
the oncology centre (18.9%) and all other hospitals combined (20%) (HR 0.9; 95% CI 0.5-1.4). 
In a sub-analysis of the second period (1998-2003) we compared the risk of isolated locoregional 
recurrence (i.e. in the absence of concomitant distant metastasis) between various hospital 
types. In high volume hospitals (> 10 cystectomies per year: three hospitals), intermediate 
volume (5-10: two hospitals) and low volume (<5: thirteen hospitals) stratified for sex, 
morphology, T-stage, N-stage and margins, no statistically different risk of local recurrence was 
observed (>10 (reference) = 1; 5-10 HR= 0.9; <5 HR=0.8). 
survival after cystectomy
One, three and five year survival after cystectomy was 79%, 56% and 47%, respectively. Five 
year-survival after locoregional recurrence was only 12%. In a multivariate Cox-regression 
model the following variables were independent prognosticators for locoregional recurrence 
and relative risk of death: T-stage, N-stage, margins, morphology, treatment period.
discussion
relation between Volume and outcome
Many studies on the association of volume and outcome after cancer surgery have been 
performed. In most of them, the relation between volume and short term outcome is strong 
and consistent, especially for high risk cancer surgery. 6;13;14 A recent study comparing hospital 
characteristics between low and high volume hospitals in the US showed that differences in 
the processes of care play an important role in post operative mortality. Hospital capacity, 
staffing level, clinical services, diagnostic and interventional health services were at a 
considerably lower level at low volume hospitals as compared to high volume centres.7 All 
these hospital related differences influence morbidity and postoperative mortality. Despite 
this evidence, the underlying mechanisms of the volume outcome relation still remain unclear7;9 
This is further illustrated by Dutch studies comparing survival after surgery for oesophageal 
and pancreatic cancer in low and high volume hospitals, showing contradictory results.15-17The minimum number of cystectomies one should perform to achieve the best outcome is 
difficult to determine. Neither the literature nor this study can answer this question. In this study the total number of cystectomies was analysed, not the number of cystectomies per 
surgeon. Others have tried to determine the optimum caseload per surgeon. In the UK an 
optimum cut-off value of eight cystectomies per year per surgeon was found.1 However, cut-off 
values for low and high volume hospitals and surgeons seem arbitrary and vary in different 
studies.1;5;8;9;11. With a mortality rate between 0.5-5.5% and a morbidity rate from 22-57%, 
cystectomy is considered a high risk procedure.18 These findings have led to centralization of 
such procedures in the United States.9;19 Although no part of a consensus policy, in the greater 
Amsterdam region there seems to be a tendency to centralization, demonstrated by the rise in 
the annual percentage of cystectomies performed at the oncology centre in relation to the total 
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number of cystectomies. Especially between 1997 and 1998, when the annual number of 
cystectomies raised from 7 to 21 and increased to 30 from that moment on. This swift increase 
was the result of the expansion of the urology department in the oncology centre. At this 
moment, 30% of cystectomies in the greater Amsterdam region and almost 10% of the total 
number of cystectomies in the Netherlands is being performed at the oncology centre. 
postoperative mortality
We found an overall postoperative mortality of 3.2%, in range with most recent studies (0.5-
5.5%).9;13;14;19-22 Like in most studies, we observed a lower postoperative mortality rate in the 
oncology centre compared to other hospitals, especially in the second period of our study, after 
an increase of annual cystectomies, although this difference was not statistically significant. 
The median age at cystectomy was lower in the oncology centre as compared to the other 
hospitals. While this may cause better outcome figures, the relation between age and post 
operative mortality in cystectomy is not so strong as compared to gastric and esophageal cancer 
procedures.15-17 Recently, May et al. compared the outcomes of patients younger than 75 years 
and older than 75 years at the time of cystectomy. They found no difference in perioperative 
mortality.23 Other reports confirm their findings.24;25 
Comorbidity could be of utmost importance. 21 However in this population based comparison 
between the two hospital types comorbidity should not play a role, because one would expect 
that comorbidity is equally distributed between all bladder cancer patients in the CCCA region 
treated with cystectomy. However, if selective referral of patients with more comorbidity from 
community hospitals to the oncology centre occurred (as we expect) than the postoperative 
mortality would be higher in the centre. In contrast, the postoperative mortality was lower in 
the centre as compared to the community hospitals. 
In three other hospitals also more than 10 cystectomies per year were performed, and these 
hospitals might be categorized as high volume according to the literature.6 In two out of these 
three hospitals postoperative mortality remained the same during the whole study period. In 
the oncology centre a lower postoperative mortality was seen for the second period when 30 
cystectomies per year were performed. Many changes were introduced at the oncology centre 
after the first period including standardized post operative care, direct postoperative enteral 
feeding, no bowel preparation. Whether these changes are responsible for the difference can 
only be assessed by in depth analysis of hospital and surgeon related factors, which is beyond 
the scope of this analysis.
local recurrence and survival after cystectomy
Differences in definition of local recurrence make it hard to compare recurrence rates between 
studies.26 We found an isolated local recurrence rate of 10% in range with most reports (4%-
25%).27;28 When we look at the overall local recurrence rate with concomitant distant metastases 
this percentage was 19.7%. In patients with a T3 or T4 tumour, the local recurrence rate was 
even higher, 26.6% and 33.3%, respectively.  
A 3% reduction in overall local recurrence rate was observed between the first and second 
period (HR 0.7; 0.5-0.9). Perioperative chemotherapy (3.3% of patients between 1989-1997 
and 6.5% of patients between 1998-2003) might have influenced the risk of developing a local 
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9recurrence in our series. However, because only a few patients (32 neoadjuvant, 14 adjuvant) 
received this treatment no separate analysis was possible. 
In the second period, more patients with stage IV bladder cancer were treated with 
chemotherapy only instead of cystectomy which might explain the lower locoregional recurrence 
rate after cystectomy in the second period. Stage migration between the first and second period 
might play an additional role in the lower locoregional recurrence rate in the second period. 
In the second period the number of stage III/IV patients increased due to better staging 
modalities. When correcting the locoregional recurrence rate for stage in the Cox-regression 
model, the overall (all stages) recurrence rate decreased because of better stratification in the 
various stages.
We found no significant difference between the oncology centre and the other hospitals 
regarding the risk of developing local recurrence. When we compared low (<5 cystectomies/
year), intermediate (5-10 cystectomies/year), and high volume hospitals (>10 cystectomies/
year), again no significant difference on local recurrence was observed. In contrast to the comparison of short-term outcomes after cystectomy, there is only one study 
that reports of the association between volume (hospital or surgeon) and long-term outcome. 
No significant relation between urologist (low volume) and urologic oncologist (high volume) 
and risk of local recurrence after cystectomy was found.10 One of the limitations of our study 
is that we don’t have information about the number of cystectomies per surgeon. Volume 
related differences in survival after cystectomy are small compared to other cancer surgery, 
so large numbers of patients are needed to find a difference.6 Just recently a study was 
published comparing low and high volume hospitals and survival after cystectomy. Five year 
survival rates after cystectomy between low and high volume hospitals were 35 and 39%, 
respectively.6 
In theory, local recurrence and mortality might be good indirect indicators of quality of surgery 
because they are more likely to be dependent on the skills’ and experience of the individual 
surgeon than on hospital related factors.7  Here again, with small differences, much larger 
number of procedures have to be compared to find statistically significant differences. In our 
opinion, hospital related factors could be as important as surgeon related factors in the case 
of cystectomy. Moreover these factors are related to each other. This is underscored by the 
literature, showing higher number of cystectomies being done in larger (semi)academic 
hospitals, having more technical and personal resources.
conclusions
We observed a lower postoperative mortality rate in the oncology centre compared to the low 
volume hospitals, but this difference did not reach statistical significance. Neither could we 
prove a statistical significant relation between hospital volume, local recurrence rate and 
survival after cystectomy. More procedures have to be compared to prove or refute the 
advantages of centralization of cystectomy.  
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absTracT
PurposeTo compare the outcome of two peri-operative protocols with respect to postoperative 
management of cystectomy patients.
Patients and Methods
Between June 2007 and November 2008, 85 consecutive patients with bladder cancer were 
treated with cystectomy and urinary diversion. Patients were operated in 2 hospitals by 4 
experienced urologic surgeons. In protocol A patients were enterally fed via a postpyloric tube 
while the nasogastric tube (NGT) was removed within 24 hrs after cystectomy and selective 
bowel decontamination was given until normal oral intake. In protocol B post cystectomy 
management consisted of total parenteral nutrition (TPN) by a central venous line and NGT 
removal after 24hrs. Hospital stay and complications were compared between the two 
hospitals. 
Results 
More than half of all patients (52%) developed one or more complications within 30 days after 
surgery, 37% in protocol A and 71% in protocol B, p=0.002.
Higher ASA score and protocol type were the only factors significantly associated with early 
complications in both univariate and multivariate analyses. Length of stay was significantly 
shorter with protocol A as compared to B, 13 days vs. 19 days (p=0.006).
Conclusions
Cystectomy and urinary diversion is a procedure with considerable risk of complications. 
Enteral nutrition might be advantageous as compared to parenteral nutrition showing fewer 
complications and shorter hospital stay. A high ASA score is associated with more early 
complications. Selective bowel decontamination may have an additional role in preventing 
infectious complications after cystectomy.
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10inTroducTion
Radical cystectomy is considered therapy of first choice for patients with muscle invasive 
bladder cancer. Although mortality rates have decreased in recent years (0.8-5.0%), 
complications after this procedure are common and may occur in up to half of the patients.1-6 
Patient related factors, such as age, comorbidity, and body mass index (BMI) have been identified 
to be associated with postoperative complications.2-4,7 Surgical expertise is of importance, 
impacting on both the procedure itself and postoperative care. While a threshold for the 
minimum number of procedures is difficult to deduce from the published literature, high 
volume surgeons and high volume hospitals seem to perform better.8,9 However, the underlying 
mechanisms of the volume-outcome relation still remain unclear, making it difficult to identify 
single factors to improve the postoperative course.10 A frequent complication after cystectomy 
is postoperative ileus (POI). Factors such as optimal pain management, removal of nasogastric 
tubes (NGT) within 24 hrs after surgery, and early enteral nutrition (EEN) are thought to play 
a role in the duration of POI. Studies in general surgery and gynaecology have shown a reduced 
incidence of POI in patients without NGT after surgery, suggesting that NGT may actually 
contribute to the development of POI.11 Furthermore, it has been suggested that early enteral 
nutrition as compared to total parenteral nutrition may reduce the duration of POI and 
subsequent postoperative complication and hospital stay in these patients.12
While selective decontamination of the digestive tract (SDD) is used to reduce infections and 
mortality in surgical patients admitted to the intensive care unit, SDD remains to be proven in 
elective surgery.13,14 In urological literature only few studies on postoperative feeding and peri-
operative management after cystectomy have been published.15,16 In cystectomy patients no 
studies on SDD were found. In contrast to gastrointestinal surgery, “fast track” protocols in 
Dutch urology departments are not common practice as many cystectomy patients are still 
treated with NGT and total parenteral nutrition.
Hospital A is a medium sized teaching hospital with a research laboratory, devoted to the 
treatment of cancer. With more than 50 cystectomies by four surgeons per year both the 
hospital and the surgeons are considered “high-volume” according to Dutch standards. To 
illustrate this: in 2006, 47% of all Dutch hospitals performed less then 5 cystectomies per year, 
39% between 5 and 10, and only 14% performed more than 10 cystectomies per year.
In 2000, the “classic” protocol of parenteral feeding by a central venous line after cystectomy 
and leaving the NGT more than 24 hours in cystectomy patients was replaced by a “fast track” 
protocol comprising early enteral feeding via a postpyloric tube and removal of NGT within 24 
hrs (protocol A). 
Hospital B is a general, medium sized, teaching hospital. Since 2006 all cystectomy patients 
are operated by staff members of Hospital A, while postoperative management is kept in the 
hands of the Hospital B staff. In this hospital (Hospital B), post cystectomy management 
included a “classic” protocol comprising total parenteral nutrition (TPN) by a central venous 
line and NGT removal after 24hrs (the nasogastric tube remained in situ until first bowel 
movements, no nausea and a low NGT production)(protocol B). This situation allowed 
comparing the postoperative course in patients after cystectomy in two hospitals with different 
peri- and postoperative management in a patient population operated by the same surgeons.
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PaTienTs and meThods
Between June 2007 and November 2008 all consecutive patients who underwent cystectomy 
for bladder cancer in Hospital A or Hospital B were selected. All patients were seen before 
surgery in the outpatient clinic of Hospital A, scheduled for surgery in one of two hospitals and 
operated by one of the staff members of Hospital A. Hospital stay was measured from the day 
of admission until discharge after cystectomy. Blood loss and duration of surgery were 
registered as noted by the anesthesiology staff. 
pre-operative care
All patients started on low molecular weight heparin the evening before surgery. No bowel 
preparation was performed and patients may drink clear fluids up to four hours before surgery 
and then nil by mouth. In protocol A, all patients were admitted one day before surgery for 
consultation by an entero-stomal therapist, dietician, physiotherapist, and to place a jejunal 
feeding tube (Bengmark®). In addition, patients in protocol A started the evening before surgery 
with three antibiotics: Amfotericin B, Polymyxin E, Ciprofloxacin, and Chlorhexidin Gluconate 
mouth wash as SDD. These three antibiotics were given until first solid oral diet or when enteral 
feeding exceeds one litre after surgery. In protocol B, all patients were admitted the night before 
surgery. On the day of surgery all patients received a NGT and central venous line for TPN.
surgery
All patients were operated by one of four staff urologists’ of hospital A (HP, AB, WM, SH). Three 
types of urinary diversions are offered to patients at both institutes: ileal conduit (Bricker), 
continent cutaneous diversion according to Indiana and orthotopic neobladder (Studer).  In 
males standard cystectomy consisted of removal of the bladder (including peritoneal covering 
with perivesical fat), prostate and seminal vesicles. In females the bladder was removed 
together with the anterior vagina wall, uterus, adnexa and urethra. Cystectomy was preceded 
by dissection of all lymphatic tissue between the ureter crossing of the common iliac artery, 
genitofemoral nerve, bladder wall, branches of the internal iliac artery, lateral pelvic wall, and 
complete obturator fossa. Both hospitals used a combination of general and regional anesthesia. 
Fluid intake during surgery was not measured. Antibiotic prophylaxis was started approximately 
half an hour before the start of surgery and consisted in both hospitals of a combination of 
metronidazole and cephalosporines. No antibiotics were given after surgery (except SDD) 
unless indicated.
post-operative care
Postoperative routine comprised of early enteral nutrition (EEN) in protocol A, total parenteral 
nutrition (TPN) through a central venous line in protocol B. In protocol A the nasogastric tube 
was removed within 24 hours after surgery, in B the nasogastric tube remained in situ until 
first bowel movements, no nausea and a low NGT production. Protocol A patients started with 
enteral nutrition at 20 ml/hr and oral liquids on the 1st day after surgery. On day two enteral 
nutrition was raised to 40 ml/hr and patients are stimulated to eat soft foods. From day three 
till five enteral nutrition was gradually raised to 60 ml/hr and patients were allowed to eat 
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10normally if possible. If patients eat normally enteral nutrition is stopped. Protocol B patients 
started with fluids after removal of the nasogastric tube and oral diet was slowly extended if 
possible. TPN was stopped 24 hours after starting oral diet without problems. In both protocols, 
epidural anaesthesia was gradually lowered and non opoid drugs were given to control pain. 
Opiates as anaesthetic agents were avoided. 
complications
Morbidity after cystectomy was assessed with detailed hospital and outpatient clinical records 
and collected in a database. All events leading to prolonged hospital stay or requiring 
medication or surgical intervention were scored as a complication. Early (postoperative) 
complications were defined as those occurring in-hospital and/or within 30 days after surgery. 
Complications were scored as minor (requiring no treatment or medication only) or major 
(requiring surgical intervention, prolonged hospitalisation and/or admission to an intensive 
care unit). Complications were divided into cystectomy related or non-cystectomy related. All 
complications were graded according to the Clavien grading system (table 1).17 Urinary tract infections were scored if urinary cultures were positive, or if patients developed fever with 
the urinary tract as most likely focus. Ileus was considered prolonged (POI), when it was 
present at day five after surgery. 
statistical analysis
Chi-square tests were used to compare patient and hospital characteristics. Mann-Whitney 
U-tests were used to compare operation time, blood loss, and hospital stay between the two 
protocols. Uni- and multivariate logistic regression models were used to assess factors 
associated with early complications. P-values < 0.05 were considered statistically significant. 
All statistics were performed with SAS 9.1.3. 
resulTs
patients’ characteristics
In hospital A and B 51 and 34 patients were treated, respectively. Of those, 68 were male and 
17 female. As shown in table 2, none of the patients’ characteristics differed significantly 
between both hospitals.
Table 1  postoperative complication grading system according to clavien
grade 0 No events 
grade 1 use of oral medications or bedside intervention
grade 2 use of intravenous medications, total parenteral nutrition (tpN), enteral nutrition, or blood 
transfusion
grade 3 Interventional radiology, therapeutic endoscopy, intubation, angiography, or operation
grade 4 residual and lasting disability requiring major rehabilitation or organ resection
grade 5 Death of patient
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operation time, blood loss, and hospital stay
Table 3 shows the operation time, blood loss, and hospital stay per diversion and protocol. 
There was no significant association between type of deviation and operation time, blood loss, 
or hospital stay. 
complications
Table 4 shows all complications within 30 days after surgery according to protocol, with 
multiple complications in some patients. The number of urinary tract infections was more then 
three times higher in protocol B as compared to protocol A (Table 4). 
Table 2  patients & protocol characteristics
Protocol
a (n=51)
n (%)
B (n=34)
n (%)
Total
n (%) p-value
Gender
male 39 (77) 29 (85) 68 (80)
female 12 (23) 5 (15) 17 (20) ns
Age in years
median [range] 66[39-84] 59[38-74] 62[38-84] ns
Deviation Type
bricker 24 (47) 12 (35) 45 (53)
Neobladder 24 (47) 21 (62) 36 (42) ns
indiana 3 (6) 1  (3) 4 (5)
Pathological tumor category@
ptis/a/1 11 (22) 5  (15) 16 (19)
pt2 17 (33) 10 (29) 27 (32) ns
pt3 16 (31) 15 (44) 31 (36)
pt4 7 (14)  4  (12) 11(13)
Pathological Nodal status *
Negative 35 (69) 24 (71) 59 (69)
positive 16 (31) 10 (29) 26 (31) ns
Previous Radiotherapy+
yes 10  (20) 5(15) 15 (18) ns
Neoadjuvant Chemotherapy
yes 10 (20) 3  (10) 13 (15) ns
ASA-score
asa 1 15 (29) 14 (41) 29 (34)
asa 2 30 (59) 20 (59) 50 (59) <0.05
asa 3 6  (12) 0 (0) 6  (7)
Total 51 (60) 34 (40) 85 (100)
@  according to highest stage after turB. * pathological lymph node status: some pts underwent  FNa/lymph 
node dissection before cystectomy and received neoadjuvant chemotherapy. + salvages after radiotherapy 
included 
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complications. The significant association of protocol and early complications remained after 
adjusting for ASA scores. None of the other variables was associated with early complications. 
Table 3  post operative outcome 
Protocol a (n=51) B (n=34) Total p
operation time in hours
median [range] 4,0[2,5-7,5] 5,0[3,5-7,5] 4,5[2,5-7,5] <0.001
Blood loss in cc
median [range] 1000[100-4700] 2000[550-6150] 1200[100-6150] <0.001
Hospital stay in days
median [range] 13[7-32] 19[7-122] 16[7-122] 0.006
Table 4  early complications (≤30 days) according to protocol with multiple complications in some patients 
Protocol  Total a B 
 n   (%) (%) n (%)
Overall Complication rate 44 (51.7) 19 (37.3) 25 (73.5)
Related to cystectomy 34 (40.0) 14 (27.5) 20 (58.8)
Related to cystectomy
Minor
wound infection 8 (10) 4 (7.8) 4 (12)
prolonged ileus 12 (14) 6 (12) 6 (18)
urinary tract infection 14 (17) 4 (7.8) 10 (29)
Major
rectal injury 1 (1.1) - 1 (3.0)
Fascial dehiscence 4 (4.7) 4 (7.8) 2 (5.8)
ureteroileal leakage 6 (7.1) 3 (5.8) 3 (8.8)
lymphokele 1 (1.1) 1 (2.0) -
Infected central line 2 (2.2) - 2 (5.8)
Bleeding 2 (2.2) 1 (2.0) 1 (3.0)
sepsis 6 (7.1) 2 (3.9) 4 (12)
Death 1 (1.1) - 1 (3.0)
Not related to cystectomy
Minor
Pneumonia 3 (3.5) 1 (2.0) 2 (5.8)
Major
pulmonary embolus 2 (2.2) 1 (2.0) 1 (3.0)
respiratory failure 1 (1.1) - 1 (3.0)
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Table 5 shows the complications per patient according to protocol graded according to Clavien. 
Apart from the difference in the number of patients that experienced no complications, grade 
2 complications were far more common in protocol B as compared to protocol A, 32% vs. 4%, 
respectively.
discussion
The risk of complications in cystectomy patients is associated with characteristics at many 
levels, at the patient level (co morbidity, age, gender, tumour stage, etc.), at the hospital level 
(low volume vs. high volume, academic vs. non academic, oncology vs. general hospital etc.) at 
the level of surgeons (years of experience, average yearly number of cystectomies, oncological 
vs. general urologist etc.) at the level of anaesthesiologists and finally, post-operative procedures 
(TPN vs. EEN, early vs. late removal of NGT, pain management etc.). While controlling for al these factors has been shown to be complicated, we had the opportunity to compare two 
postoperative treatment strategies in a population of bladder cancer patients scheduled for 
cystectomy and operated by the same team of surgeons.10 
Apart from protocol type, we focussed on three different elements: postoperative feeding, 
removal of NGT, and selective bowel decontamination. 
In an earlier study we found an early complication rate of 44% comparable to 37% in this 
cohort.18 The complication rate in protocol B (73%) is higher than earlier reported rates.2,5,7 
However, urinary tract infections (UTI) are not always reported in the literature and account 
for one third of all complications in protocol B. The percentage of UTI in protocol A is lower as 
compared to earlier series, 7.8 versus 12.8%.18 Because the higher number of UTI´s in Protocol 
B which resulted in more frequent use of intravenous antibiotics grade 2 complications were 
more common in protocol B as compared to protocol A. As expected, surgical complications 
(e.g. ureteroileal leakage) were comparable between both protocols because all patients were 
operated by the same group of surgeons and there was no significant difference in the 
characteristics of the patients or the type of surgery.
Table 5  complications per protocol and grade 
Protocol Total* a (n=51) B (n=34)
n (%) n (%) n (%)
grade 0 41 (48.2) 32 (62.7) 9 (26.5)
grade 1 11 (12.9) 7 (13.7) 4 (11.8)
grade 2 13 (15.3) 2 (3.9) 11 (32.4)
grade 3 17 (20.0) 9 (17.6) 8 (23.5)
grade 4 2 ( 2.4) 1 (2.0) 1 (2.9)
grade 5 1 ( 1.2) 0 (0.0) 1 (1.2)
* If more than one complication occurred in one patient, the highest grade was scored
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Total parenteral feeding has long been standard postoperative care, but was changed in 
Hospital A to early enteral feeding based on studies in abdominal surgery showing a decreased 
mortality in patients that were enterally fed (within 24 hrs after abdominal surgery) 
compared to patients without enteral feeding.19 Also a reduced risk of infectious complications 
and decreased hospital stay was found with early enteral nutrition (EEN).19,20  Studies 
comparing EEN and TPN alone after cystectomy could not be identified. In one study EEN 
and TPN alone after oesophagogastric surgery were compared with respect to complications 
and length of stay (LOS). ICU stay, total stay, and interval till first bowel movements were 
significantly shorter in the EEN group as compared to the TPN group. Complications and 
mortality rates were similar in both groups.21 In a trial of 156 critically ill surgical patients 
septic complications were significantly reduced among enterally fed patients as compared 
to those who receiving TPN.22 In a randomized controlled trial among 177 patients undergoing 
major pelvic surgery, EEN was as effective as TPN and reduced septic complications, LOS, 
and costs.23 In the US standard LOS is about 7-8 days median which is relatively short as 
compared to both protocols. 
In our study, patients that received EEN experienced significantly less complications and the 
LOS (corrected for age and diversion type) was significantly shorter as compared to those 
receiving TPN. This was further illustrated as two patients in protocol B developed septicemia 
because of  the subclavian vein catheter. Thus, EEN after cystectomy might be beneficial in 
reducing complications, POI, costs, and LOS. 
removal of Nasogastric tubes 
The use of nasogastric tubes after gastrointestinal surgery has been the traditional method to 
prevent prolonged ileus. Prolonged postoperative ileus (POI) is a frequent complication after 
cystectomy and identified as a major cause of prolonged LOS.12,24 Usually the NGT is removed 
after first bowel movements have been reported. Studies in abdominal surgery have shown, 
however, that NGT increases the risk of pulmonary complications and in contrast to general 
belief, bowel recovery is slower and risk of POI increases.11 Moreover there was no increase in 
anastomotic leakage after early removal (<24hrs) of NG tubes.25 A relative small study in 
cystectomy patients already suggested a reduction in complication rate, earlier bowel recovery, 
and shorter hospital stay.26 Therefore in the US nasogastric tubes are currently not used as 
standard.  In our study the number of patients developing prolonged postoperative ileus was 
lower in protocol A (12%) than protocol B (18%). Because the number of patients is small and 
definition of POI may vary between observers, these percentage are suggestive and have to be 
interpreted with caution.24
selective Decontamination of the Digestive tract in elective surgery
In critically ill patients SDD reduces infections and mortality.13,27,28 In elective colorectal SDD 
reduced the number of urinary tract infectious.14  Thus, selective decontamination of the bowel 
(protocol A) might play a role in the reduction of infectious complications. The number of 
patients that developed a infectious complications (e.g. UTI, wound infection) was significantly 
lower in protocol A as compared to protocol B  patients and although prolonged POI can be 
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responsible for postoperative complications, selective decontamination of the bowel in 
protocol A patients might play an additional role in preventing infectious complications in 
these patients.14,27,28 
Intra-operative parameters
We found significant less blood loss and shorter operation time in protocol A patients as 
compared to B. We hypothesized that a difference in administration of intra operative fluids 
between the two hospitals might explain this difference in blood loss. This interesting factor 
is subject for a future analysis. Nevertheless, blood loss was not associated with a higher risk 
of complications in both uni- and multivariate analyses. While both hospitals are teaching 
hospitals, the less experienced residents are usually stationed in hospital B, giving an 
explanation for longer operation time. However, in the uni- and multivariate regression models 
operation time was not associated with a higher risk of early complications. 
The major limitation of this study is the fact that so many factors at hospital level are hard to 
account for and may confound this comparison. Especially regarding peroperative fluid 
management and postoperative nursing care. These potential confounders impact on the 
outcomes independent of any dietary modifications. In hospital A,  EEN and early removal of 
NGT was already introduced in 2000 and no adverse effects were noted with early removal of 
the nasogastric tube and early enteral feeding. So this strategy seems to benefit cystectomy 
patients and it is reasonable to assume that results from gastrointestinal surgery are compatible 
with urological surgery. Based on the results of this study we embarked on harmonizing the 
peroperative management and the postoperative nursing management.
conclusions
Cystectomy and urinary diversion is a procedure with a considerable risk of complications. 
Early enteral nutrition and early removal of NGT in cystectomy patients might result in fewer 
complications and shorter hospitalization time. High ASA score is associated with more early 
complications. Selective decontamination might have an additional role in preventing infectious 
complications after cystectomy. The role of other factors, like anaesthesia and postoperative 
nursing care should be assessed.
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inTroducTion 
In patients with high risk superficial urothelial cancer of the bladder not responding to 
intravesical Bacillus Calmette Guerin (BCG) therapy, treatment consists of pelvic lymph node 
dissection and cystectomy. After this procedure the risk of tumour progression ranges from 
approximately 5% in patients with pT1G3-N0 bladder cancer to almost 100% in patients with 
pN2 disease.1 Relapsing disease may be systemic, local in the pelvis, in the loco-regional or 
supra-regional lymph nodes, in the urothelial remnants of the upper urinary tract, or urethra.1,2 
Follow up investigations in patients suspicious for upper urinary tract recurrences consist of 
regular urinary cytology examination and intravenous pyelography (IVP). Peritoneal metastases from urothelial cancer are described in the literature, however in all cases patients had muscle 
invasive or extravesical tumours.3 We describe a case of high risk superficial urothelial cancer 
which develops malignant ascites four years after cystectomy and nefroureterectomy and 
discuss the etiology.
case report
A 45-year old female patient was referred to our hospital with a 20-year history of recurrent 
superficial bladder cancer. After restaging by transurethral resection and imaging she was 
diagnosed with a noninvasive high grade tumour with concomitant carcinoma in situ, stage 
TaG3-TisN0M0. The patient was treated with six weekly courses of BCG. Repeat cystoscopy 
showed a small tumour in the urethra. Biopsies were performed. Pathologic examination again 
revealed carcinoma in situ. The patient was treated with six weekly courses of BCG and after 
three months a second series of biopsies was again positive for carcinoma in situ (CIS) and 
high grade superficial urothelial cancer (pT1G3). She subsequently underwent a cystectomy 
with an Indiana pouch. Pathological examination of the cystectomy specimen revealed no 
tumour in the bladder and lymph nodes(19), pT0N0Mx.
Nine months after surgery, urinary cytology was positive for high grade urothelial cancer. X-IVP 
showed a left-sided obstructing mid-ureteral filling defect. Ureterorenoscopy revealed a ureteral 
tumour on the left side. Because of symptomatic distal ureteral obstruction a nefrostomy was 
placed. After one week the patient returned with abdominal pain and leakage along the 
nefrostomy catheter which was replaced. She subsequently underwent a left sided nephro-
ureterectomy and para-aortic lymph node dissection. The left kidney was removed by a transperitoneal approach, to prevent tumour spill the pouch was drained with a catheter and 
the ureter anastomosis was excised from the emptied pouch and followed by immediate closure 
by suture ligation. Pathologic examination revealed CIS in the pyelum and ureter, negative 
margins without lymph node metastases (pTisN0Mx). 
Two years later urinary cytology was again suspicious for high grade urothelial cancer cells. 
On CT-scan no focus was found. Renewed urinary cytology was normal. However 6 months 
later she complained of abdominal distention and pain. A contrast enhanced abdominal 
computerized tomography (CT) showed multiple cysts in the pelvis, intraperitoneal fluid 
(ascites), suggestive for ovarian cancer, not seen at the previous with CT-scan 3 months earlier 
(Figure 1). 
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She underwent a bilateral removal of the ovaries, an infracolic omentectomy, and liver biopsies 
because of suspicious lesions on the liver. Pathological examination revealed peritoneal, nodal 
and liver metastases from urothelial cancer. Immunohistochemistry was positive for CK7 and 
CK 20 but negative for CA125. At this moment she is still alive and is receiving systemic palliative 
chemotherapy. 
discussion 
Intra peritoneal spread of bladder cancer is a rare event in contrast to advanced ovarian, colon, 
gastric, pancreatic, and breast cancer. As a result, malignant ascites may develop because of 
obstruction of lymphatic drainage by tumour cells that prevent the drainage of peritoneal fluid 
and proteins. Peritoneal dissemination of tumour cells can occur by continuous spread in the 
peritoneal cavity, by ascitic fluid containing tumour cells, or by tumour emboli in lymph and 
blood vessels. Direct spread is very likely in tumour growth through the peritoneal face of the 
bladder. This can not be the explanation in our patient as the tumour was organ confined. 
Another explanation could be tumour spill during the several surgical procedures; a sub clinical 
perforation during transurethral resections, urinary spill at nephro-ureterectomy, spill at 
nephrostomy placement, and perforation of the urinary diversion. However, these interventions 
were performed years before the onset of clinical symptoms and the diagnosis at imaging with 
CT-scan. A previous CT-scan performed three months earlier for routine follow-up disclosed 
no pathology. This patient with a very long history of bladder cancer presented with clinical 
signs and pre-operative imaging of ovarian cancer, however pathological examination revealed 
Figure 1 contrast enhanced ct-scan of the abdomen, * within intraperitoneal fluid collections.
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extensive peritoneal dissemination from transitional cell carcinoma (TCC) of the bladder.
Although rare, transitional cell tumours of the ovary exist and can be very difficult to distinguish 
from transitional cell carcinoma from the urinary tract. Furthermore transitional cell bladder 
cancer metastases to the ovaries are described in literature.4 Useful immunohistochemical 
markers that can be used are cytokeratins (CK) 7 and 20. CK 7 is positive and CK 20 is negative 
in primary ovarian transitional cell carcinoma. In transitional cell carcinoma from the bladder 
CK 7 and CK 20 are both usually positive, other markers such as uroplakin III and 
thrombomodulin are also positive.5,6 Brenner tumours of the ovary show urothelial 
differentiation and are positive for markers mentioned above and are very difficult to distinguish 
from urothelial tumours.7
However microscopic findings are different in these tumours and enables to separate the two 
entities. The seeding potential of high-grade TCC is well known and illustrated by recent reports 
of port site metastases after laparoscopic surgery.8-10
Although the exact mechanism is not completely clear in this patient, this case most probably 
underscores the seeding potential of transitional cell carcinoma.
lisT of abbreviaTions 
CIS: Carcinoma in situ
BCG: Bacillus Calmètte Guérin 
TCC: Transitional Cell Carcinoma
CK: Cytokeratin
CA-125: Cancer antigen –125 
IVP: Intravenous pyelography 
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samenvaTTing 
In moderne oncologische behandelstrategieën is orgaanbehoud een belangrijk streven. Bij een 
groot aantal kwaadaardige aandoeningen zoals borstkanker,  kanker in het hoofd-halsgebied, 
endeldarmkanker en weke delen tumoren van de ledematen is behandeling met behoud van 
functie tegenwoordig standaard. Bij patiënten met spierinvasief blaascarcinoom wordt radicale 
cystectomie al dan niet gecombineerd met chemotherapie echter nog steeds beschouwd als 
de standaard behandeling. De al lang bestaande orgaansparende behandeling van het 
spierinvasieve blaascarcinoom is lange tijd internationaal een ondergeschoven kindje geweest 
maar mag zich nu verheugen in een toenemende belangstelling. De resultaten van blaassparende 
behandeling lijken wat betreft prognose en overleving vergelijkbaar met de huidige standaard, 
totale cystectomie. Als casus wordt een 69-jarige patiënt besproken die blaassparend behandeld 
is met brachytherapie.
summary
Organ preservation has been a major goal in modern oncological treatment strategies. For 
many other types of malignancies such as: breast cancer, head- and neck cancer, rectal cancer 
and soft tissue sarcomas of the limbs conservative treatment is standard care. However, for patients with muscle-invasive bladder cancer total cystectomy, with or without chemotherapy, 
is still considered as standard treatment. On the other hand, bladder preserving treatment is 
an already longstanding serious option. Results are promising and prognosis and survival are 
comparable to total cystectomy. In the following case, a 69-year old male patient treated with 
brachytherapy is reviewed.
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12inleiding
In Nederland wordt ieder jaar bij ongeveer 1600 mannen en 500 vrouwen invasief blaaskanker 
vastgesteld en overlijden hier jaarlijks 1000 patiënten aan. De gemiddelde leeftijd ten tijde van 
de diagnose is 64-68 jaar. Ongeveer 90% van de tumoren gaat uit van het overgangsepitheel 
(ook wel urotheel).1 
Bij ongeveer 80% van de patiënten beperkt de tumor zich tot het blaasoppervlak en gedraagt 
deze zich relatief goedaardig. Deze groep patiënten kan met transurethrale resectie van de 
tumor (TURT), al dan niet met adjuvante intravesicale chemo- en immunotherapie en 
regelmatige follow up blaassparend behandeld worden. Het recidief percentage van de tumoren 
(50-70%) is erg hoog ondanks adequate therapie.2 Ongeveer 10% van deze recidiverende 
tumoren wordt spierinvasief. Wanneer patiënten een slecht gedifferentieerde oppervlakkige 
tumor hebben neemt het risico op spierinvasie toe tot wel 50%.3 In 20% van de gevallen groeit 
bij de eerste presentatie de tumor al in het spierweefsel of zelfs buiten de blaas. Wanneer de 
tumor spierinvasief is neemt het risico op occult systemische ziekte toe. 
De gouden standaard voor de behandeling van patiënten met spierinvasieve  tumoren is een 
totale cystectomie. De laatste jaren staat de blaassparende behandeling voor het spierinvasieve 
blaascarcinoom echter steeds meer in de belangstelling. Met de komst van de 
blaassubstitutie(neoblaas) waarbij patiënten een continent urinereservoir van darm hebben, 
is de kwaliteit van leven toegenomen. Daarnaast wordt een zorgvuldig geselecteerde groep 
mannen en vrouwen behandeld met een “sexualiteit preserverende cystectomie en 
neoblaas”(SPCN), waarbij ook de seksuele functie in de meeste gevallen gespaard kan worden.4 
Maar welk type blaasvervanging ook wordt gekozen, geen enkele kan de functie van de eigen 
blaas van de patiënt voor 100% vervangen.
Henningsohn et al. vergeleken de kwaliteit van leven bij patiënten met een neoblaas na 
cystectomie met controles uit de normale populatie.5 De patiënten die een cystectomie hadden 
ondergaan hadden aanzienlijk meer darmproblemen, verminderde seksuele functies, 
urineweginfecties en een verminderd gevoel van aantrekkelijkheid. Daarbij werd achteraf aan 
de patiënten gevraagd of ze een blaassparend alternatief zouden kiezen als ze nog een keer 
konden kiezen. Hierbij zou het grootste deel van de patiënten niet kiezen voor blaassparende 
alternatieven als die de prognose op overleving met minder dan 1% zouden verminderen.5
Eén ding staat vast; bij het grootste deel van de patiënten is voor een blaassparende behandeling 
meer dan één type behandeling nodig, om goede lokale controle te verkrijgen. Behandeling 
bestaat vrijwel altijd uit een combinatie van TURT, adjuvante intravesicale chemotherapie en/
of immunotherapie, partiële cystectomie, uitwendige - en inwendige radiotherapie en systemische 
chemotherapie. Bij het kiezen voor een blaassparende behandeling zijn op dit moment twee 
opties voorhanden; brachytherapie en de combinatie van chemotherapie en uitwendige 
radiotherapie. De volgende casus illustreert de afwegingen die gemaakt worden bij het kiezen 
van blaassparende therapie voor een patiënt met spierinvasief urotheelcelcarcinoom. 
casus 
Een 69-jarige patiënt wordt op de polikliniek gezien in verband met strangurie en microscopische 
hematurie. Bij cystoscopie wordt één exofytische, necrotische tumor met een diameter van 3,0 
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cm op de linker blaaswand gezien. Er wordt een transurethrale resectie van de tumor verricht 
waarbij het PA-onderzoek een hooggradig slecht gedifferentieerde spierinvasieve tumor toont, 
T2G3. Beeldvormend onderzoek levert geen aanwijzingen voor metastasen. De patiënt wordt 
verwezen voor brachytherapie. In eerste instantie wordt 15 x 2Gy uitwendige bestraling 
gegeven en vervolgens worden holle draden door middel van een operatie geïmplanteerd in 
de blaas voor de interstitiële radiotherapie ter plaatse van de tumor en een marge van gezond 
blaasweefsel.De dosis die wordt gegeven bedraagt 40 Gy. Na 14 dagen kan de patiënt het 
ziekenhuis in goede conditie verlaten. Bij follow up onderzoek na vier jaar heeft de patiënt 
geen klachten en een goede blaasfunctie. Tevens zijn er bij cystoscopie na vier jaar geen 
aanwijzingen voor een lokaal recidief. 
behandeling
transurethrale resectie 
TURT en adjuvante intravesicale chemotherapie en/of immunotherapie worden toegepast 
wanneer er geen aanwijzingen zijn voor systemische ziekte en de tumor oppervlakkig groeit, 
d.w.z. geen ingroei in de spierlaag. Bij het grootste deel van de patiënten wordt hiermee een 
goede lokale controle van de ziekte verkregen.6-9 Echter wanneer de tumor oppervlakkig groeit 
en hooggradig is (pT1G3), is er ondanks adequate therapie een aanzienlijke kans op spierinvasie 
(tot 50%) en een hogere kans op recidieven.6,10 Bij deze groep patiënten bij wie blaassparende 
behandeling in 50% een optie is, is het tijdstip waarop een cystectomie moet worden uitgevoerd 
een controversieel punt. Wordt de prognose negatief beïnvloed door eerst een blaassparende 
behandeling te geven?3,11,12 Transurethrale resectie alleen, voor spier-invasieve tumoren, is 
geen goede blaassparende optie. De lokale controle na TURT alleen is in vergelijking met andere 
blaassparende behandelingen slecht. 
partiële cystectomie 
Partiële cystectomie is bij minder dan 10% van de patiënten een behandelingsoptie. Patiënten 
moeten hiervoor aan een aantal voorwaarden voldoen: solitaire laesie, geen carcinoma in situ 
(CIS) en de locatie van de tumor moet een complete resectie mogelijk maken.13,14
In tegenstelling tot de transurethrale resectie, waarbij in 33-50% van de patiënten de tumor 
“onder gestadieerd” wordt ( pathologisch onderzoek laat in 33-50% spierinvasie zien, i.t.t het 
weefsel van de transurethrale resectie), is het mogelijk om de volledige dikte van de blaaswand 
te reseceren en een regionale lymfklier resectie te doen.15,16 De 5-jaars overleving van de totale 
groep patiënten is 69%.13
radiotherapie
Verbeteringen in de selectie van patiënten hebben ertoe geleid dat een blaassparende 
behandeling een alternatief kan zijn voor een selecte groep patiënten. Tevens hebben 
verbeteringen in de radiotherapie ertoe bijgedragen dat de prognose van patiënten na 
radiotherapie is verbeterd.
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Uitwendige radiotherapie is een alternatief voor patiënten die in een lichamelijk slechte conditie 
zijn of geen chirurgische behandeling willen ondergaan.Uitwendige bestraling alleen bij spier-
invasieve tumoren levert een matige lokale controle (40-50%) op.17
radiochemotherapie 
Door uitwendige bestraling te combineren met systemische chemotherapie worden de 
tumorcellen in theorie gevoeliger voor radiotherapie met als gevolg een betere respons.18 
De chemotherapie wordt neoadjuvant of tegelijkertijd met de radiotherapie gegeven en 
bestaat meestal uit een combinatie van Methotrexaat, Vinblastine, Doxyrubicine (Adriamycine) 
en Cisplatina (M-VAC). Hoewel de combinatie van radiotherapie met chemotherapie nog 
nooit door middel van gerandomiseerd onderzoek is uitgezocht, zijn de resultaten 
veelbelovend.19 
Hoewel het principe van deze behandeling in alle centra gelijk is, is met name de follow up 
na TURT en in sommige gevallen na inductietherapie verschillend.20,21 In de twee centra met 
de meeste ervaring op dit gebied, de universiteit van Erlangen in Duitsland en het 
Massachusetts General Hospital Cancer Center in de Verenigde Staten wordt de patiënt op 
verschillende wijze behandeld. In Erlangen geeft men radiochemotherapie en vervolgens 
ondergaat de patiënt een tweede TURT. Wanneer er een complete response is, wordt de 
patiënt alleen vervolgd. Wanneer er geen response is wordt een (salvage) cystectomie 
verricht. In Massachusetts wordt er daarentegen eerst inductie radiochemotherapie gegeven 
en daarna een cystoscopie verricht om te kijken of er een complete response is. In dat geval 
wordt de rest van de radiochemotherapie gegeven. Wanneer er geen volledige response is 
wordt een “salvage”cystectomie verricht.20,21
Met deze behandelingen wordt een complete remissie bereikt in 60-70% van alle patiënten. 
Langdurige lokale controle zonder metastasen wordt in de meerderheid van deze patiënten 
bereikt. Ongeveer 80% van de patiënten die langdurig overleven behouden de blaas.18,22
Brachytherapie in combinatie met uitwendige radiotherapie
Patiënten met solitaire tumoren beperkt tot de blaas (pT1-2, TNM 2002), met een diameter 
kleiner dan 5 cm kunnen worden behandeld met een combinatie van uitwendige radiotherapie 
en inwendige radiotherapie. De patiënt wordt eerst bestraald met uitwendige radiotherapie 
gevolgd door inwendige radiotherapie. Uitwendige radiotherapie wordt gegeven om te 
voorkomen dat er uitzaaiingen ontstaan naar het litteken. Bij een aantal patiënten wordt de 
macroscopische tumor chirurgisch verwijderd, omdat de tumor in de blaaskoepel ligt of 
omdat de overgebleven tumor te groot is voor brachytherapie alleen. Inwendige bestraling 
of brachytherapie, bestaat uit het implanteren van holle draden in het tumorgebied die 
vervolgens worden geladen met radioactief 122Iridium. (Afbeelding 1) Met deze therapie 
wordt een relatief hoge dosis straling in een klein gebied gegeven, waardoor het omliggende 
gezonde weefsel zo veel mogelijk wordt gespaard. Een groot voordeel van deze benadering 
is dat er geen systemische chemotherapie nodig is.
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Quality of life na blaassparende behandeling
Er is weinig onderzoek gedaan naar de kwaliteit van leven na blaassparende behandeling en 
na cystectomie. De meest betrouwbare studie op dit gebied, door Henningsohn et al. is al 
genoemd in de inleiding.5
In het merendeel van de patiënten die hun blaas hebben behouden, is de blaasfunctie normaal. 
In een klein deel van de patiënten(2-3%) is de compliance (elasticiteit, waardoor bij kleine 
vulling van de blaas al snel een mictiedrang optreedt) van de blaas verminderd. Bij een klein 
aantal vrouwen is er sprake van incontinentie. Controle over de darmen is bijna nooit een 
probleem. Hoewel er weinig onderzoek is gedaan naar seksuele functie na blaassparende 
behandeling, lijkt meer dan de helft van de mannen die radiotherapeutisch behandeld zijn een 
adequate erectiele functie te hebben en tevreden te zijn met hun seksuele activiteit. Over 
vrouwen is hierover geen betrouwbare informatie beschikbaar.5,23-25
overleving 
TURT in combinatie met externe radiotherapie en tegelijkertijd chemotherapie lijkt een veilige 
optie in een zorgvuldig geselecteerde patiëntengroep. Patiënten die na inductie met chemo-
radiatie klinisch een volledige respons hebben(60-70%) zijn kandidaat voor een blaassparende 
behandeling. De overleving in deze groep patiënten is vergelijkbaar met patiënten behandeld 
na totale cystectomie. (40-63% na 5 jaar ) 
80% van de patiënten die een volledige respons hebben (60-70%) behouden de blaas na 
langdurige overleving. Patiënten die na inductie therapie geen volledige remissie hebben 
Afbeelding 1   
Drie Brachytherapie loops 
geïmplanteerd in het gebied 
van de blaastumor met een 
marge gezond blaasweefsel. 
De tumour is omcirkeld. De 
pijl wijst naar één van de drie 
loops. eén loop door het tu-
mourgebied en twee langs de 
tumour.
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12kunnen een “salvage” cystectomie (met of zonder adjuvante chemotherapie) ondergaan . De 
prognose na een “salvage” cystectomie in de patiënten behandeld met radiochemotherapie is 
vergelijkbaar met die na een primaire cystectomie.20,21
Brachytherapie heeft het voordeel dat patiënten geen systemische chemotherapie krijgen. 
Nadeel is dat alleen patiënte met een solitaire tumor kleiner dan 5 cm behandeld kunnen 
worden. Bij 75% van de patiënten wordt een goede lokale controle verkregen en 90% van de 
patiënten behoudt de blaas.
Vergelijkingen tussen radiotherapie en cystectomie zijn een probleem omdat brachytherapie 
patiënten solitaire tumoren kleiner dan 5 cm hebben en dat in de meeste cystectomie studies 
niet het geval is. Daarnaast wordt in de meeste cystectomie studies de pathologische TNM 
classificatie wordt gebruikt i.t.t. de klinische stadiëring in radiotherapiestudies, dit kan leiden 
tot onderstadiëring in de brachytherapie groep. Maar ondanks deze beperkingen lijkt de 
overleving in brachytherapie studies vergelijkbaar met die in de meeste cystectomie studies26,27
Behandeling recidief na blaasparende therapie
Na radiotherapie worden patiënten iedere 3-4 maanden vervolgd d.m.v. cystoscopie. In 25-40% 
van de gevallen is er een lokaal recidief of persistente ziekte, afhankelijk van het 
tumorstadium.17 
Patiënten met oppervlakkige tumorrecidieven kunnen conservatief behandeld worden met 
TURT en intravesicale chemo/immunotherapie. Wanneer de tumor spierinvasief is of er zijn 
multipele oppervlakkige tumoren wordt er een “salvage” cystectomie verricht. Patiënten met 
metastasen op afstand of een lage performance score zijn geen kandidaten voor cystectomie. 
Minder dan 10% van de brachytherapie patiënten hebben uiteindelijk een“salvage“ cystectomie 
nodig i.t.t. ongeveer 33% bij de patiënten die behandeld zijn met radiochemotherapie. Het is 
nog niet duidelijk of er een verschil in overleving is tussen patiënten die een “salvage” 
cystectomie ondergaan na uitwendige radiotherapie of brachytherapie. Het lijkt erop dat 
patiënten na brachytherapie een betere prognose hebben.28
praktische aanwijzingen
(Figuur 1)
Wanneer patiënten zich presenteren met een spierinvasieve blaastumor en er geen aanwijzingen 
zijn voor metastasen zijn er een aantal blaassparende alternatieven beschikbaar. Brachytherapie, 
voor patiënten met solitaire tumoren met een diameter kleiner dan 5 cm, waarbij de tumor 
niet in de blaashals gelegen is. Hierbij wordt een overleving bereikt vergelijkbaar met totale 
cystectomie. Radiochemotherapie voor patiënten met een goede performance score, die een 
tumor hebben die groter dan 5 cm in diameter is. Ook hierbij zijn de resultaten vergelijkbaar 
m.b.t. de overleving met die na totale cystectomie. Echter, een nadeel bij deze vorm van therapie 
is dat de patiënt naast radiotherapie ook chemotherapie krijgt.  
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Figuur 1  Flow diagram behandelmogelijkheden blaascarcinoom
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Radical cystectomy is considered standard as curative therapy for muscle invasive bladder 
cancer. The aim of this thesis was to describe the treatment results of a contemporary series 
of cystectomy in the Netherlands.
Understaging of invasive bladder cancer patients is a well-known problem.1,2 In chapter 3, 
pathological stage after cystectomy was higher than clinical stage in more than half of the 
patients. Understaging is not only the result of the shortcomings of imaging but also related to 
the treatment delay of invasive tumours. It is well known that prognosis worsens when 
cystectomy for muscle invasive bladder cancer is delayed more than 3 months after initial 
diagnosis.3,4 Identifying tumours who are high risk for progression (TaG3, T1G3) remains a 
major challenge and the inability to select candidates for immediate or early cystectomy may 
result in overtreatment in these patients but is more often advocated because of the good 
prognosis after cystectomy in comparison to muscle invasive patients.5-9 The option of an ileal 
neobladder with preservation of continence might play an additional role towards choosing 
for “earlier” cystectomy in this difficult patient group.10,11
The role of urinary markers for diagnosis, monitoring recurrence and progression of non 
invasive tumours is still limited, but could become important in the future, because of rising 
incidence of NMIBC (Chapter 1) and to minimize the number (and costs) of repeated 
cystoscopies for surveillance of non invasive tumours.12-15
In localized disease primary treatment of muscle invasive bladder cancer is radical cystectomy. 
In advanced or disseminated disease, systemic therapy is the only option to achieve prolonged 
progression free survival. From 1989 onwards, when platinum based chemotherapy was 
introduced several modifications to the original regimen have been made.16,17 In recent years 
the combination of Cisplatin and Gemcitabin therapy is widely used because of less toxicity 
and equal response rates. With this combination response rates of 60% have been 
reported.18 
Because up to half of the patients with muscle invasive disease harbour micro metastases or 
have locally advanced disease, cystectomy as primary therapy seems insufficient in these 
patients. A combination of surgery and chemotherapy in these patients might be a solution to 
achieve better outcomes.19-24
The 5-year survival benefit of patients with muscle invasive bladder treated with neoadjuvant 
chemotherapy and cystectomy is around 5%.21 Delay of cystectomy (>12 weeks) because of 
the administration of neoadjuvant chemotherapy might be associated with adverse outcome 
in patients who undergo primary surgery.7,25 However, recently it was shown that cystectomy 
can be delivered within 10 weeks after neoadjuvant chemotherapy without compromising 
patient survival.26
Chemotherapy after cystectomy might advantageous because primary treatment is not deferred, 
but the survival benefit for adjuvant chemotherapy is even less clear. There is insufficient 
evidence on which to reliably base treatment decisions. Results of appropriately sized 
randomised trials, such as the EORTC-30994 trial were eagerly awaited to answer this question 
but unfortunately this trial was closed prematurely because of poor recruitment. 
The question if (neoadjuvant) chemotherapy should be given to all patients with muscle invasive 
bladder cancer remains controversial. Some patients would certainly benefit but for others it 
would be overtreatment and expose them to significant toxicity.19 New biomarkers that can 
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13detect subclinical early metastases may be helpful in selecting patients who would benefit of 
additional chemotherapy. In a recent study it was found that patients with clinically non-
metastatic bladder cancer that harbour circulating tumour cells have a higher risk of early 
disease relapse and death. This group of patients might benefit from additional 
chemotherapy.27In Chapter 4 we describe the use of neoadjuvant chemotherapy as a selection criterion to 
proceed with cystectomy if a clinical response is achieved in patients with (supra-regional) 
tumour positive lymph nodes.28,29 With this strategy we might be able to select patients that 
benefit from subsequent cystectomy (and extended lymph node dissection) and those who 
probably wouldn’t.
Small cell carcinoma of the bladder (SCCB) is a rare histological entity.30 Because most patients 
present with advanced stage and dismal prognosis on short term, cystectomy in these patients 
is probably not the therapy of first choice. In analogy to limited disease small cell carcinoma 
of the lungs the mainstay of treatment is systemic chemotherapy with local control being less important as has been shown in several reports (Chapter 5).31-34 In small cell cancer of the 
lung, where brain metastases are common (2-30%) prophylactic cranial irradiation is 
considered standard therapy.35 However, in SCCB brain metastases occur less frequently and 
prophylactic cranial irradiation is not recommended as standard therapy.31,36 
After cystectomy some form of urinary diversion is needed. The increase in the number of cystectomies in comparison with radiotherapy as primary therapy in elderly patients (Chapter 
1) indirectly to leads an important question: what form of deviation to perform in which 
patient? Does age, tumour stage, previous chemotherapy and other factors influence the choice 
of diversion? In Chapter 6 an attempt was made to answer this question. The ideal urinary 
diversion must prevent deterioration of kidney function and provide good functional results 
in continent diversions. The choice of diversion is dependent on various factors such as kidney 
function, age, and patients’ choice if possible. At our institute we have seen a partial shift from 
incontinent diversions (ileal conduit) and continent reservoirs (Indiana pouch) to orthotopic 
continent diversions (neobladder). We found no evidence that age, ASA-score, positive lymph 
nodes, extravesical tumour growth, or previous radiotherapy are contraindications for any 
type of diversion. 37,38 Furthermore, in a recent analysis on this subject, it was shown that in 
patients with and orthotopic bladder substitution and pre-existent hypertension or diabetes 
renal function could be preserved in a higher percentage as compared with patients and an 
ileal conduit ten years after surgery.39  
Metabolic complications after cystectomy occur in almost 25% of all patients, with a higher 
frequency in continent diversions in comparison to incontinent diversions (Chapter 6). 
Although less than half of these patients needed treatment, recent developments in tissue 
engineering, i.e. the development of an artificial bladder made of stem cells might resolve these 
metabolic complications.40
Whereas oncological outcome was the only important factor in historical series, in modern 
oncological treatment strategies organ preservation and function becomes more and more 
important. Quality of life is becoming more and more important. 
In bladder cancer, quality of life after cystectomy and urinary deviation is still poorly assessed. 
The use of orthotopic continent deviations has led to improved quality of life as compared to 
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ileal conduits. However, several studies have shown the adaptability of patients to an ileal 
conduit.41,42 In one Swedish study cystectomy patients with a orthotopic neobladder were 
compared with controls in the normal population. They found that cystectomy patients 
experienced more intestinal problems, impaired sexual functions and urinary tract infections. 
Interesting in this study was the fact that if patients could choose again (afterwards) for bladder 
sparing alternatives and prognosis of survival would be diminished with less than 1% they 
would choose for cystectomy despite lesser quality of life.43 
The impact on sexual functions after radical cystectomy in both males and females is a serious 
one. The prostate sparing cystectomy as described in chapter 7 can preserve sexual functions 
in the absolute majority of patients without jeopardizing the oncological results.44-47 Meticulous selection of patients is the key to success and we consider this procedure as safe as standard 
cystectomy in a selected group of patients.48-50 
In most high risk surgical procedures outcome is directly related to the number of procedures 
performed both on hospital as well as on surgeons’ level.51-54 For cystectomy this relationship 
is strong and consistent (at the hospital level) for 30 days mortality, however for long term 
results this is not clear yet. In our study (Chapter 9) we didn’t find a significant relation between volume and mortality 
in the Greater Amsterdam region, however recently the relation between high volume and 
lower mortality was confirmed in a larger nationwide study.55
At the moment, the Dutch urological society has developed quality criteria for cystectomy. As 
of January 2012 all Dutch cystectomy patients have to be registered in a nationwide database. 
Furthermore, average 30 day-mortality has to be below 6% in the past three year (adjusted 
for case mix factors).
One of the main criteria is to perform more than 10 cystectomies annually per hospital. Recently 
a large health insurance company (3,4 million policy holders) followed and published a “black 
list” with hospitals that do not meet these criteria and are not contracted to perform 
cystectomies in 2012. However, these numbers are arbitrary and the optimal number is difficult 
to deduce from the literature.56-60 Ten cystectomies annually seems low when taken into account 
that they are performed in one hospital by two or even more surgeons. A number of 
approximately 100 or more per year in one hospital seems more appropriate if we compare 
these numbers with high volume cancer centres in the US. In the Netherlands, approximately 
600 cystectomies are performed annually so if we want to reach the threshold of 100 
cystectomies per year, we would need only 5 to 6 hospitals with 12 to 15 specialized oncologic 
urologists. 
The high rate of postoperative complications after cystectomy even when performed by 
specialized oncologic urologists in specialized centres is a serious problem.61-66 In Chapter 10 
we described a group of cystectomy patients treated by the same surgeons in two different 
hospitals. Although this study was not randomized it indicated that differences in postoperative 
management of cystectomy patients can make a difference in postoperative outcomes. 
Early enteral feeding and early removal of nasogastric tubes in the frame of a “ fast track” 
protocol which is common in gastrointestinal surgery could play an important role in optimizing 
the short term outcome and minimizing hospital stay after cystectomy.66-73 However, randomized 
trials in cystectomy patients are scarce and more research in this field is needed. 
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13In critically ill patients in the ICU, selective decontamination of the digestive tract (SDD) reduced 
infectious complications and mortality.74,75 In elective patients that underwent colorectal 
surgery, SDD prevented infectious complications but did not influence hospital stay and 
mortality.76 The role of SDD in cystectomy patients is not clear and needs to be investigated in 
a randomized setting.
Intra-operative fluid management in cystectomy patients might also play an important role in 
the occurrence of postoperative complications. Fluid overload during surgery may lead to 
paralytic ileus, pulmonary complications and impaired wound healing.77,78 Restrictive fluid 
administration may play a role in prevention of complications in cystectomy patients. However 
until now results are conflicting and for cystectomy patients no studies exist on this 
subject.79,80
In a recent analysis in our hospital the peri-operative fluid balances of 50 consecutive cystectomy 
patients were examined. Twenty nine out of 50 (58%) patients had a positive fluid balance of 
more than two litres directly after surgery, ranging from 339 cc to 4633 cc. 
After ICU day one still 44 patients had a positive fluid balance of more than 2 litres, among 
them 10 more than 4 litres. For future analysis it would be interesting to compare these patients 
in relation to fluid balance, complications and hospital stay.
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summary
A short overview of the etiology, diagnosis, treatment, and prognosis of bladder cancer is given in chapter 1. Chapter 2 describes the incidence and survival data of bladder cancer between 
1989 and 2009 in the Netherlands. For both males and females the incidence of non invasive bladder cancer increased, the incidence of invasive bladder remained the same in males and 
slightly increased in females. Reasons for this might be the increased awareness of both patients 
and urologists of signs and symptoms of early bladder cancer. The number of cystectomies in 
stage II and III bladder cancer patients is still rising for both patients below and above the age 
of 75. So far survival did not improve.
Identifying the patients in whom non-muscle invasive bladder cancer (NMIBC) will progress 
despite bladder sparing therapy is a major challenge. In chapter 3 we described a group of 
patients presenting with NMIBC that progressed to muscle invasive disease and compared 
survival in patients with patients presenting with primary muscle invasive bladder cancer, all 
treated by cystectomy and regional lymph node dissection. Survival in patients who progress 
to muscle invasion is not any better than patients presenting with primary muscle infiltrating 
cancer. Patients with high-risk NMIBC who progress to muscle invasive disease before 
cystectomy have even a worse prognosis compared to patients with low-intermediate risk 
NMIBC who progress to muscle invasion. The number of patients with locally advanced and 
lymph node positive disease was unexpectedly high in the group that progressed to muscle 
invasive disease. The optimal timing of cystectomy is difficult to determine, active restaging 
(re-TUR) during conservative management of non muscle invasive bladder cancer and the use 
of EORTC tables can be helpful. T-stage and grade progression are probably just as important 
signs for early cystectomy as the traditional criterion of muscle invasion.
Chapter 4 describes a small group of bladder cancer patients presenting with supra-regional 
lymph node metastases without synchronous hematogenic metastases treated with combination 
therapy. When patients achieve a clinical complete or partial response after chemotherapy, 
cystectomy follows. In this selected group 24% of patients survive 5 years after cystectomy. In 
Chapter 5 we retrospectively evaluate the clinical and oncological outcome in a series of 16 
patients with limited-disease small cell carcinoma of the bladder (LD-SCCB), who were treated 
with sequential chemoradiation. Due to poor prognosis because of early hematogenic spread 
a bladder-preserving strategy with sequential chemoradiation is an attractive concept in 
contrast to focus on local control by cystectomy. Long-term remission and potentially cure can 
be achieved in some, with 2 of the patients (11.7%) in this series still free of disease after more 
than 5 years at a local recurrence rate of 23.5%. The fact that none of the patients died of 
locoregional tumour progression supports our view that cystectomy is not the preferred initial 
treatment for LD-SCCB. Chapter 6 deals with the association of clinical factors, complications 
and functional results of 4 different diversions after cystectomy. In total 281 patients underwent 
a cystectomy and urinary deviation: Of these patients 118 received an ileal conduit (IC), 51 an 
Indiana pouch(IP), 62 a neobladder(CN), and 50 a sexuality preserving cystectomy and 
neobladder (SPCN). 124 patients developed one or multiple complications within the first 30 
days, leading to an early complication rate of 44%. High ASA-score was the only factor 
significantly associated with early major complications in both univariate (ASA 1 vs. 3: HR 0.32; 
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95%C.I. 0.14-0.72) and multivariate analyses (HR 0.36; 95%C.I. 0.14-0.91). None of the other 
variables were associated with early major or minor complications. Late complications occurred 
in 139 patients (51%). Patients with an ileal diversion had lower risk of developing late 
complications compared to patients with a neobladder; 49%(IC), 62%(IP), 59%(CN), 
60%(SPCN), respectively. Provided that patients’ choice is based on thorough pre-operative 
consultation, we found no evidence that age, ASA-score, positive lymph nodes, extravesical 
tumour growth, or previous radiotherapy are contraindications per se for any diversion. 
Organ preservation has been a major goal in modern oncological treatment strategies. For 
many other types of malignancies such as: breast cancer, head- and neck cancer, rectal cancer and soft tissue sarcomas of the limbs conservative treatment with preservation of function is 
standard care. However, for patients with muscle-invasive bladder cancer radical 
cystoprostatectomy, with or without chemotherapy, is still considered standard treatment. In 
Chapter 7 the long term oncological results of the prostate sparing cystectomy(PSC) are 
presented. Goal of this procedure is to preserve sexual functions without jeopardizing 
oncological outcome. A selected group of 63 men underwent a PSC, and were matched with 73 
men who received a standard cystectomy and orthotopic neobladder. No statistically significant 
differences were found in local recurrence rate or distant metastases (7.9% and 16%, p=0.1; 
29% and 33%, p=0.4 in the PSC and in the SC, respectively). The 3 and 5-year disease specific 
survival rates were 77% and 66% in the PSC group and 68% and 64% in the SC group (log-rank, 
p=0.6). In the multivariate analysis, only extravesical disease (HR 3.58, p=0.003) and tumour 
positive lymph nodes (HR 5.75, p=0.0004) were significantly associated with survival. Two 
patients in the PSC group developed prostate cancer, one died after 126 months due to 
metastatic bladder cancer; the other is still alive at 50 months of follow-up. In the SC group, 
incidental prostate cancer was found in nine patients (18%). None of the local recurrences in 
the PSC group was in the remnant prostatic urethra or prostate. 
After cystectomy pelvic recurrence rates vary between 4-34%, while distant metastases occur 
in up to 50% of all patients, both highly dependent on stage. In Chapter 8 we analysed patterns 
of recurrence and relapse presentation in association with clinicopathological factors, and the 
tools used for diagnosis. We studied 343 consecutive patients treated with cystectomy and bilateral lymphadenectomy for bladder cancer at the Netherlands Cancer Institute-Antoni van 
Leeuwenhoek Hospital from 1990 till 2006. Pelvic recurrences were more often seen with 
increasing pathological T-stage and after non-radical procedures. Sexuality preserving 
procedures were associated with less pelvic recurrences. Only pT4b tumours were independently 
associated with pelvic recurrence in multivariate analyses. In multivariate analyses tumour positive lymph nodes, and pre-operative dilatation of the upper urinary tract remained 
independent risk factors for development of distant recurrences. 84% of all recurrences 
occurred within 2 years, the latest recurrence was detected 7.9 years after cystectomy. Of all 
recurrences 64% was symptomatic at the time of diagnosis, while the minority (34%) was 
diagnosed at the standard follow-up. Follow-up after cystectomy should be based on risk 
adjusted schedules. Although the majority of recurrences presents with symptoms, these data 
show a survival benefit after a-symptomatic recurrence. High pathological T-stage, tumour positive lymph nodes, pre-operative dilatation of the upper urinary tract, and tumour positive 
surgical margins are clinicopathological factors that can help selecting patients at high and low 
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risk for recurrence, resulting in less frequent and more cost-effective follow-up. For now, 
therapeutic options in patients with symptoms at time of recurrence are limited and prognosis 
is poor. In Chapter 9 the outcome after treatment of bladder cancer is compared between low volume 
hospitals and an oncology centre (NKI-AVL) in the Greater Amsterdam Region(CCCA). All 
primary bladder tumours diagnosed and treated during 1989-2003 were selected from the 
CCCA Registry, a population based cancer registry with complete regional coverage (population 
3.0 million). A total of 1185 cystectomies were performed in the twenty hospitals of the CCCA 
region. The postoperative mortality (≤ 30 days after cystectomy) for all hospitals combined 
was 3.2%, but ranged from 0% to almost 10%. Between 1989-2003 the postoperative mortality 
was 1.8% at the oncology centre compared to 3.5% in all other hospitals combined. 184 patients 
(19.9%) developed a locoregional recurrence after cystectomy, including six more than five 
years after cystectomy. The vast majority (91%) of recurrences occurred within three years 
after cystectomy, 81% within two years. No statistically significant difference in locoregional 
recurrence rate was observed between the oncology centre (18.9%) and all other hospitals 
combined (20%). More procedures have to be compared to refute or prove the benefits of 
centralization. In Chapter 10 the short term outcome of cystectomy patients is described 
comparing two different perioperative protocols. Between June 2007 and November 2008, 85 
consecutive patients with bladder cancer were treated with cystectomy and urinary diversion. 
Patients were operated in 2 hospitals by 4 experienced urologic surgeons. In hospital A patients 
were enterally fed via a postpyloric tube while the nasogastric tube (NGT) was removed within 
24 hrs after cystectomy and selective bowel decontamination was given until normal oral 
intake. In hospital B post cystectomy management consisted of total parenteral nutrition (TPN) 
by a central venous line and NGT removal after 24hrs. Hospital stay and complications were 
compared between the two hospitals. More than half of all patients (52%) developed one or 
more complications within 30 days after surgery, 37% in hospital A and 71% in hospital B. 
Patients treated in hospital A had a shorter length of stay 13 days vs. 19 days, as compared to 
hospital B patients. Enteral nutrition might be advantageous as compared to parenteral 
nutrition showing fewer complications and shorter hospital stay. Selective bowel 
decontamination may have an additional role in preventing infectious complications after 
cystectomy.Intra peritoneal spread of bladder cancer is a rare event in contrast to advanced ovarian, colon, 
gastric, pancreatic, and breast cancer. In Chapter 11 we describe a 45-year old female patient 
with a 20-year history of recurrent non-muscle invasive bladder cancer treated with BCG instillations and repeat transurethral resections and eventually a cystectomy and nefro-
ureterectomy. This patient with a very long history of bladder cancer presented with clinical 
signs and pre-operative imaging of ovarian cancer four years after cystectomy, however 
pathological examination revealed extensive peritoneal dissemination from transitional cell 
carcinoma (TCC) of the bladder. The seeding potential of high-grade TCC is well known and 
illustrated by recent reports of port site metastases after laparoscopic surgery. Although the 
exact mechanism is not completely clear in this patient, this case most probably underscores 
the seeding potential of transitional cell carcinoma. In Chapter 12, bladder sparing strategies 
are discussed and a bladder cancer patient treated with brachytherapy is described.
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In hoofdstuk 1 wordt een korte introductie gegeven over de etiologie, behandeling en prognose 
van het blaascarcinoom. Hoofdstuk 2 beschrijft de incidentie en overleving van blaascarcinoom 
patiënten in Nederland tussen 1989 en 2009. Voor zowel mannen als vrouwen steeg de 
incidentie van het niet invasieve blaascarcinoom terwijl de incidentie van het invasieve 
blaascarcinoom gelijk bleef bij mannen en iets daalde bij vrouwen. Verklaringen hiervoor zijn 
mogelijk toegenomen bewustzijn en alertheid ten aanzien van de eerste symptomen van 
blaascarcinoom bij zowel patiënten als urologen.
Het aantal cystectomieën als primaire therapie voor stadium II en III blaascarcinoom is nog 
steeds aan het toenemen voor zowel patiënten onder de 75 jaar als patiënten boven de 75. 
Ondanks deze toename is de overleving niet verbeterd. 
Vroege herkenning van patiënten die ondanks blaassparende therapie voor niet spierinvasief 
blaascarcinoom (NSIBC) spierinvasief blaascarcinoom(SIBC) ontwikkelen is een grote uitdaging. In hoofdstuk 3 beschrijven we een groep van NISBC patiënten die spierinvasief blaascarcinoom 
ontwikkelden. Deze groep werd vergeleken met patiënten met primair spierinvasief 
blaascarcinoom die een cystectomie ondergingen. De overleving in beide groepen was niet 
verschillend. Patiënten met hoog risico NSIBC en die progressie vertoonden hadden een 
slechtere overleving in vergelijking met laag/intermediair risico NSIBC na cystectomie voor 
spierinvasief blaascarcinoom. Het aantal patiënten met vergevorderde ziekte was onverwacht 
hoog in the groep patiënten die progressie vertoonden naar spierinvasieve ziekte. Het  optimale 
moment van cystectomie is moeilijk te bepalen, actieve herstadiëring (re-TUR) gedurende 
conservatieve behandeling van NSIBC en het gebruik van EORTC tabellen kunnen hierbij helpen. 
Progressie van T-stadium en differentiatiegraad zijn waarschijnlijk net zo belangrijke criteria 
voor vroege cystectomie als het traditionele criterium van spierinvasie. Hoofdstuk 4 beschrijft 
een groep blaascarcinoom patiënten die zich presenteren met supra-regionale lymfeklier 
uitzaaiingen zonder hematogene uitzaaiingen. Deze patiënten werden behandeld met 
combinatietherapie bestaande uit neoadjuvante chemotherapie gevolgd door  een cystectomie 
bij een partiële of complete klinische respons. In deze selecte patiëntengroep overleeft 24% 
van de patiënten 5 jaar na cystectomie. In hoofdstuk 5 worden de klinische en oncologische 
resultaten geanalyseerd van een groep van 16 patiënten met kleincellig blaascarcinoom die 
werden behandeld met chemoradiatie. Vanwege de slechte prognose door snelle hematogene 
metastasering lijkt een blaassparende behandeling aantrekkelijker dan de traditionele 
benadering van een cystectomie om lokale controle te verkrijgen. In een aantal patiënten kan 
hiermee lange remissies en zelfs genezing worden bereikt. Het feit dat geen van de patiënten 
overleed als gevolg van lokale progressie van de tumor geeft aan dat cystectomie als initiële 
behandeling niet de voorkeur heeft. Hoofdstuk 6  beschrijft de associatie van klinische factoren, 
complicaties en functionele resultaten van 4 verschillende urinedeviaties na cystectomie. In 
totaal ondergingen 281 patienten een cystectomie en urinedeviatie: 118 een deviatie volgens 
Bricker (IC), 51 een Indiana pouch(IP), 62 een neoblaas(CN), en 50 een seksualiteit 
preserverende cystectomie en neoblaas(SPCN).124 patiënten ontwikkelden een of meer 
complicaties binnen 30 dagen, een complicatie percentage van 44%. Hoge ASA-score was als 
enige factor geassocieerd met meer vroege complicaties in zowel uni-(ASA 1 vs. 3: HR 0.32; 
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95%C.I. 0.14-0.72) als multivariate analyse (HR 0.36; 95%C.I. 0.14-0.91). Geen van de andere 
variabelen was geassocieerd met vroege of late complicaties. Late complicaties traden op in 
139 patiënten(51%). Patiënten met een deviatie volgens Bricker hadden een lager risico op 
het ontwikkelen van late complicaties in vergelijking met neoblaas patiënten; 49%(IC), 62%(IP), 
59%(CN), 60%(SPCN), respectievelijk. Leeftijd, ASA-score, tumorpositieve lymfeklieren, 
extravesicale tumorgroei, of preoperatieve radiotherapie hoeven geen absolute contra-indicaties 
te zijn bij de keuze voor een deviatie.
In moderne oncologische behandelstrategieën is orgaanbehoud een belangrijk streven. Bij een 
groot aantal kwaadaardige aandoeningen zoals borstkanker, kanker in het hoofd-halsgebied, 
endeldarmkanker en weke delen tumoren van de ledematen is behandeling met behoud van 
functie tegenwoordig standaard.
Bij patiënten met spierinvasief blaascarcinoom wordt radicale cysto(prostate)ctomie al dan 
niet gecombineerd met chemotherapie echter nog steeds beschouwd als de standaard 
behandeling. In hoofdstuk 7 worden de langtermijns resultaten van de prostaatsparende 
cystectomie(PSC) beschreven. Doel van deze ingreep is behoud van seksuele functies zonder 
nadelige gevolgen voor de oncologische resultaten. Een selecte groep van 63 mannen 
ondergingen een PSC en werden vergeleken met een groep van 73 mannen die een standaard 
cystoprostatectomie (SC) ondergingen. Er waren geen statistisch significante verschillen in 
lokaal recidief percentage en het aantal metastasen op afstand(7.9% and 16%, p=0.1; 29% and 
33%, p=0.4 in de PSC en in de SC, respectievelijk). 
The 3 en 5-jaars ziektespecifieke overleving was 77% and 66% in de PSC groep and 68% and 
64% in the SC groep (log-rank, p=0.6). In de multivariate analyse waren alleen extravesicale 
ziekte (HR 3.58, p=0.003) en tumor positieve lymfeklieren(HR 5.75, p=0.0004) significant 
geassocieerd met een slechtere overleving. Twee patiënten in de PSC groep ontwikkelden 
prostaatcarcinoom, een overleed na 126 maanden als gevolg van uitzaaiingen van 
blaascarcinoom; de andere is nog in leven na 50 maanden. In de SC groep, werd incidenteel 
prostaatcarcinoom gevonden in 9 patiënten(18%). Geen van de lokale recidieven in de PSC 
groep bevond zich in de urethra prostatica of prostaat. 
Het percentage recidieven in het kleine bekken na cystectomie varieert van 4-34%, terwijl 
uitzaaiingen op afstand optreden in ongeveer 50% van alle patiënten, beide zijn afhankelijk 
van het initiële tumor stadium. In hoofdstuk 8 onderzochten we het patroon van recidieven, 
de relatie met klinische en pathologische factoren en diagnostiek. Hiertoe werden 343 
cystectomie patiënten die in het NKI-AVL werden behandeld en vervolgd, bestudeerd. De kans 
op recidief was verhoogd bij hoger T-stadium, niet radicale chirurgie, tumorpositieve 
lymfeklieren, en pre-operatieve dilatatie van de hogere urinewegen. 84% van alle recidieven 
trad op binnen 2 jaar na cystectomie, met slechts één recidief dat na bijna 8 jaar optrad. Van 
alle recidieven was 64% symptomatisch bij diagnose, terwijl 34% werd gevonden tijdens de 
standaard follow-up. Hoewel de meerderheid van de patiënten zich presenteerde met 
symptomen ten tijde van diagnose, hadden patiënten met a-symptomatisch recidief een betere 
overleving.
Hoog T-stadium, tumorpositieve lymfeklieren, pre-operatieve dilatatie van de hogere 
urinewegen, en irradicale chirurgie zijn factoren die kunnen helpen bij de selectie van patiënten 
die een lage of hoge recidiefkans hebben. Dit zou kunnen resulteren in een minder frequent 
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en meer kosteneffectief follow-up schema. Echter, op dit moment zijn de therapeutische opties 
voor patiënten met een symptomatisch recidief zeer beperkt en de prognose is dan ook 
slecht.
Er zijn veel studies over de relatie tussen volume en resultaten na oncologische chirurgie. In 
de meeste studies wordt er een sterke relatie tussen korte termijn resultaten en volume 
gevonden in het bijzonder bij hoog risico ingrepen. In hoofdstuk 9 onderzochten we de 
resultaten na cystectomie voor blaascarcinoom vergeleken tussen laag volume ziekenhuizen 
en een oncologisch centrum(NKI-AVL) in de IKCA-regio. Alle blaascarcinomen die werden 
gediagnosticeerd en behandeld tussen 1989-2003 werden geselecteerd uit de registratie van 
het Integraal Kanker Centrum Amsterdam (IKCA). In totaal werden 1185 cystectomieën 
uitgevoerd in de twintig ziekenhuizen van de IKCA regio. De postoperatieve mortaliteit(≤30 
dagen na cystectomie) was 3.2%, variërend van 0% tot 10%. Tussen 1989-2003 was de 
postoperatieve mortaliteit in het oncologisch centrum(NKI-AVL)1.8% in vergelijking met 3.5% 
voor alle andere ziekenhuizen. 184 patiënten (19.9%) ontwikkelden een locoregionaal recidief 
na cystectomie. De meerderheid (91%) van de recidieven ontwikkelde zich binnen 3 jaar na 
cystectomie, 81% binnen 2 jaar. Slechts zes patiënten ontwikkelden een recidief meer dan 5 
jaar na cystectomie. 
Er was geen statistisch significant verschil in het optreden van het aantal locoregionale 
recidieven tussen het oncologisch centrum (18.9%) en alle andere ziekenhuizen(20%). Om de 
voordelen van centralisatie aan te tonen of juist te af te wijzen zullen grotere patiënten 
populaties moeten worden vergeleken.
Hoofdstuk 10 beschrijft de korte termijn resultaten na cystectomie waarbij 2 verschillende 
perioperatieve protocollen werden vergeleken. Tussen juni 2007 en november 2008 werden 
85 blaascarcinoom patiënten behandeld met een cystectomie en urinedeviatie. Alle patiënten 
werden geopereerd in 2 ziekenhuizen door 4 urologen. In ziekenhuis A werden patiënten vroeg 
enteraal gevoed via een jejunumsonde, werd de neusmaagsonde binnen 24 uur na operatie 
verwijderd en kregen alle patiënten selectieve darm decontaminatie. In ziekenhuis B bestond 
het posoperatieve beleid uit totale parenterale voeding via een centrale lijn en werd de 
neusmaagsonde na 24 uur verwijderd. Opnameduur en complicaties werden vergeleken tussen 
de twee ziekenhuizen. Meer dan de helft van alle patiënten(52%) ontwikkelde een of meer 
complicaties binnen 30 dagen na cystectomie, 37% in ziekenhuis A en 71% in ziekenhuis B. 
Patiënten die in ziekenhuis A werden behandeld hadden een kortere opname duur; 13 dagen 
in vergelijking met patiënten in ziekenhuis B. Vroege enterale voeding zou gunstig kunnen zijn 
in vergelijking met parenterale voeding en leiden tot minder infectieuze complicaties en kortere 
opnameduur. Selectieve darm decontaminatie speelt mogelijk een toegevoegde rol in de 
preventie van infectieuze complicaties na cystectomie. 
Intraperitoneale uitzaaiingen van het blaascarcinoom zijn relatief zeldzaam in vergelijking met 
bijvoorbeeld vergevorderd ovarium, colon, maag, pancreas, en borstcarcinoom. In hoofdstuk 
11 wordt een 45 jarige patiënte beschreven met een voorgeschiedenis van 20 jaar recidiverend 
niet spierinvasief blaascarcinoom behandeld met herhaaldelijke transurethrale resecties en 
uiteindelijk een cystectomie en nefro-ureterectomie. Deze patiënte presenteerde zich 
uiteindelijk met klinische verschijnselen van een ovarium carcinoom 4 jaar na cystectomie. 
Pathologisch onderzoek toonde echter uitgebreide peritoneale uitzaaiingen van een 
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urotheelcelcarcinoom van de blaas. Het vermogen tot uitzaaien is bekend van hooggradig 
urotheelcelcarcinoom en al beschreven in recente beschrijvingen over trocarmetastasen bij 
laparoscopische chirurgie. Alhoewel het exacte mechanisme niet geheel duidelijk is in deze 
patiënte, wordt het vermogen tot uitzaaiien door deze ziekte geschiedenis nogmaals 
onderstreept. In hoofdstuk 12 worden blaassparende behandelingen besproken, tevens wordt een 
blaaskanker patiënt die behandeld werd met brachytherapie gepresenteerd.
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danKWoord
Eindelijk klaar!
Het NKI-AVL, in 2005 begonnen als onderzoeker en later ook als AGNIO op de afdeling HOD, 
mijn eerste baan als dokter in een uniek ziekenhuis. Heel veel geleerd in een korte tijd. Ik vind 
het nog steeds een eer dat ik hier heb kunnen werken. Velen hebben direct of indirect 
bijgedragen aan dit proefschrift, een aantal wil ik in het bijzonder noemen in dit dankwoord. 
Allereerst Prof.dr. S. Horenblas, beste Simon, mijn promotor, toen ik kwam solliciteren in het 
NKI-AVL zouden we beginnen met micro-array onderzoek om het gedrag van invasieve 
blaastumoren te voorspellen. Dat ik geen statistische of laboratorium ervaring had maakte jou 
niet uit, enthousiasme en nieuwsgierigheid vond jij het belangrijkst. Nu na 7 jaar (eindelijk) 
klaar, geen micro-arrays, maar klinische rapportage van de blaascarcinoom patiënten uit het 
NKI-AVL. Soms lastig te slijten aan de internationale tijdschriften, maar voor Nederland zeer 
bruikbare informatie. Dank voor jouw enthousiasme, goede ideeën en hulp bij de artikelen in 
dit boekje. Buiten het onderzoek ben jij ook zeer betrokken, de fietstochtjes van de beruchte 
Ronde Hoep, waar jij toch telkens weer als eerste het bordje Amsterdam wist te passeren, nadat 
je de hele rit in het wiel gehangen had. De vroege “zondagochtendespresso”op de Avogadrostraat 
om te informeren hoe het schrijven verliep, jij in strakke schaatsbroek, wij in pyjama. Ik heb 
ontzettend veel van je geleerd en hoop nog veel van je te leren.
Dr. W. Meinhardt, beste Wim, dank voor jouw bijdrage aan dit proefschrift, het stuk over de 
para-aortale lymfeklieren was jouw idee. Ook jouw begeleiding in de kliniek en op OK toen ik 
als arts-assistent of de afdeling urologie werkte was zeer leerzaam. En natuurlijk de interesse 
voor muziek, op de OK draaide jij “Beef”, maar de live muziek van mijn Bigband dat kon jij ook 
waarderen! 
Dr. A. Bex, beste Axel, ik wil jou bedanken voor de hulp bij het solliciteren in Duitsland, jij kwam 
met goede tips en hebt mij enorm geholpen met de vertaling van mijn sollicitatiebrief, gelukkig 
was dit allemaal uiteindelijk niet nodig. Viel Spass mit der Trompete! 
Dr. H.G. Poel, beste Henk, nog nooit heb ik een manuscript zo snel volledig gecorrigeerd met 
helder commentaar terug gehad, 1,5 uur!!! Dank voor al jouw goede ideeën en commentaar op 
de stukken.
Dr. O. Visser, beste Otto, ik weet nog goed wat jouw eerste opmerking was over het 
blaascarcinoom bij onze eerste ontmoeting in het IKCA, “ blaaskanker, mijn hobby is het niet“. 
Juist daarom wil ik je bedanken voor alle analyses en hulp bij het schrijven van 
de(epidemiologische) stukken. 
Naast de promotor, mede auteurs ben ik natuurlijk veel dank verschuldigd aan de leescommisie 
voor de beoordeling van dit proefschrift: Prof.dr. R.J.A. van Moorselaar, Prof.dr. J.H.R.L. Bosch, 
Prof.dr. J.J.M.C.H. de la Rosette, Prof.dr. J.A. Witjes, dr. J.M. Kerst, dr. O. Visser.  
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Dan de heren van de statistiek, Dr. H. van Tinteren en A. Vincent, beste Harm, dank voor jouw 
kritische input en analyses van deze retrospectieve data, misschien niet de hoogste impact 
factor maar toch nuttig werk voor de Nederlandse Urologie. Andrew, thanks for all your analyses 
on the manuscript about the initial presentation of bladder cancer patients. 
Tony van de Velde, de geestelijk vader van de cystectomie database, geen query in Acces was 
te lastig voor jou, dank voor je hulp!
Beste Joke, kwam ik weer met een enorme lijst aan statussen die uit het archief moesten worden 
opgevraagd, nooit een probleem voor jou, dank voor je hulp.
Prof.dr. L.A.L.M. Kiemeney en dr. H.E. Karim-Kos , beste Bart en Henrike, dank voor 
jullie(epidemiologische) hulp bij het incidentiestuk. 
Drs. P. Kauer, beste Paul, dank voor jouw inzet, zonder de SLAZ patiënten geen hoofdstuk 10. 
Mijn voorganger dr. Jakko Nieuwenhuijzen, “Jakko Jan”, dank voor jouw hulp bij de eerste 
stukken. 
Mijn opvolgster, Laura Mertens, heel veel succes met de “blazen”, er is nog veel werk te doen, 
dat gaat zeker een mooi boekje opleveren met jouw enthousiasme.
Dan de collega artsonderzoekers in willekeurige volgorde: Roelien, Karel, Philip, Maartje, 
Ronald, Robbert, Maurits, Ingrid, Lisette, Iris, en Marieke. Dank voor de altijd gezellige 
onderzoekerslunch en koffiebreaks tijdens het “drukke” wetenschappelijke werk.
Ja, dan de onderzoekers van de urologie, of eigenlijk het peniscarcinoom een stel apart: Bin, 
Joost en Niels. Af en toe keek ik met jaloerse blik naar het ogenschijnlijke gemak waarmee jullie 
stukken werden geaccepteerd. “Ja blaascarcinoom: het is geen peniscarcinoom”, maar ik ben 
blij dat het mij ook gelukt is.
Dan de heren van Djorbaszango, Kees `Zango`, Ipo `Zango`, Tomas `Zango`, Jelte `Zango`, 
Bart`Zango` en Rick `Zango`, ook jullie bijdrage is zeker niet onbelangrijk. Naast jullie 
vriendschap, af en toe letterlijk en figuurlijk “stoom afblazen” in het café van Ron. Optredens 
in Parijs, Ghana, Berlijn en afgelopen april in Sint Petersburg hebben mij de broodnodige 
ontspanning en inspiratie gegeven. 
Mijn paranimfen; Patrick en Jeroen, dank dat jullie mij terzijde willen staan. Jeroen, na een 
mooie studententijd in Utrecht, wonen we verder uitelkaar(helaas net iets te ver voor jouw 
elektrische vouwfiets). Dank voor je vriendschap. 
Patrick, je bent een sportieve kameraad en een echte broer, waar ik afgelopen jaren veel steun 
aan heb gehad. Gelukkig kan je erbij zijn en ben je niet op reis,hoop ik.
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Familie Vogel, beste Nel en Andre, Marien en Linda, dank voor jullie interesse en steun, niet de 
koude kant, maar een extra “warme” kant. Marien, jij bent de beste knecht om de Col Agnel op 
te fietsen deze zomer, dank voor het kopwerk. 
Beste Pa en Ma, Jan en Guusje, ongelooflijk veel dank voor jullie onvoorwaardelijke steun en 
interesse; jullie staan altijd voor mij klaar! Ik kan mij geen betere ouders wensen. Beste Timo, 
mijn muzikale kameraad op de trompet, weinig woorden maar des te meer daden. Dank voor 
je hulp.
Lieve Bibi, je bent net zo ongeduldig als je vader, 40 weken is ook lang wachten, zeker als je zo 
nieuwsgierig bent als jij…
Lieve Marlou dat jij als laatste genoemd wordt is omgekeerd evenredig met jouw bijdrage aan 
dit proefschrift, dank voor jouw geduld, enthousiasme en bovenal liefde. 
Op naar het volgende project, ik wacht nu al zolang tot je me vraagt...
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curriculum vitae
curriculum viTae
Remco Richard de Vries werd geboren op 6 mei 1976 te Amersfoort. Hij behaalde zijn VWO 
diploma in 1995 op de Katholieke Scholengemeenschap te Hoofddorp. Tijdens zijn examenjaar 
volgde hij tevens de vooropleiding Trompet Lichte muziek bij Eric Vloeimans aan het 
Conservatorium te Utrecht. In 1997 voltooide hij de propedeuse hoofdvak Trompet Lichte 
muziek. In 1998 startte hij de opleiding Geneeskunde aan de Universiteit Utrecht. In het laatste 
jaar van zijn doctoraalfase volgde hij zijn wetenschappelijke stage “Ischemische 
cerebrovasculaire ziekten op de kinderleeftijd” in het Wilhelmina Kinderziekenhuis bij de 
afdeling Kinderneurologie onder begeleiding van Dr.K.P.J.Braun. Dit resulteerde in een eerste 
publicatie; de interesse voor het doen van onderzoek was geboren. Na het keuzecoschap 
Urologie en Kinderurologie in het UMCU was de interesse voor de urologie gewekt. Hij behaalde 
zijn Artsexamen in mei 2005.
In juni 2005 startte hij met het promotieonderzoek naar invasief blaascarcinoom bij in het 
Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis. Vanaf juni 2006 werd 
het onderzoek gecombineerd met een baan als AGNIO heelkunde in hetzelfde ziekenhuis. 
Vanaf januari 2008 tot januari 2009 werkte hij als AGNIO Urologie in het Meander ziekenhuis 
te Amersfoort. Daarna volgde hij de Vooropleiding Heelkunde in het Onze Lieve Vrouwe 
Gasthuis te Amsterdam. Op 1 januari 2009 is hij gestart met de opleiding tot uroloog in het 
opleidingscluster Utrecht; opleider Prof.Dr.J.L.H.R.Bosch. Op dit moment is hij werkzaam in 
het Jeroen Bosch Ziekenhuis te ’s Hertogenbosch; opleider Dr. H.Beerlage.
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